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ABSTRACT 
Steroidogenic CYP enzymes are responsible for the biosynthesis of steroid hormones, which regulate vital 
physiological processes. Pathologically elevated levels of these hormones are closely related to severe 
hormone dependent diseases. Therefore, down-regulations of these hormone levels by inhibition of the 
corresponding synthase are promising pharmacotherapies. 
Abnormally high concentrations of aldosterone are associated with severe cardiovascular diseases such as 
congestive heart failure, hypertension, and myocardial fibrosis. Since CYP11B2 is the crucial enzyme in the 
biosynthesis of aldosterone, the inhibition of CYP11B2 is proposed as an innovative treatment for the related 
diseases. Although our previously designed naphthalene pyridine type of CYP11B2 inhibitors showed strong 
potency and good selectivity toward CYP11B1, notable inhibition toward hepatic enzyme CYP1A2 was 
observed. In order to improve the selectivity toward CYP1A2, modifications were performed on the core 
structure by altering cycle size and presenting H-bond forming groups and / or bridge bonds leading to a 
series of 3-pyridinyl substituted aliphatic cycles. It was discovered that dearomatisation of the lipophilic core 
and destruction of planar configuration significantly reduced CYP1A2 inhibition. Thus, potent and selective 
CYP11B2 inhibitors, e.g. I-12, were obtained. Furthermore, via ligand-based drug design approach a series 
of N containing heterocycle substituted indolines and indoles were designed and synthesized. It has been 
found that the bulkiness of amido moiety is detrimental for CYP11B2 inhibition. Accordingly, Me was the 
most suitable substituent. Electron donating groups on the pyridyl increased the potency, whereas electron 
withdrawing groups reduced the inhibition. This study yielded highly potent and selective toward CYP11B1 
CYP11B2 inhibitors, e.g. II-20. 
Moreover, breast cancer patients under CYP19 inhibitor therapy are vulnerable to cardiovascular diseases 
because estrogen deficiency leads to elevated levels of aldosterone and thus to a higher risk. Therefore, dual 
inhibitors of CYP19 / CYP11B2 are promising therapeutics for breast cancer patients with the benefit of 
reducing cardiovascular diseases. By combining the key structural features of selective CYP19 and 
CYP11B2 inhibitors into one molecule, a series of pyridinylmethyl substituted 1,2,5,6-tetrahydro-
pyrrolo[3,2,1-ij]quinolin-4-ones were designed and synthesized with III-25 as the most promising CYP19 / 
CYP11B2 dual inhibitor with good potency and selectivity. 
Furthermore, CYP11B1, which is responsible for the biosynthesis of cortisol, is a promising target for the 
treatment of hypercortisolism (Cushing’s syndrome). Starting from etomidate several structure modifications 
led to compound IV-4 as a potent CYP11B1 inhibitor.  
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ZUSAMMENFASSUNG 
Steroidogenic CYP-Enzyme sind verantwortlich für die Biosynthese von Steroid-Hormonen, die wichtige 
physiologische Prozesse regulieren. Pathologisch erhöhte Werte dieser Hormone stehen in engem 
Zusammenhang mit einigen schwerwiegenden hormonabhängigen Krankheiten. Daher bestehen in der 
Absenkung dieser Hormonspiegel durch Hemmung der entsprechenden Synthase vielversprechende 
Pharmakotherapien. 
Ungewöhnlich hohe Konzentrationen von Aldosteron sind mit schweren kardiovaskulären Erkrankungen 
wie Herzinsuffizienz, Hypertonie und myokardialer Fibrose assoziiert. Da CYP11B2 das entscheidende 
Enzym bei der Biosynthese von Aldosteron ist, wurde die Hemmung von CYP11B2 als vielversprechende 
Behandlung für die Krankheiten vorgeschlagen. Obwohl unsere Naphthalin Pyridin CYP11B2 Inhibitoren 
eine starke Aktivität und gute Selektivität gegenüber CYP11B1 zeigten, wiesen sie dennoch eine 
bemerkenswerte Hemmung gegenüber dem hepatischen CYP1B2 auf. Um die Selektivität zu diesem 
hepatischen Enzym zu verbessern, wurden Veränderungen an der Kernstruktur durch Veränderung von 
Zyklus Größe und H-Brücken bildenden Gruppen durchgeführt und so eine Serie von 3-Pyridinyl 
substituierten aliphatischen Zyklen erhalten. Es wurde gefunden, dass Dearomatisierung des lipophilen 
Kerns und die Aufhebung der planaren Konfiguration erheblich die CYP1A2-Hemmung reduziert. So 
wurden potente und selektive CYP11B2 Inhibitoren, z.B. I-12, erhalten. Ferner wurden durch Ligand-
basiertes Wirkstoff-Design eine Reihe von N heterocyclisch substituierten Indolinen und Indolen 
synthetisiert. Es wurde festgestellt, dass die Sperrigkeit der Amido-Einheit für die CYP11B2 Hemmung 
nachteilig ist. Entsprechend ist Me der am besten geeignete Substituent. Elektronen spendende Gruppen am 
Pyridyl erhöhen die Potenz, während Elektronen ziehende Gruppen die Hemmung reduzieren. Diese Studie 
führte zu hoch potenten und selektiven CYP11B2 Inhibitoren, z.B. II-20. 
Brustkrebspatientinnen unter CYP19 Inhibitor Therapie sind anfällig für Herz-Kreislauf-Krankheiten, weil 
Östrogenmangel zu hohen Aldosteron Konzentrationen führt und damit das Risiko erhöht. Daher sind duale 
Inhibitoren von CYP19 / CYP11B2 für Brustkrebspatientinnen hochinteressant, da sie kardiovaskuläre 
Komplikationen verhindern können. Durch Kombination der wichtigsten strukturellen Merkmale von 
selektiven CYP19 und CYP11B2 Inhibitoren, wurde eine Reihe von Pyridinylmethyl substituierten 1,2,5,6-
Tetrahydropyrrolo [3,2,1-ij] chinolin-4-onen entwickelt, z. B. III-25. 
CYP11B1 ist die verantwortlich für die Biosynthese von Cortisol und damit ein vielversprechendes Target 
für die Behandlung von Hypercortisolismus (Cushing-Syndrom). Ausgehend von Etomidat wurde durch 
verschiedene Structurmodifizierungen IV-4 als potenter CYP11B1 Inhibitor erhalten. 
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1 Introduction 
1.1 Cytochrome P450 Superfamily 
1.1.1 General 
Cytochrome P450 (abbreviated as CYP) is a super family of isoenzymes containing a cysteine bound 
protoporphyrin IX as prosthetic group (Figure 1A). The name of CYP was derived from a unique 
spectroscopic property. When heme iron in the reduced state binds to carbon monoxide, an intense Soret 
peak at 450 nm is found.1 Not all heme-containing proteins but CYP enzymes exhibit an absorption peak at 
450 nm due to a thiolate anion from the cysteine residue is present as the 5th ligand. CYPs are ubiquitous in 
nature, and exist in all species from prokaryotes to humans. According to amino acid sequence identity, 
CYPs are categorized into families and subfamilies. Families share > 40% of sequence identity, whereas 
subfamilies have > 55% of sequence identity. The members of CYP superfamily continue to increase as 
more and more genomic sequences are identified. Up to date, more than 9000 genes are identified. For 
humans, there are 18 families and 44 subfamilies.2 
For humans and animals, CYP enzymes are membrane bound, and play a wide range of functions in 
humans through mixed-function oxidations. In order to carry out the oxidative reactions, CYPs require a 
source for electrons, which is implemented via an electron transfer chain. Two distinct types of electron 
transfer chains exist according to the location in the cell of the CYP. CYP enzymes (e.g. CYP11B1, 
CYP11B2) located in the mitochondrial inner membrane follow NADPH → ferredoxin reductase → 
ferredoxin → CYP to transfer electrons, whereas CYPs located in the endoplasmic reticulum (e.g. CYP17, 
CYP19) pass electrons through NADPH → NADPH CYP reductase → CYP. In some cases (e.g. CYP17, 
CYP3A4), cytochrome b5 plays a role in the electron transfer chain. 
1.1.2 Oxidative Mechanism of CYP Enzymes 
CYPs as monooxidases refer to incorporation of one atom of oxygen molecule into the corresponding 
substrate and another one atom into water. They can catalyze a diverse range of oxidative reactions, such as 
hydroxylation of aliphatic or aromatic CH groups, oxidation of hereroatoms, epoxidation of double bonds 
and dealkylation reactions. The classic catalytic mechanism3 is depicted in Figure 1. The process of catalytic 
reaction is divided into several consecutive steps, including substrate binding, 1st electron transfer, oxygen 
molecule binding, 2nd electron binding, two protonations and release of the product. In the active center, 
heme iron is located. The catalytic oxidation thus starts from the resting state 1, in which a molecule of water 
is coordinated to the iron as the sixth ligand, on the side opposite to the cysteine residue.  As the substrate 
binds in the active site, the water molecule is usually displaced and arrives at complex 2. Also, the state of 
the heme complex often varies from low spin to high spin. CYPs inhibitors are able to competitively bind to 
the active iron and exhibit inhibitory potency for the treatment of some relevant diseases. Accompanying the 
change of electronic state, an electron is transfered from NAD(P)H to heme complex via electron transfer 
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chain, resulting in the reduction of the ferric iron to ferrous iron 3. As follows, an oxygen molecule 
covalently binds to the heme iron at the distal axial coordination position of the heme center, resulting in an 
oxy-P450 complex 4, as the last relatively stable intermediate. A second electron is subsequently transferred 
to the oxy-P450 complex to form a peroxo-ferric complex 5a. Afterwards, it is instantly protonated by local 
transfer from water or from surrounding amino acid residues to form a hydroperoxo-ferric complex 5b. A 
second protonation accompanying hemolytic scission of O–O bond and releasing one water molecule results 
in a highly oxidative iron(IV)-oxo species 6. Oxygen atom transfer from 6 to the bound substrate leads to the 
oxygenated product complex 7. After release of the product, the catalytic cycle completes with a water 
molecule returning to occupy the distal coordination position. Under physiological conditions, some side 
reactions can also occur, which causes an abortive result by the return of the hemoenzyme to the state 2. 
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Figure 1. A) CYP cofactor. B) CYP catalytic circle. 
1.1.3 Functions of CYP Enzymes 
In nature, CYP enzymes play a diverse range of functions. In general, they contribute to the maintenance 
of homeostasis of endogenous and exogenous substances. In humans and animals, CYP1–3 families are 
predominantly located in the liver, responsible for the elimination of exogenous chemicals including drugs 
by providing the molecules with polar groups such as OH, whereas, CYP 4–51 families play an important 
role in the biosynthesis or deactivation of crucial endogenous substances, which regulate the development 
and homeostasis of the body, such as steroidal hormones, arachidonic acid, fatty acids, thromboxane, bile 
acids, prostacyclins and vitamins. 
1.1.4  Hepatic CYP Enzymes 
As mentioned above, due to the predominant location of CYP1–3 families in the live, they are termed as 
hepatic CYP enzymes. Another characteristic of these enzymes is that there is a broad range of substrates for 
each enzyme. This ensures a vast majority of the exogenous chemicals can be metabolized by hepatic CYPs 
to protect the body from toxic effects. It is estimated that metabolism including phase I and phase II in the 
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liver accounts for the elimination of approximately 75% of the 200 top prescribed drugs (Figure 2A).4 In 
phase I, CYP1–3 families provide the drugs with polar functional groups, mostly OH, which can be further 
attached to a hydrophilic compound in phase II to form a conjugate in order to facilitate the excretion of the 
modified drugs as more water soluble forms.  There is approximately 75% of metabolism achieved by CYPs. 
Among them, CYP3A subfamily (predominantly CYP3A4) is responsible for 46% of drug oxidations, 
whereas CYP2C9 for 16% and CYP2C19 plus CYP2D6 for 12%. The metabolism percentage for each CYP 
enzyme may be explained by its corresponding expression ratio in the liver (Figure 2B). CYP3A4, the 
predominant enzyme expressed in the liver, accounts for 34.4% of the total CYP1–3 families, whereas 
CYP2C9 for 17.3%, and CYP2E1 and CYP1A2 for 14.6% and 12.5% respectively4,5. 
 
Figure 2. A) Metabolism and elimination of 200 top prescribed drugs. B) Liver expression ratio of CYP enzymes. 
Since hepatic CYPs play a vital role in drug metabolism, adverse drug reactions caused by CYPs should 
be taken into account, e.g. too short half-life, toxic metabolites or unfavorable drug-drug interactions. 
Sometimes a drug needs to be given together with other drugs which may show inhibition of CYP enzymes 
(involved in the drug’s metabolism). As a result, the drug can be overdosed in the patient, and thus causes 
side effects or even leads to death. On the other hand, if they induce the activity of CYP enzymes, the drug 
can decrease levels due to over metabolism and cause ineffectiveness. Therefore, whether or not drug 
candidates show effects on hepatic CYP enzymes is important to be taken into account before they enter into 
clinical use in order to decrease attrition rates in drug development. The insight into substrate features or X-
ray structures of metabolizing CYPs may allow for the design of compounds with more favorable drug 
metabolism properties. For example, CYP3A4 oxidizes a wide range of lipophilic compounds, while 
CYP1A2 prefers relatively small and planar lipophilic molecules. This is due to the fact that in the binding 
site of CYP1A2 is surrounded by a few aromatic residues.6 Moreover, a polymorphism refers to a difference 
in DNA sequence, which is found in at least 1% of a population. This can lead to a different CYP 
metabolizing activity, resulting in poor metabolizer, normal metabolizer or high metabolizer. This may result 
in that drug dosage given does not give rise to curative effects in high metabolizers, but is able to cause 
overdose which results in subsequent toxicity in poor metabolizers. Since CYP1A2, 2D6, 2C9, 2C19 and 
3A4 account for over 90% of drug metabolism, generally taking care of them can be very helpful for drug 
design and development.  
A B
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1.1.5 Steroidogenic CYP Enzymes 
By contrast with hepatic CYP enzymes, steroidogenic CYPs are specific due to one enzyme only has one 
or a few substrates, which are always steroids. Sterodogenic CYP enzymes include CYP11A1, CYP11B1 
(11ß-hydroxylase), CYP11B2 (aldosterone synthase), CYP17 (androgen synthase), CYP19 (estrogen 
synthase) and CYP21. They are of great importance in the biosynthesis of crucial hormones which are 
responsible for the regulation of vital physiological processes in the body. Their biosyntheses starting from 
cholesterol are depicted in Figure 3. Exogenous or endogenous cholesterol undergoes side-chain cleavage 
catalyzed by CYP11A1 to provide pregnenolone which is transformed to progesterone by 3ß-HSD. 
Pregnenolone and progesterone thus undergo hydroxylation and lyase reaction, catalyzed by CYP17, to form 
dehydroepiandrosterone (DHEA) and androstenedione, respectively. They are important precursors of 
androgens such as androstenediol, testosterone and dihydrostestosterone. In addition, androstenedione and 
testosterone can be catalyzed by CYP19 to synthesize estrogens, estrone and estradiol, respectively. On the 
other side, CYP21 oxidizes progesterone and 17α-hydroxyprogesterone to form 11-deoxycorticosteone 
(DOC) and 11-deoxycortisol, which are further catalyzed by CYP11B2 and CYP11B1 to yield aldosterone 
(major mineralocorticoid) and cortisol (major glucocorticoid), respectively.  
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Figure 3. Steroidogenic CYP enzymes in the biosynthesis of steroid hormones. 
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In the whole biosynthesis route, all CYP enzymes are indispensable for in vivo physiological processes. 
Their appropriate amount and activity determine whether or not the physiological functions are normal. The 
majority of them has been employed as pharmaceutical targets for the treatment of the diseases relevant to 
their overexpression and consequently elevated levels of their products, steroidal hormones. CYP11B1, 
which is responsible for the synthesis of cortisol, is used as a target for Cushing’s syndrome for over five 
decades. Nevertheless, CYP11B2 inhibitors, as a promising alternative pharmaceutical therapy for severe 
cardiovascular diseases such as congestive heart failure (CHF) and hypertension associated with high 
aldosterone concentration are of interest for preclinical development. Besides, CYP17, key enzyme of 
androgen biosyntheses, is a promising target for the treatment of hormone dependent prostate cancer. 
Similarly, the inhibition of CYP19, involved in estrogen biosynthesis, The only CYP enzyme which has 
already been widely implemented in the clinic is CYP19 in patients with postmenopausal breast cancer (BC), 
as it catalyzes the last step of estrogen biosynthesis. 
1.2 CYP11B2 Inhibitors and Cardiovascular Diseases 
1.2.1 Aldosterone: Physiology and Pathology 
1.2.1.a. Molecular Mechanism of Action and Regulation of Fluid Homeostasis 
Aldosterone plays an essential role in the regulation of electrolyte and volume homeostasis. In genomic 
manner, aldosterone binds to mineralocorticoid receptor (MR), which is a member of nuclear receptor family, 
in epithelia of the distal tubules and the collecting ducts in kidney. This causes MR/aldosterone complex 
conformation change in the ligand-binding domain, and induces the dissociation of associated proteins such 
as heat shock protein. After quick translocation to the nucleus, MR/aldosterone complex binds, as a dimer, to 
hormone response elements, and regulates the expression of aldosterone-responsive genes like serum 
glucocorticoid-regulated kinase (SGK1)7 which is a key aldosterone-responsive gene responsible for the 
retention of sodium, resulting in stimulation of transepithelial ion transport. The typical transepithelial ion 
channel is amiloride-sensitive epithelial sodium channel (ENaC) and basolateral Na+/K+-ATPase pump, 
which leads to absorption of sodium and water at the expense of potassium excretion, consequently causing 
the increase of blood volume and pressure. The latency from binding reaction to final effect normally lasts 2 
h – 4 h. Moreover, aldosterone in physiological concentration was found to act in a nongenomic manner to 
rapidly increase (within minutes) intracellular calcium and pH value in human distal colon via regulation of 
basolateral K+ channels.8 
1.2.1.b. Aldosterone in the Pathological Progression of Hypertension, Myocardial Fibrosis 
and Congestive Heart Failure 
However, numerous studies demonstrated that high plasma levels of aldosterone are associated with the 
pathogenesis of cardiovascular diseases such as hypertension, myocardial fibrosis and congestive heart 
failure. After excessive aldosterone binds to MR, a resultant over-expression of sodium channels in the target 
cells stimulates sodium absorption. The increase in blood pressure causes natriuresis, and the release of 
natriuretic factors. Thus, this results in the excretion of a lot of sodium and reduces the elevated fluid volume, 
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in spite of excessive aldosterone. When the plasma volume is restored, blood pressure continues to rise. This 
correlates with the development of a rise in systemic vascular resistance. Furthermore, abnormally high 
levels of aldosterone exhibit different adverse effects on the heart9. One of the most documented impacts of 
aldosterone on the heart is myocardial fibrosis which is an important feature of cardiac hypertrophy and left 
ventricular dysfunction, although the mechanism is not well understood to date. In rat models, treatment with 
a MR antagonist resulted in a blockage of fibrosis at doses that do not improve the hypertension10,11. This 
indicates that the effect of aldosterone on fibrosis is independent of hemodynamic processes, and may 
directly effect the deposition of collagens in cardiac fibroblasts12,13 and the induction of tissue necrosis via a 
reparative process14, resulting in worsening the myocardial stiffness. It is well established that in addition to 
adrenal production of aldosterone, local aldosterone synthesis, e.g. in heart15, is identified. It is postulated 
that the extra-adrenal synthesis of aldosterone contributes to pathogenesis of heart diseases. Besides, the fact 
that MR is found in non-epithelial tissues16 such as heart and vasculature provides the basis of local effect of 
aldosterone on the cardiac tissues. Moreover, aldosterone, acting as a potent pro-inflammation factor17,18, 
induces reactive oxygen species19. This also contributes to vascular fibrosis and endothelium stiffening20, and 
may be closely associated with atherosclerosis21,22. Accompanying severe myocardial fibrosis, cardiac 
hypertrophy and adverse structural remodelling of myocardium occur, and lead to diastolic dysfunction. As a 
consequence, the reduction of cardiac output and renal hyporefusion result in congestive heart failure (CHF). 
In addition, inflammation, hypertension, reperfusion injury, and myocardial infarction induced by excessive 
aldosterone contribute to the progression of heart failure23,24. 
1.2.2 Regulation of Aldosterone Secretion by  AngII, Potassium and ACTH 
It has been shown that aldosterone’s essential role in salt and volume homeostasis is controlled by 
negative feedback loops of renin-angiotesin-aldosterone system (RAAS) and potassium. There are three 
major stimuli in regulation of aldosterone secretion (Figure 4), including angiotensin II (AngII), potassium 
and adrenocorticotropic hormone (ACTH). 
Renin an aspartyl protease is synthesized in renal juxtaglomerular apparatus. Renin catalyzes circulating 
angiotensinogen produced in liver to form inactive angiotensin I, which is converted to AngII by angiotensin 
converting enzyme (ACE) located in multiple tissues. After Ang II binds to its receptor AT1, aldosterone 
synthesis is stimulated and the hormone is released from the adrenal cortex. Stimulation factors of renin 
secretion include renal perfusion pressure, β-adrenergic stimulation and prostaglandins, while potassium and 
Ang II as well as atrial natriuretic peptide are inhibitory factors.25 It is noteworthy to mention that elevated 
Ang II inhibits renin secretion via a small negative feedback loop, independent of blood pressure and 
aldosterone concentration. Moreover, the amount of aldosterone secreted is strongly stimulated by potassium, 
which is independent of RAAS. An increase of potassium causes a rise in aldosterone secretion, and the 
change of aldosterone levels, in turn, depresses the increase of potassium via a small negative feedback loop. 
In addition, other regulatory factors such as ACTH, endothelin and serotonin25 are characterized as response 
to stress. ACTH is a pituitary peptide, acting as the most potent stimulator of acute aldosterone secretion; 
however, chronic stimulation leads to an unexpected decrease in aldosterone release. 
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1.2.3 Components of RAAS and Treatment of High Levels of Aldosterone 
Related Diseases –– State of Art 
Due to the fact that high aldosterone levels are closely 
associated with the progression of several cardiovascular 
diseases as mentioned above, a direct or indirect block 
aldosterone is applicable to the treatment of the relevant 
diseases. Since aldosterone is totally involved in the 
RAAS, it is feasible to find appropriate targets from the 
components of the system. Depression of aldosterone 
secretion or inhibition of its function could be such 
targets. In clinical use, several strategies are 
implemented, consisting of MR antagonists, ACE 
inhibitors, AT1 receptor antagonists, and renin inhibitors. 
In addition, a novel promising approach of direct 
inhibition of aldosterone production by CYP11B2 
inhibitors is still of interest.  
1.2.3.a. Mineralocorticoid Receptor 
Antagonists 
To date, only two steroidal MR antagonists are brought to the market for the treatment of hypertension and 
heart failure, i.e. spironolactone, eplerenone (Figure 5). In recent years, several series of non-steroidal MR 
antagonists have been designed and patented by pharmaceutical companies, such as imidazole 
carboxamides26 from Exelixis and 3,3-bisaryl oxindoles27 from Lilly (Figure 5). In clinical trails, both 
spironolactone28 and eplerenone29 have been demonstrated that they showed effective in decreasing 
morbidity and mortality in patients with heart failure. However, severe adverse effects like gynaecomastia 
and breast pain are found28, due to poor selectivity of spironolactone toward other members of nuclear 
receptor family such as androgen receptor (AR) and progesterone receptor (PR). Although the sex hormone 
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Figure 5. Typical MR antagonists: steroids (spironolactone, eplerenone) and nonsteroids (imidazole carboxamide, 3,3-bisaryl 
oxindole). 
related side effects have been weakened by the more selective steroidal MR antagonists eplerenone, long-
term treatment leaves high levels of aldosterone unaffected30, which can lead to further exacerbation of heart 
dysfunction in a MR independent non-genomic manner31 Moreover, both spironolactone and eplerenone can 
 
Figure 4. Regulation of aldosterone secretion by 
RAAS, potassium and ACTH (adoption from 
http://www.zazzle.com/wordsunwords/gifts?cg=19694
8684080670328) 
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cause hyperkalemia which further leads to death. 
1.2.3.b. ACE Inhibitors 
ACE is located in multiple tissues, predominantly in the lung, and is the key enzyme to produce Ang II. 
The latter stimulates vasoconstriction and aldosterone secretion. Captopril (Figure 6), the first ACE inhibitor, 
was approved by FDA in 1981 for the treatment of hypertension and CHF. This was regarded as a 
breakthough due to both the novel mechanism of action and the pioneering in structure-based drug design. 
Moreover, ACE inhibitors are also used in the treatment of diabetic renal failure to delay the progress of 
diabetic nephropathy32. More recently other non-sulphydryl-containing ACE inhibitors came to the market 
following enalapril (Figure 6) in order to improve patient compliance. However, ACE inhibitors may cause a 
persistent cough in common and angioedema33 associated with elevated bradykinin levels. Besides, long-
term inhibitory effects of ACE inhibitors on plasma aldosterone levels are reduced due to the phenomenon of 
“aldosterone escape”34,35 via ACE-independent pathways36. 
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Figure 6. Typical ACE inhibitors. 
1.2.3.c. Angiotensin II Receptor antagonists 
Since ACE exhibits multiple effects and not all of them are mediated through angiotensin II receptors, 
therefore, blockage of angiotensin II receptors may result in more specific actions and less side effects than 
observed with ACE inhibitors. There are various subtypes of angiotensin II receptors, of which both AT1 and 
AT2 are classified to the superfamily of G-protein coupled receptors37. Most of the known biologic effects of 
angiotensin II, including the stimulation of aldosterone secretion, are mediated by AT1 receptor. In contrast, 
the AT2 receptor plays an important role in counteracting some of angiotensin II effects mediated by the AT1 
receptor38. Losartan (Figure 7) is the first orally active and specific AT1 receptor antagonist, which was 
approved by FDA in 1994 for the treatment of hypertension. In addition, AT1 receptor antagonists also serve 
as an approach for diabetic nephropathy and CHF. After losartan, other AT1 receptor antagonists (Figure 7) 
with different pharmacokinetic profiles were marketed. Due to a good tolerability profile, AT1 receptor 
antagonists are primarily implemented for hypertensive patients, who are intolerant of ACE inhibitor therapy. 
However, long-term AT1 receptor antagonist treatment leads to chronically increased levels of Ang II and its 
biodegradation products, which may produce their own effects in vivo39. With the aim of achieving the 
maximal benefits of blocking the RAAS, the combination of an ACE inhibitor and an AT1 receptor 
antagonist seems attractive to improve the overall blockade of this system, but the benefits of the 
combination are still controversial40. 
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Figure 7. Typical AT1 receptor antagonists. 
1.2.3.d. Renin Inhibitors 
Renin plays a pivotal role in the RAAS as the first component, and renin inhibitors are applied for the 
treatment of hypertension. There are three generations of renin inhibitors: peptide compounds, peptide-like 
compounds and non-peptide compounds. The first and second generation of renin inhibitors, CPG29287 and 
CGP38560 (Figure 8) as representative inhibitors respectively, exhibited strong activity in vitro but were 
discontinued due to immune reaction or lack of oral bioavailability. Optimization of peptide analogue 
CGP38560 led to the first orally active renin inhibitor, aliskiren (Figure 8), developed by Novartis in 
cooperation with Speedel and approved in 2007 by FDA as an antihypertensive agent41. Over a decade, more 
renin inhibitors with less chiral centers and less complexity in synthesis were designed, e.g. piperidines42–45, 
piperazinones46,47 (Figure 8). 
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Figure 8. Typical renin inhibitors of 1st to 3rd generation and other rennin inhibitors. 
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1.2.4 Selective CYP11B2 Inhibitors for the Treatment of Hypertension, 
Myocardial Fibrosis and Congestive Heart Failure 
Aldosterone is the terminal component of RAAS, which is closely related to the pathological progression 
of some severe cardiovascular diseases such as hypertension, myocardial fibrosis and CHF as mentioned 
above. Direct reduction of aldosterone biosynthesis by inhibition of aldosterone synthase (CYP11B2), which 
is primarily located in the zona glomerulosa of the adrenal cortex, is a promising strategy to treat those 
diseases associated with abnormally high aldosterone levels. This idea was proposed as early as in 199448 by 
our working group. Although to date there is no CYP11B2 inhibitor launched as a drug, recent in vivo 
studies in rats have demonstrated that CYP11B2 inhibitors can reduce plasma aldosterone levels49,50. Long-
term administration of FAD286 (R-enantiomer of fadrozole, Figure 9) to rats with heart failure improves 
cardiac haemodynamics and cardiac function, which is more significant than those by MR antagonist, 
spironolactone51. With respect to the design of CYP11B2 inhibitors, in addition to potency, selectivity 
towards other important steroidal CYPs such as CYP11B1, CYP17, and CYP19 should also be emphasized 
since selectivity is closely associated with severe side effects. Especially selectivity toward CYP11B1 is a 
challenging issue due to the high homology (over 93%)52 between CYP11B1 and CYP11B2. 
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Figure 9. Fadrozole and its analogues. 
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1.2.4.a Fadrozole and Its Analogues 
Fadrozole has been developed as an aromatase (CYP19) inhibitor by Novartis for the treatment of  
postmenopausal breast cancer. Besides the potency toward CYP19, fadrozole shows potent inhibition of 
CYP11B2. Its two enantiomers show distinct potency toward CYP11B2. Among them, R-enantiomer prefers 
inhibiting CYP11B2 (IC50: CYP11B2 = 6.0 nM, selectivity factor of IC50 CYP11B1 / IC50 CYP11B2 = 20), whereas 
S-enantiomer takes the preference for CYP11B1 (IC50: CYP11B2 = 171 nM, selectivity factor of IC50 CYP11B1 
/ IC50 CYP11B2 = 0.23) 53. In recent studies, fadrozole and its enantiomers were used as model compounds in in 
vivo tests to investigate their impact on aldosterone levels and thus to study their beneficial effects on the 
improvement of diseases related to aldosterone. Later on, modifications of the fadrozole backbone from 
different directions were made in order to find CYP11B2 inhibitors with a good selectivity profile by 
Novartis54, Speedel55, and others56. Generally, five optimization approaches were carried out. i) direct 
introduction of substituents to phenyl and / or imidazolyl and / or cyclohexyl moieties; ii) replacement of 
phenyl and / or imidazolyl by other cycle or N-containing heterocycle, respectively; iii) replacement of 
cyclohexyl by other substituted cycles or remove of it; iv) fusion of additional cycles (aliphatic, aromatic or 
hetero cycles) to imidazolyl; v) rearrangement of the three cycles. Usually, these approaches are employed in 
combination. Through these optimizations, many CYP11B2 inhibitors are obtained with strong potency and 
significantly improved selectivity. 
1.2.4.b N-containing Heterocycle Substituted Methylene Tetrahydronaphthalenes or 
Dihydroindenes 
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Figure 10. N-containing heterocycle substituted methylene tetrahydronaphthalenes or dihydroindenes 
In our group, the hit compounds (Figure 10) were identified by screening an in-house CYP library 
containing approximately 500 compounds57–62. Through further modification of the hits, a series of N-
containing heterocycle substituted methylene tetrahydronaphthalenes or dihydroindenes were identified as 
potent (IC50 < 10 nM) and selective (SF > 100 versus CYP11B1) CYP11B2 inhibitors. Moreover, Z-isomers 
were found to be more potent than the corresponding E-isomer63,64. 
1.2.4.c Pyridinyl Naphthalenes and Indenes: Semi-unsaturation and Heteroatom Insertion 
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Figure 11. Design conception of pyridinyl naphthalenes. 
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Figure 12. Optimization of pyridinyl naphthalene: benzyl substitution on naphthalene core, and substituents on pyridine. 
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Figure 13. Optimization of pyridinyl naphthalene and indene: semi-unsaturation and heteroatom inserting. 
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Further structural modification in our group was made by annulation of the exocyclic double bond in 3-
pyridinyl methylene dihydroindenes into a new cycle fused to the phenyl ring and thereafter removal of the 
original five-membered ring, thus affording pyridinyl naphthalenes (Figure 11) 65,66. The resulting type of 
compounds were very potent and selective, however, they exhibited strong inhibition against hepatic 
CYP1A2. This means these compounds are not feasible to be developed to drug candidates due to the 
expected drug-drug interactions. Direct introduction of additional substituents to the pyridinyl naphthalene 
core includes two approaches: benzyl substitution67 on the naphthalene core, and substituents on the 
pyridine68 (Figure 12). These modifications made beneficial effects on both potency and selectivity profile 
toward other steroidogenic and hepatic enzymes. In addition, on the basis of the knowledge that CYP1A2 
predominantly hydroxylates those substrates with planar structure, it seemed to be reasonable to decrease 
CYP1A2 inhibition by dearomatisation of the naphthalene core and thus reducing the planar structure of the 
molecule. Several attempts were made for this purpose. The naphthalene core was semi-saturated to a certain 
degree either at the left ring or the right part (Figure 13) 66,68,69. Moreover, introduction of heteroatoms into 
the saturated ring69 and / or fusion of a third ring to the tetrahydronaphthalene70 leads to distinct structures 
with increased solubility and improved pharmacokinetic properties. Besides, a ring contraction of 
naphthalene resulting in indenes (Figure 13)66, led to the most selective CYP11B2 inhibitor toward 
CYP11B1. After these optimizations, not only the inhibitory potency of CYP1A2 was significantly reduced, 
but also the potency and selectivity were improved. 
1.3 CYP11B1 Inhibitors and Cushing’s Syndrome 
1.3.1 Cortisol: physiology and pathology 
Cortisol is a major human glucocorticoid. Apart from primarily playing an important role in the regulation 
of glucose metabolism, cortisol is also pivotal in development, metabolism, neurobiology, cell growth and 
apoptosis, as well as other biological functions71. In genomic manner, cortisol action is mediated by 
glucocorticoid receptor (GR), a member of nuclear receptor superfamily of ligand-dependent transcription 
factors. GR is expressed in almost all cells, and is located in the cytoplasm associated with a multiprotein 
chaperone complex, of which the key component is the heat shock protein Hsp90, in its inactive state. After 
cortisol binding to the glucocorticoid receptor, GR is activated, and renders hyper-phosphorylated72. The 
activated GR dissociates from the multiprotein complex, and leads to the translocation of ligand-binding GR 
from cytoplasm to nucleus. Afterwards, GR binds to glucocorticoid-responsive elements (GREs), and then 
activates the target gene transcription and thus unfolds physiological effects. In addition, some gene 
transcriptions require not only binding to GREs but also association with glucocorticoid responsive units73. 
Besides, the GR complex can also repress the gene transcription by interaction between the GR complex and 
negative GREs74. Expect for genomic action, rapid nongenomic mechanisms of cortisol action on prolactin 
were also observed through interactions with the plasma membrane75. 
However, chronic hypersecretion of circulating cortisol by adrenal cortex causes Cushing’s syndrome 
(also termed as hypercortisolism)76. According to the causes of high cortisol levels, Cushing’s syndrome can 
be categorized to ACTH-dependent and ACTH-independent Cushing’s syndrome77. ACTH-dependent 
1 Introduction 
Lina Yin Dissertation 
- 14 - 
Cushing’s syndrome is characterized by chronic hypersecretion of ACTH, which consequently stimulates 
growth of adrenal glands and production of cortisol. According to different locations resulting in 
hypersecretion of ACTH, ACTH-dependent Cushing’s syndrome can be separated into Cushing’s disease, 
which stems from pituitary adenoma, and ectopic Cushing’s syndrome, which can be seen in diseases like 
small-cell lung cancer, pancreatic islet cell tumor, pheochromocytoma, thymoma and medullary thyroid 
cancer. ACTH-independent Cushing’s syndrome is characterized by excess production of cortisol, most 
commonly resulting from adrenal tumors. Symptoms of Cushing’s syndrome include central obesity, 
hyperhidrosis, increased thirst, thinning of the skin, fatigue, backache, headache, muscle atrophy, 
hypertension, impotence, infertility, osteoporosis, gastrointestinal disturbances, opportunistic infections and 
impaired wound healing, hyperglycemia, and neuropsychological disturbances.76 
1.3.2 Regulation of Cortisol Secretion 
Cortisol is biosynthesized from 11-deoxycortisol in the final step catalyzed by 11ß-hydroxylase 
(CYP11B1), which is located in the zona fasciculata / reticularis of adrenal cortex78. Normally, the 
production and secretion of cortisol is circadian, and controlled acutely by ACTH via a negative feedback 
loop of hypothalamic-pituitary-adrenal axis. The hypothalamus, as a sensor, varies as the environmental 
stimuli. Two hypothalamic neurohormones, corticotrophin-releasing hormone (CRH) and arginine 
vasopressin (AVP), are transported to the anterior pituitary gland, and interact with their specific receptors to 
stimulate the release of the ACTH to blood circulation. Subsequently, ACTH interacts with melanocortin 
receptor type II in the adrenal cortex to thereby result in the production and secretion of cortisol. In turn, the 
elevated levels of cortisol function as a suppressive factor of the release of CRH and AVP. Additionally, 
increase in potassium was reported to have a positive effect on the secretion of ACTH and cortisol79. 
1.3.3 Treatment of Cushing’s Syndrome –– State of Art 
Among the different subtypes of Cushing’s syndrome, Cushing’s disease accounts for ca. 70% of patients, 
ectopic Cushing’s syndrome for ca. 10%, and ACTH-independent Cushing’s syndrome for ca. 20% 80. The 
mortality and morbility of Cushing’s syndrome drive the attention to approaches to its effective treatment. 
Although surgery is the primary therapy for the treatment of patients with Cushing’s syndrome, not every 
patient is endurable or willing to undergo a surgical therapy and thus the convenient medical therapy 
becomes important. Furthermore, severe complications of the syndrome, resulting in increased risk of 
surgery, as well as recurrent cases after operation can be largely reversed by medical therapy. The medical 
therapy can be employed by modulation of ACTH release at pituitary gland or ectopic site, blockage of the 
glucocorticoid receptors and inhibition of cortisol production at adrenal cortex. 
1.3.3.a ACTH Release Neuromodulators 
The medical agents in clinic impact on the release of CRH and thus ACTH secretion and include 
cyproheptidine, bromocriptine, valproic acid and octreotide (Figure 14). Cyproheptidine is an unselective 5-
hydroxytryptamine receptor blocker, and also exhibits inhibition of histamine, dopamine and cholinergic 
activity. The efficacy of normalization of cortisol levels by regulation of ACTH secretion was evaluated81,82. 
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Bromocriptine, as a dopamine agonist, is not only used for the treatment of Cushing’s disease, but also 
approved for the treatment of Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, and 
type 2 diabetes. In order to reach responsive effect in the patients with Cushing’s disease, a high daily dose 
of more than 35 mg has been suggested83. However, another study indicated that bromocriptine was similarly 
effective to placebo in the rapid decrease in cortisol levels in patients with Cushing’s disease84. Sodium 
valproate, a gamma aminobutyric acid (GABA)-transaminase inhibitor, can increase the GABA levels, 
which may induce the decrease in the CRH secretion or direct effect on pituitary tumor85. The mechanism in 
which octreotide, a somatostatin analogue, effects on the reduction of ACTH release has not been well 
demonstrated. The suppressive effects of octreotide on ACTH secretion are controversial86–90. Moreover, 
octreotide need several times of subcutaneous injections per day due to its short half time, and thus its 
application is limited in clinic. In addition, severe side effects are not avoided, due to the fact that these 
neuromodulator also play import roles in multiple targets. 
HN
S
S
NH H
N
O
NHO
O
N
H
OH
H
O
NH
O
NH2
NH
NH2
O
N
H
O
HO
HO
N
Cyproheptidine
HN
Br
N
H
H
O
N
H
N
O
O
N
O
H
HO
H
Bromocriptine
O O-Na+
Sodium valproate Octreotide
 
Figure 14. Typical ACTH release neuromodulators: 5-hydroxytryptamine receptor blocker cyproheptidine, dopamine D2 receptor 
agonist bromocriptine, GABA-ergic compound sodium valproate and somatostatin analogue octreotide. 
1.3.3.b Glucocorticoid Receptor Antagonist 
Through blockage of GR-mediated effects, GR antagonists can make some benefits on improvement of 
metabolic or psychological disorders related to hypersecretion of cortisol. Mifepristone (Figure 15) is an 
unselective glucocorticoid receptor antagonist, and competitively antagonizes both GR and progesterone 
receptor (PgR). Due to the antiprogestagenic activity, mifepristone is also implemented as an abortifacient 
agent in clinic. Afterwards, several classes of mifepristone derivatives have been reported in order to elevate 
the selectivity toward GR91, comprising 11-monoaryl derivatives, 11,21-bisaryl derivatives and 11-aryl,16-
hydroxy derivatives (Figure 15). Although the selectivity toward GR was improved through deterioration of  
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Figure 11. Glucocorticoid receptor antagonist mifepristone and its derivatives. 
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the affinity to GR, these derivatives showed less potency in vivo in comparison to mifepristone. 
1.3.3.c Steroidogenesis Inhibitors 
Steroidogenesis inhibitors can directly decrease overproduction of cortisol. Generally, steroidogenesis 
inhibitors consist of single enzyme inhibitors and multiple enzyme inhibitors. Metyrapone and trilostane are 
regarded as primarily inhibiting one ezymatic reaction by inhibition of CYP11B1 and 3ß-hydroxysteroid 
dehydrogenase (3ß-HSD) respectively, whereas, etomidate (CYP11B1, CYP11B2), ketoconazole (CYP17, 
CYP11A1, CYP11B1, CYP11B2), aminoglutethimide (CYP11A1, CYP17, CYP21B, CYP11B1, CYP11B2 
and CYP19), and mitotane (CYP11A1, CYP11B1, CYP11B2, 3ß-HSD) inhibit several enzymatic steps92. 
By blockage of the final step of cortisol synthesis by inhibition of the responsible enzyme CYP11B1, 
metyrapone can rapidly reduce of cortisol levels. However, the selectivity toward its highly homologous 
enzyme CYP11B2 needs to be improved. A recent study in our group uncovered a series of CYP11B2 
inhibitors by modification of metyrapone, which exhibited improved potency and selectivity toward 
CYP11B293. 
Trilostane is an inhibitor of 3ß-HSD, involved in the conversion of pregnenolone or 17α-hydroxy- 
pregnenolone to progesterone or 17α-hydroxyprogesterone. Since trilostane blocks the early step of the 
steroidogenetic reactions, it impacts on the production of important hormones, including glucocorticoids, 
mineralocorticoids, estrogens and androgens. Similarly, multiple enzyme inhibitors effect on several steps of 
steroidogenesis due to poor selectivity, and thus result in severe side effects. Etomidate is an anesthetic agent, 
which is also the only drug used for the treatment of Cushing’s syndrome and is administrated intravenously. 
Recently, a series of etomidate derived compounds was reported with potent inhibition of CYP11B194. Other 
multiple enzyme inhibitors, such as ketoconazole and aminoglutethimide, were initially used as an antifungal 
agent, or an anticonvulsant, respectively. Mitotane, an analogue of an insecticide, can not only inhibit 
steroidogensis, but was also found to lead to adrenocortical atrophy and necrosis and thus was used for the 
treatment of adrenocortical carcinoma92. 
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Figure 14. Steroidogenesis Inhibitors: metyrapone and trilostane, etomidate, ketoconazole, aminoglutethimide, and mitotane. 
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1.4 Dual Inhibitor CYP19 / CYP11B2 to Cure 
Cardiovascular Diseases in Breast Cancer Patients 
With respect to the pharmaceutical approach of selective multi-target-directed ligands used for the 
treatment of complex diseases, it has lower risk of drug-drug interaction and better compliance compared to 
the therapy of drug cocktails and multicomponent drugs. This drug discovery paradigm, especially dual 
inhibitors or dual antagonists, has already been employed for the treatment of different diseases, e.g. 
nonsteroidal antiinflammatory drugs inhibiting both cyclooxygenase-2 and 5-lipoxygenase, dual inhibitors of 
angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) used for the treatment of 
hypertension and CHF as well as PPARα/PPARγ dual agonists for metabolic diseases95. 
Worldwide, breast cancer (BC) accounts for ca. 10% of all cancer incidences in female, rendering it the 
most common type of non-skin cancer among women. Due to earlier diagnosis by BC screening96 and 
especially the implementation of adjuvant endocrine therapy in the earlier stage97, the mortality of BC has 
been markedly reduced. Endocrine treatment of BC stemmed from the fact that estrogen regulates the 
proliferation of hormone sensitive BC97, which comprise over 60% of all BC cases. Therefore, blockage of 
estrogen action has been regarded as a promising approach for the treatment of hormone sensitive BC. 
Selective estrogen receptor modulators (SERM) 98, e.g. tamoxifen and raloxifen (Figure 15), were introduced 
into the clinic for the treatment of hormone-positive early BC in postmenopausal women. However, the poor 
risk / benefit profiles lead to discontinuous application of tamoxifen for over five years. In addition, severe 
side effects such as endometrial cancer and thrombosis were reported99. On the other hand, aromatase 
inhibitors have been proposed on the basis that aromatase (CYP19) is the pivotal enzyme catalyzing the final 
step of estrogen biosynthesis from testosterone or androstenedione. Thus, inhibition of CYP19 can directly 
decrease estrogene production, and consequently stops tumor proliferation. The third generation aromatase 
inhibitors, e.g. anastrozole, letrozole and exemestane (Figure 15), were launched to the market, and exhibited 
better efficacy and tolerability than tamoxifen. Aromatase inhibitors are today first-line therapeutics for  
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Figure 15. Selective estrogen receptor modulators: tamoxifen and raloxifen; and aromatase inhibitors: anastrozole, letrozole, 
fadrozole and exemestane. 
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BC in postmenopausal women. It is reported that the plasma estrogen concentration is significantly reduced 
to undetectable levels after administration of aromatase inhibitors100,101. Moreover, clinic trials elucidated 
that aromatase inhibitors as adjuvant therapy dramatically ameliorate disease-free survival and relapse-free 
survival102–105. 
However, a study indicates that non-BC-related deaths were more common than BC-specific deaths in 
those five-year breast cancer survivors, especially in older patients106. It also demonstrates that 
cardiovascular diseases (CVD) among other diseases were found as a major cause of non-BC-related 
deaths106. Therefore, it is of importance to deal with CVD in order to improve the overall survival of BC 
patients. Another observation that estrogen deficiency is closely associated with CVD stems from the fact 
that CVD incidences in post-menopausal women are 3-fold higher than those in pre-menopausal women at 
the same age107,108. Recent studies have shown that estrogens show beneficial effects on the heart109–115 and 
kidney116. Estrogen treatment prevents the development of post-myocardial infarction remodelling113 and 
improves left ventricular hypertrophy and structural and functional remodelling114,115. 
Obviously, the treatment of post-menopausal BC patients by aromatase inhibitors can further decrease the 
estrogen production to very low levels, and consequently gives rise to even higher risk of CVD. It has been 
described above that high concentrations of aldosterone lead to the progression of severe CVD. Estrogen 
depletion has been proved to not only directly increase circulating aldosterone levels, but to upregulate other 
RAAS components, such as renin, Ang II, ACE and AT1 receptor, which further stimulate aldosterone 
secretion117–122. Moreover, estrogen deficiency also increases the concentration of potassium in the plasma 
which is a key factor resulting in the promotion of aldosterone secretion123,124. Therefore, abnormally high 
levels of aldosterone as a consequence of estrogen deficiency exhibit detrimental effects on the progression 
of CVD. 
It is rational to propose that normalizing of aldosterone levels in BC patients under treatment of aromatase 
inhibitors should be a promising strategy to manage the accompanying CVD125. As CYP11B2, a member of 
the same CYP superfamily as CYP19, is the key enzyme in aldosterone biosynthesis catalyzing the terminal 
step, dual inhibition of CYP11B2 and CYP19 should be superior to reduce aldosterone levels and thus to 
improve the overall survival of BC patients.  
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2 Aim and Scope of the Work 
Since steroidogenic CYP enzymes are closely associated with severe diseases, they are considered as 
promising targets. As discussed in the introduction, inhibition of CYP11B2 can be used for the treatment of 
cardiovascular diseases caused by abnormally high aldosterone concentrations, while inhibition of CYP19 is 
an important treatment for breast cancer, and CYP11B1 inhibition is regarded as a good pharmaceutical 
therapy for patients with Cushing’s syndrome. 
2.1 CYP11B2 Inhibitors 
Currently, two main therapies are clinically employed to suppress the components of RAAS, including 
ACE inhibitors and MR antagonists for the treatment of patients with hypertension, and / or congestive heart 
failure. In order to overcome the drawbacks of these two therapies, such as “aldosterone escape” by ACE 
inhibitors and hyperkalemia by MR antagonists, respectively, selective CYP11B2 inhibitors are proposed to 
be a new approach. Due to the homology among members of CYP enzymes, selectivity is regarded as a 
challenge in order to avoid side effects caused by interaction with other steroidogenic CYP enzymes like 
CYP11B1, CYP17 and CYP19 as well as important hepatic enzymes such as CYP1A2. In section 3.I and 3.II, 
novel potent and selective CYP11B2 inhibitors have to be designed, synthesized and evaluated.  
2.2 CYP19 / 11B2 Dual Inhibitors 
The application of aromatase inhibitors to post-menopausal breast cancer patients increases the risk of 
cardiovascular diseases, which is believed to be caused by the estrogen deficiency and mediated to a large 
extent through abnormally high concentration of aldosterone. Dual inhibitors of CYP19 and CYP11B2 are 
therefore proposed as a novel therapy for an adjuvant therapy to reduce the CVD risk for these patients. 
Although the homology among CYP superfamily often leads to a challenge of selectivity, it renders the 
possibility of dual inhibition. In section 3.III, potent and selective dual CYP19 / CYP11B2 inhibitors are 
developed.  
2.3 CYP11B1 Inhibitors 
Apart from surgical therapy to remove some adrenal or pituitary tumors, CYP11B1 inhibition as a 
pharmaceutical approach to block cortisol biosynthesis is an important alternative in the treatment of 
Cushing’s syndrome. Although several unselective CYP11B1 inhibitors are employed clinically, they are 
accompanied by severe side effects. This situation of absence of effective and safe therapy for the treatment 
of Cushing’s syndrome encourages us to look for more potent and more selective CYP11B1 inhibitors. In 
section 3.IV, novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones as 
potent and selective CYP11B1 inhibitors are designed, synthesized and tested. 
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3 Results and Discussions 
The design, syntheses and bio-evaluation of CYP11B2 inhibitors, dual inhibitors CYP19 / 11B2 as well as 
CYP11B1 are described in detail in the following: 
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3.I. 3-Pyridinyl Substituted Aliphatic Cycles as 
CYP11B2 Inhibitors: Increased Selectivity over 
CYP1A2 by Dearomatisation of the Core 
 
Introduction 
Cardiovascular diseases are the leading cause of death in the United States and the majority of the 
European countries. Some forms of hypertension, congestive heart failure (CHF) and myocardial fibrosis 
(MF) are closely associated with high aldosterone levels.[1–3] Phisiological aldosterone concentrations are 
crucial for the regulation of electrolyte and volume homeostasis. After binding to mineralocorticoid receptors 
(MR), aldosterone promotes the retention of sodium and water at the expense of potassium excretion, 
subsequently resulting in the increase of blood volume and hypertension. Moreover, high aldosterone levels 
also stimulate synthesis and accumulation of collagens in cardiac fibroblasts leading to MF. The resulting 
increase in myocardial stiffness causes diastolic dysfunction and ultimately heart failure.[3] 
Therefore, deprivation of aldosterone from its pathological effects is a feasible therapeutic approach to 
treat the related diseases. Currently, two main pharmacotherapies are clinically implemented to suppress the 
components of the renin-angiotesin-aldosterone system (RAAS), which controls the secretion of aldosterone 
via a negative feedback loop, including angiotensin-converting-enzyme (ACE) inhibitors such as enalapril 
(Figure 1) and MR antagonists like spironolactone and eplerenone (Figure 1). ACE inhibitors are used for the 
treatment of hypertension and CHF by down-regulation of angiotensin II and subsequent aldosterone 
secretion. However, long-term suppressive effects of ACE inhibitors on plasma aldosterone levels are 
weakened due to the phenomenon known as “aldosterone escape”.[5, 6] Although clinical studies revealed that 
blockade of MR by spironolactone has reduced the risk of both morbidity and mortality in patients with 
severe heart failure, the MR antagonists show severe adverse effects such as gynaecomastia or breast pain 
due to their steroidal structure exhibiting a residual affinity to other steroid receptors.[7] Despite the fact that 
eplerenone as a selective MR antagonist achieves some improvement in terms of side effects as compared to 
spironolatone, severe hyperkalemia and less potency have been reported.[8] Furthermore, treatment with MR 
antagonists leaves high levels of aldosterone unaffected,[9] which can result in further exacerbation of heart 
function in a MR independent nongenomic manner.[10] CYP11B2 is a mitochondrial cytochrome P450 
enzyme catalyzing the conversion of 11-deoxycorticosterone to aldosterone in three consecutive steps 
(Scheme 1).[11] Its inhibition was proposed as a new strategy for the treatment of aldosterone related 
cardiovascular diseases as early as 1994.[12] Recent in vivo studies in rats have demonstrated that CYP11B2 
inhibitors can reduce plasma aldosterone levels.[13, 14] Long-term administration of FAD286 (R-enantiomer of 
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fadrozole, Figure 1) to rats with heart failure improves cardiac haemodynamics and cardiac function, which 
is more significant than those by spironoloactone.[15]. However, FAD286 also shows strong inhibition of 
CYP11B1 and CYP19, thus urging us to design selective CYP11B2 inhibitors. 
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Figure 1. Structures of ACE inhibitor Enalapril, MR antagonists Spironolactone and Eplerenone, CYP11B2 
inhibitor Fadrozole and aromatase inhibitor Exemestane. 
Our group has designed and synthesized several series of CYP11B2 inhibitors.[16] These compounds not 
only exhibited potent inhibition toward CYP11B2, but also showed good selectivity over CYP11B1, which 
is the key enzyme involved in the glucocorticoid biosynthesis. This selectivity is very difficult to achieve due 
to the high homology up to 93% between these enzymes. However, some of these potent compounds showed 
strong inhibition of CYP1A2, which is probably due to the planar aromatic structure of the molecules. 
Therefore, in this study the Dearomatisation of the core was performed to improve the CYP1A2 selectivity 
leading to a series of 3-pyridinyl substituted aliphatic cycles 1 – 21. The percent inhibition and IC50 values of 
the inhibitors for CYP11B2 and CYP11B1 are presented in comparison to fadrozole. Inhibition of CYP1A2 
was tested for potent and selective compounds 2, 4, 7, 8 and 10. 
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Scheme 1. Biological synthesis of aldosterone catalyzed by CYP11B2. 
Inhibitor Design Concept 
In the last few years, a wide range of compounds were designed as CYP11B2 inhibitors[16] based on the 
mechanism that an inhibitor sp2 hybrid N coordinates to the heme iron located in the protoporphyrin center 
of the enzyme. This mechanism was first identified for aromatase inhibitors,[17] but subsequently was proven 
to be valid for inhibitors of other steroidogenic enzymes such as CYP17.[18] Since all cytochrome P450 (CYP) 
enzymes, not only steroidogenic but also hepatic CYPs, consist of a heme as the catalyzing unit, they are 
potential targets of inhibitors acting through this mechanism. Therefore, it is crucial to develop CYP11B2 
inhibitors exhibiting selectivity toward these enzymes, especially CYP11B1 which shows a homology of 
approximately 95% to the target enzyme. Another focus of selectivity is hepatic CYP enzymes due to their 
important roles in the metabolism of drugs and xenobiotics. Our previously designed inhibitors are quite 
potent toward CYP11B2 and very selective over CYP11B1, however, their selectivity toward CYP1A2 still 
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needs to be improved. CYP1A2, which accounts for approximately 13% of totally expressed CYP450 
enzymes in the liver, is responsible for metabolizing neutral or basic planar substances.[19] Since the 
heterocycles providing the sp2 hybrid N must not be modified, the key to selectivity lies in the hydrophobic 
core. After we had seen that partial dearomatisation of naphthalene compound I[16e] (Figure 2), showing a 
strong CYP1A2 inhibition of 98% at a concentration of 2 µM (Table 3), resulted in a decrease in CYP1A2 
inhibition (compounds II[16a] and III[16c], 80 and 73%, respectively), but did not change high inhibitory 
potency toward CYP11B2 and good selectivity against CYP11B1, we wanted in more detail to investigate 
these relationships. In the following we describe the influence of structural modifications of the core 
structure regarding aromaticity, planarity, structural flexibility/rigidity, cycle size, presence of H-bond 
forming groups and removal of bridge bonds on activity (CYP11B2) and selectivity (CYP11B1 and 
CYP1A2). 
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Figure 2. Inhibitors design. 
Results and Discussion 
Chemistry 
The synthetic strategy employed is shown in Scheme 2–5. The triflation[20] of the starting ketone 
compounds using trifluoromethanesulfonic anhydride and 2,6-di-tert-butyl-4-metyhylpyridine gave 
corresponding enol triflates. These were then coupled with 3-pyridyl boronic acid leading to the 
corresponding products with an α-double bond (2, 7, 11, 13, 15, 18 and 20). The subsequent hydrogenation 
catalyzed by Pd / C was used to reduce the α-double bond and thereby to yield the saturated compounds (1, 
3, 8, 12, 14, 16, 19 and 21). Several interesting points need to be addressed: 1b obtained from the triflation of 
octahydronaphthalen-2(1H)-one was a mixture of two isomers with Δ 1, 2- or Δ 2, 3- double bond, 1 
equivalent of trifluoromethanesulfonic anhydride needed to be strictly controlled in the triflation of diones 
2b and 7b, which were converted to the respective ketones 2, 3, 7 and 8 following the general strategy 
described above. The latter were then reduced to the hydroxy compounds 5, 6, 9 and 10 using NaBH4. 
Compound 3 underwent Wittig reaction to provide compound 4. As for asymmetric (±) 9-methyl-5(10)-
octaline-1,6-dione, the triflation occured selectively in 6-position with the rearrangement of the conjugated 
double bonds[21] resulting in 17a, which after Suzuki coupling led to 17. Compound 21 was obtained as an 
endo / exo mixture in a ratio of 5:1, which was tested without further separation. 
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Scheme 2 a 
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a Reagents and conditions: a) Method A: Tf2O, CH2Cl2, 2,6-Di-tert-butyl-4-methylpyridine, 2 h; b) Method B: Pd(PPh3)4, Pyridine-
3-boronic acid, Na2CO3, DME, H2O, 90 °C, 2 h; c) Method C: 5% Pd / C, MeOH, H2, RT, 2 d. 
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a Reagents and conditions: a) Method A: Tf2O, CH2Cl2, 2,6-Di-tert-butyl-4-methylpyridine, 2 h; b) Method B: Pd(PPh3)4, Pyridine-
3-boronic acid, Na2CO3, DME, H2O, 90 °C, 2 h; c) Method C: 5% Pd / C, MeOH, H2, RT, 2 d. d) Method D: NaBH4, MeOH, RT, 2 
h; e) CH3PPh3Br, n-BuLi, THF, 30 min at -78 °C, 2 h at RT, f) BH3-THF, 3M NaOH, 35% H2O2, THF, g) PCC, CH2Cl2, reflux 2 d. 
2 
Scheme 4 a 
O
O
TfO
N
O
a) b)
1717a
O
 
a Reagents and conditions: a) Method A: Tf2O, CH2Cl2, 2,6-Di-tert-butyl-4-methylpyridine, 2 h; b) Method B: Pd(PPh3)4, Pyridine-
3-boronic acid, Na2CO3, DME, H2O, 90 °C, 2 h. 
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Scheme 5 a 
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18a, 18b, 18, 19: m = 1; X = C; R = H
20a, 20b, 20, 21: m = 2; X = N; R = Me  
a Reagents and conditions: a) Method A: Tf2O, CH2Cl2, 2,6-Di-tert-butyl-4-methylpyridine, 2 h; b) Method B: Pd(PPh3)4, Pyridine-
3-boronic acid, Na2CO3, DME, H2O, 90 °C, 2 h; c) Method C: 5% Pd / C, MeOH, H2, RT, 2 d. 
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CYP11B1 and CYP11B2 inhibition 
The synthesized compounds were tested for their inhibitory potencies against CYP11B2 and CYP11B1 
with V79 MZh cells expressing the respective enzymes.[22] The results are presented in Table 1 with 
Fadrozole as a reference, which showed strong inhibition of these two enzymes with IC50 values of 0.8 and 
6.3 nM toward CYP11B2 and CYP11B1, respectively. 
Intermediate 1a, as a mixture of two isomers with the double bond at different positions, exhibited 96% 
inhibition of CYP11B2 at 500 nM and selectivity toward CYP11B1 with around 50% inhibition at the same 
concentration. However, these isomers could not be separated. Intermediate. After hydrogenation of 
compound 1a to abondon isomery, the resulting saturated analogue 1, however, showed decreased inhibitory 
potency of 76% against CYP11B2, but similar inhibition of CYP11B1 (55% at 500 nM). This result 
indicates the importance of the double bond to inhibitory potency and selectivity. To further investigate this 
phenomenon, ring size was reduced to avoid double bond isomery and a series of octahydropentalene 
analogues furnished with oxo, hydroxy or methylene was synthesized. Possessing an oxo group, the double 
bond analogue 2 exhibited an IC50 value of 34 nM and a selectivity factor of 8, whereas the corresponding 
saturated compound 3 was weaker (66%) and showed no selectivity. A similar result was observed for the 
hydroxy analogues 5 and 6. The saturated hydroxy analogue 6 even showed preference for CYP11B1 (79%). 
Moreover, since exemestane with an exocyclic double bond can covalently bind to CYP enzymes to inhibit 
the enzyme in an irreversible manner[23] (Figure 1), which is an aromatase inhibitor in clinical use for the 
treatment of breast cancer, a methylene group was introduced into the molecule to increase the binding 
affinity. As expected, compound 4 turned out to be the most potent inhibitor in this study with an IC50 value 
of 6 nM and a selectivity factor of 34. The good selectivity over CYP11B1 indicates that this methylene 
rather specifically binds to amino acid residues present in CYP11B1. 
Furthermore, to achieve more flexibility, the bridge bond was removed, resulting in a series of medium 
size cycles. When substituted by similar hydrogen bond forming groups such as oxo or hydroxy, the 
resulting compounds exhibited different activity profile patterns compared to the corresponding bridge 
compounds. For the ketone analogues 7 and 8, the activities were slightly reduced, while the selectivities 
were maintained or even improved. Nevertheless, the hydroxy analogue with a double bond 9 showed an 
increased activity of 78% against CYP11B2, but the inhibition toward CYP11B1 also increased accordingly 
to 59%, leading to a deterioration of selectivity. On the contrary, the saturated compound 10 exhibited 
similar inhibitory potency (63%) of CYP11B2 but no selectivity. A similar structure activity relationship was 
observed for the compounds furnished with a hydrogen bond forming group (ketone or hydroxy). Regardless 
of the presence of the bridge bond, the analogues with double bond were always more potent and selective 
than the corresponding saturated analogues. 
Moreover, the influence of the ring size on the inhibitory potency and selectivity was also investigated. It 
can be seen that the cyclodecane analogues, 13 and 14 showed inhibitory potency with IC50 values around 20 
nM, regardless of the presence of the double bond. Nevertheless, the double bond analogue 13 was less 
selective compared to the saturated compound 14 (selectivity factor of 12 vs. 40 for compound 13 and 14, 
respectively). After the ring size was reduced from cyclodecane to cyclooctane, the activity was slightly 
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increased. The saturated compound 12 turned out to be very potent (IC50 = 21 nM), and this compound was  
Table 1. Inhibition of human CYP11B1 and CYP11B2 by compounds 1–21. 
N
R
1 - 21  
% inhibition [a] IC50 (nM) [b] 
Compd R CYP 11B2 
[c] 
CYP 11B1 
[d] 
CYP 11B2 
[c] 
CYP 11B1 
[d] 
S. F. [e] 
1 
 
76 55 n.d. n.d. n.d. 
2 O
H
H  
79 46 34 282 8 
3 O
H
H  
66 62 n.d. n.d. n.d. 
4 
H
H
H
H
 
89 59 6 205 34 
5 HO
H
H  
69 43 n.d. n.d. n.d. 
6 HO
H
H  
69 79 n.d. n.d. n.d. 
7 O
 
69 37 n.d. n.d. n.d. 
8 O
 
53 27 n.d. n.d. n.d. 
9 HO
 
78 59 n.d. n.d. n.d. 
10 HO
 
63 67 n.d. n.d. n.d. 
11 
 
86 72 n.d. n.d. n.d. 
12 
 
90 30 21 1047 50 
13 
 
82 44 21 258 12 
14 
 
84 45 22 872 40 
15 
 
30 4 n.d. n.d. n.d. 
16 
 
44 22 n.d. n.d. n.d. 
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% inhibition [a] IC50 (nM) [b] 
Compd R CYP 11B2 
[c] 
CYP 11B1 
[d] 
CYP 11B2 
[c] 
CYP 11B1 
[d] 
S. F. [e] 
17 
O  
52 33 n.d. n.d. n.d. 
18 
 
36 19 n.d. n.d. n.d. 
19 
 
76 75 n.d. n.d. n.d. 
20 
N
 
17 10 n.d. n.d. n.d. 
21 
N
 
15 5 n.d. n.d. n.d. 
Fadrozole    0.8 6.3 8.3 
[a] Mean value of at least two experiments, standard deviation usually less than 10%; inhibitor concentration, 500 nM. [b] Mean value 
of at least four experiments, relative standard deviation usually less than 25%; n.d. = not determined. [c] Hamster fibroblasts 
expressing human CYP11B2; substrate deoxycorticosterone, 100 nM. [d] Hamster fibroblasts expressing human CYP11B1; substrate 
deoxycorticosterone, 100 nM. [e] IC50 CYP11B1/IC50 CYP11B2; n.d. = not determined. 
also the most selective inhibitor throughout this study. The increase of the ring size to cyclododecane was 
not tolerated; the inhibitory activity of resulting compounds 15 and 16 was significantly reduced to less than 
45%. Remarkably, the influence of the double bond in this case is totally contrary to that of compounds with 
hydrogen bond forming groups. These reverse effects are most likely a consequence of the different 
orientations of the compounds in the enzyme active site pocket. Comparing among compounds 7–12, it can 
be observed that the introduction of hydrogen bond forming groups (ketone or hydroxy always decreased 
inhibitory potency toward CYP11B2.With the intention of mimicking the natural substrate of CYP11B2, the 
unsaturated decalone analogue 17 was synthesized. However, only modest inhibition (52%) was observed. 
The attempt to rigidify the core structure with a one-atom bridge (C or N) resulted in compounds 18–21. 
When the bicyclo[2.2.1]heptane core was bearing the double bond, the resulting compound 18 showed only 
36% of inhibition of CYP11B2. Nevertheless, the saturated compound 19 was much more potent (76%), but 
not selective. However, for the [3.2.1] aza-bicycle analogues a total loss of activity was observed probably as 
a consequence of the bulky bicycle core that was not tolerated. 
CYP1A2 inhibition 
With the aim of overcoming a common disadvantage of naphthalene or partially saturated naphthalene 
type CYP11B2 inhibitors –– high CYP1A2 inhibition –– this series of 3-pyridinyl substituted cycloaliphatic 
compounds, which are completely non-aromatic, were designed and synthesized. The five most potent 
CYP11B2 inhibitors with good CYP11B1 selectivity 2, 4, and 12–14 were selected to determine CYP1A2 
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inhibition (Table 2). As expected, all compounds exhibited significant improvement of selectivity toward 
CYP1A2 compared to the parent compounds I–III. It is striking that compounds 2, 12 and 13 showed no 
inhibition at all at the concentration of 2 µM, whereas compound 14 with a decane cycle exhibited weak 
inhibition (17%). In contrast to the exo compounds 2 showing no CYP1A2 inhibition, the methylene 
analogue 4 showed moderate inhibition of 56%.This might be probably due to the exocyclic double bond 
being oxidized and activated by this monooxygenase to bind subsequently to the active site of the protein in 
a covalent manner. It is now clearly demonstrated that dearomatisation of the lipophilic core significantly 
increased the selectivity toward hepatic enzyme CYP1A2. 
Table 2. Inhibition of human hepatic enzyme CYP1A2 by selected compounds. 
Compd % inhibition CYP1A2 [a] Compd % inhibition CYP1A2 [a] 
I 98 4 56 
II 80 12 0 
III 73 13 0 
2 0 14 17 
[a] Recombinantly expressed enzyme from baculovirusinfected insect microsomes (Supersomes); inhibitor concentration, 2.0 μM; 
furafylline, 55% inhibition. 
 
Conclusion 
In this study, 21 analogues of 3-pyridinyl substituted aliphatic cycles were designed, synthesized and 
biologically evaluated as CYP11B2 inhibitors. Although the design conception was mainly focused on the 
improvement of CYP1A2 selectivity, these compounds exhibited potent inhibition of CYP11B2 and good 
selectivity over CYP11B1. Compounds 2, 4, 12, 13 and 14 showed IC50 values ranging from 6 to 34 nM, 
whereby compound 4 is the most potent one ( IC50 = 6 nM) and  compound 12 is the most selective one (SF 
= 50). It has been demonstrated that an α-double bond in analogues with a H-bond forming groups in 
medium size cycles promoted inhibitory activity and selectivity, whereas deterioration was observed for 3-
pyridinyl substituted medium size cycles without H-bond forming groups. Surprisingly, the presence of H-
bond forming groups reduced inhibitory potency probably due to the binding mode alternation when these 
groups interacted with some amino acid residues. After removal of bridge bond, higher flexibility was 
obtained. Yet, this did not show significant influence. Moreover, the introduction of methylene as a potential 
interacting center increased not only CYP11B2 inhibition as expected, but also the undesired CYP1A2 
inhibition. Bulk limitation was also observed. Flexible 8 to 10 membered medium or bicyclic rings are 
appropriate, whereas flexible 12-membered ring or rigid bicyclic analogues are too bulky to be tolerated. 
Furthermore, the design concept employed in this study, i.e. Dearomatisation of the lipophilic core and 
destruction planarity configuration to reduce CYP1A2 inhibition, was proven successful. For the five most 
potent and selective CYP11B2 inhibitors in this study, the CYP1A2 inhibition was significantly reduced 
compared to their aromatic precursors. Among them, compounds 2, 12 and 13 showed no inhibition at 2 µM. 
Since selectivity against hepatic CYP enzymes is always a key issue for safety reasons associated with drug 
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discovery, this task is occasionally challenging, especially in the CYP enzyme inhibitors field. The design 
concept demonstrated in this study would be helpful in the optimization of steroidogenic CYP inhibitors 
aimed at improvement of selectivity toward CYP1A2. 
As it is known that fluorine compounds are more stable in vivo than hydroxy compounds, R1 was 
sustained to be fluorine and the influence of substituents at the methylene bridge was further investigated 
(Table 3). Interestingly, the single ethyl group turned out to be the best, while twin alkyl substituted 
analogues (24–25) showed lower inhibitory potency than their single substituted analogues (23, Ref. 2). This 
is obviously due to the steric clashes with amino acids of the I-helix kink and the reduced flexibility of these 
ligands. Moreover, the similar activity of compound 27 (2-chloroethyl, IC50 = 756 nM) and compound 2 (n-
Pr) and the total loss of activity for the 2-hydroxylethyl analogue (26) demonstrate the necessity of a 
hydrophobic side chain on the methylene bridge. 
Experimental Section 
Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human CYP11B1 or CYP11B2 were incubated with [14C]-11-
deoxycorticosterone as substrate. The assay was performed as previously described.[22] 
Inhibition of human hepatic CYP enzymes 
The recombinantly expressed enzymes from baculovirus-infected insect microsomes (Supersomes) were 
used and the assay was performed according to the manufacturer’s instructions (www.gentest.com). 
Chemistry 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra 
were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a 
Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an 
internal standard for spectra obtained in CDCl3. All coupling constants (J) are given in Hz. ESI (electrospray 
ionization) mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. 
High-resolution mass spectra were measured using an LTQ Orbitrap (Thermo Electron Corporation) with 
positive ESI. The purities of the final compounds were controlled by Surveyor®-LC-system. Purities were 
greater than 98%. Column chromatography was performed using silica-gel 60 (50-200 µm), and reaction 
progress was determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Ketones and 
precursors of ketones used as starting materials were commercially obtained (Aldrich, Acros, Merck, Alfa 
Aesar, etc.). 
Method A: Triflation 
To a solution of 2,6-di-tert-butyl-4-methylpyridine (7.23 mmol) and the corresponding ketone (6.57 mmol) 
in CH2Cl2 (20 mL) was added trifluoromethanesulfonic anhydride (7.16 mmol) dropwise at 0 °C under 
nitrogen. A white precipitate was formed soon. The reaction mixture was warmed to room temperature and 
further stirred for 4 h. The solvent was removed in vacuo, and the resulting residue was diluted with 
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petroleum ether (20 mL). After removal of the solid by filtration, the filtrate was concentrated in vacuo to 
give a crude product which was used in the next step without further purification. 
Method B: Suzuki coupling 
A suspension of enol triflate (4.56 mmol), pyridine-3-boronic acid (5.92 mmol), sodium carbonate (22.8 
mmol) and tetrakis(triphenylphosphine)palladium (0) (0.23 mmol) in dimethoxyethanol (45 mL) and water 
(15 mL) was stirred at 90 °C under nitrogen for 2 h. The reaction mixture was cooled to room temperature 
naturally and diluted with water (10 mL). The aqueous layer was extracted with ethyl acetate (2 x 30 mL) 
and the combined organic layers were washed with brine twice and dried over MgSO4. After evaporation in 
vacuo, the resulting residue was purified by flash chromatography to afford the corresponding product. 
Method C: Hydrogenation 
A mixture of 3-pyridyl derivative with an α-double bond (0.50 mmol) and 5% Pd/C (45 mg) in methanol 
(15 mL) was flushed with hydrogen for 2 d at room temperature The mixture was filtered through a Celite 
cake and concentrated in vacuo to afford the corresponding product. 
Method D: Sodium borohydride reduction 
To a solution of a ketone (0.25 mmol) in methanol (5 mL) was added sodium borohydride (0.50 mmol) at 
room temperature The reaction was stirred for 4 h. After removal of MeOH in vacuo, the residue was eluted 
with water (5 mL) and then extracted with ethyl acetate (3 × 5 mL). The combined organic layers were 
washed with brine, dried over MgSO4 and concentrated in vacuo. The residue oil was purified by flash 
chromatography to give the title alcohol. 
3-(Decahydro-naphthalen-2-yl)-pyridine (1): The title compound was synthesized according to Method 
C using 1a (300 mg, 1.41mmol) and 5% Pd/C (45 mg) in methanol (15 mL) to give a pale yellow oil (257 
mg, 85%): Rf = 0.45 (EtOAc/PE,1:5); 1H-NMR (500 MHz, CDCl3): δ = 8.48 (d, J = 2.1 Hz, 1H), 8.42 (dd, J 
= 1.5, 4.8 Hz, 1H), 7.53 (dt, J = 1.9, 7.8 Hz, 1H), 7.20(dd, J = 4.8, 7.8 Hz, 1H), 2.57 (m, 1H),1.23–1.90 ppm 
(m, 16 H). 13C-NMR (125 MHz, CDCl3): δ = 149.0, 147.3, 142.8, 134.0, 123.2, 42.5, 36.4, 35.2,  33.5, 32.5, 
32.2, 28.2, 27.0, 25.8, 20.9 ppm; IR: ν˜ = 2920, 2856, 1423, 1024, 802, 714, 622 cm–1; MS (ESI) m/z = 216 
[M+H]+; HRMS: m/z [M+H]+ calcd for C15H21N: 216.1752, found: 216.1744. 
5-Pyridin-3-yl-3,3a,4,6a-tetrahydro-1H-pentalen-2-one (2): The title compound was synthesized 
according to Method B using 2a (290 mg, 1.07 mmol ), pyridine-3-boronic acid (170 mg, 1.39 mmol), 
sodium carbonate (567 mg, 5.35 mmol) and tetrakis (triphenylphosphine)palladium (0) (61 mg, 0.05 mmol) 
in dimethoxyethanol  (9 mL) and water (3 mL) to give a pale yellow oil (180 mg, 84%) after purification by 
flash chromatography (EtOAc/n-hexane,1:1): Rf = 0.19 (EtOAc/PE,2:1); 1H-NMR (500 MHz, CDCl3): δ = 
8.67 (d, J = 1.9 Hz, 1H), 8.48 (dd, J = 0.9, 4.7 Hz, 1H), 7.68 (dt, J = 1.9, 7.9 Hz, 1H), 7.24 (dd, J = 4.7, 7.9 
Hz, 1H) , 6.14 (m, 1H), 3.63 (m, 1H), 3.09–3.19 (m, 2H), 2.51–2.64 (m, 3H), 2.34 (d, J = 18.8 Hz, 1H), 2.09 
ppm (dd, J = 7.4, 19.0 Hz, 1H); 13C-NMR (125 MHz, CDCl3): δ = 219.0, 148.6, 147.3, 139.3, 132.8, 131.4, 
130.6, 123.2, 46.9, 44.9, 42.6, 40.3, 37.3 ppm; IR: ν˜ = 2904, 2360, 1733, 1567, 1486, 1424, 1411, 1324, 
1158, 1119, 1023, 871, 813, 789, 705, 620 cm–1; MS (ESI) m/z = 200 [M+H]+. 
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5-Pyridin-3-yl-hexahydro-pentalen-2-one (3): The title compound was synthesized according to Method 
C using 2 (100 mg, 0.50 mmol) and 5% Pd/C (15% wt) in methanol (10 mL) to give a colorless oil (82 mg, 
82%): Rf = 0.14 (EtOAc/PE,2:1); 1H-NMR (500 MHz, CDCl3): δ = 8.48 (s, 1H), 8.44 (d, J = 3.4 Hz, 1H), 
7.52 (dt, J = 1.7, 7.9 Hz, 1H), 7.22 (dd, J = 4.8, 7.8 Hz, 1H), 3.13–3.20 (sept, J = 6.8 Hz, 1 H), 2.82–2.91 (m, 
2H), 2.55–2.61 (m, 2 H , 2.51–2.46 (m, 2H), 2.12–2.17 (dd, J = 4.2, 19.3 Hz, 2H), 1.44–1.50 ppm (m, 2H); 
13C-NMR (125 MHz, CDCl3): δ = 148.9, 147.7, 139.1, 134.0, 123.4, 44.6, 44.2, 41.9, 39.2 ppm; IR: ν˜ = 
2949, 1733, 1575, 1427, 1169, 1025, 805, 716 cm–1; MS (ESI) m/z = 202 [M+H]+; HRMS: m/z [M+H]+ 
calcd for C13H16NO: 202.1232, found: 202.1217. 
3-(5-Methylene-1,3a,4,5,6,6a-hexahydro-pentalen-2-yl)-pyridine (4): To a suspension of 
methyltriphenylphosphonium bromide (897 mg, 2.51 mmol) in THF (10 mL) was added a solution of n-BuLi 
in hexane (2.5 M, 1 mL, 2.50 mmol) at –78 °C under N2. Subsequently, the reaction was stirred at room 
temperature for 3 h followed by cooling the reaction mixture to –78 °C. A solution of 2 (100 mg, 0.50 mmol) 
in THF (2 mL) was added slowly. The reaction was allowed to be warmed to room temperature and stirred 
for 24 h. A saturated aqueous solution of NH4Cl (3 mL) was added to quench and the resulting mixture was 
extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with brine (2 x 20 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (AcOEt/n-
hexane, 1:10) to give 4 as a colorless oil (72 mg, 73%): Rf = 0.44 (EtOAc/PE,1:1); 1H-NMR (500 MHz, 
CDCl3): δ = 8.66 (s, 1H), 8.44 (s, 1H), 7.66 (dt, J = 1.8, 7.8 Hz, 1H) , 7.21 (dd, J = 4.8, 7.8 Hz, 1H), 6.09 (q, 
J = 2.1 Hz, 1H), 4.79 (q, J = 1.8 Hz, 1H), 4.77 (q, J = 1.8 Hz, 1H), 3.42 (m, 1H) , 2.90–3.00 (m, 2H), 2.54–
2.65 (m, 2H), 2.49 (m, 1H), 2.25 (m, 1H), 2.10 ppm (m, 1H); 13C-NMR (125 MHz, CDCl3): δ = 152.2, 148.0, 
147.3, 138.1, 132.7, 132.0, 131.8, 123.1, 105.6, 50.7, 41.4, 40.5, 40.4, 38.2 ppm; IR: ν˜ = 2940, 2843, 1566, 
1474, 1411, 1311, 1186, 1023, 880, 796, 706, 620 cm–1; MS (ESI) m/z = 198 [M+H]+; HRMS: m/z [M+H]+ 
calcd for C14H16N: 198.1283, found: 198.1274. 
5-Pyridin-3-yl-1,2,3,3a,4,6a-hexahydro-pentalen-2-ol (5): The title compound was synthesized 
according to Method D using 2 (50 mg, 0.25 mmol), sodium borohydride (19 mg, 0.50 mmol) in MeOH (5 
mL) to give a pale yellow crystal (32 mg, 64%) after purification by flash chromatography (MeOH/CH2Cl2, 
1:30). Rf = 0.18 (MeOH/ CH2Cl2,1:20); mp: 110–112 °C; 1H-NMR (500 MHz, CDCl3): δ = 8.37 (d, J = 1.6 
Hz, 1H), 8.44 (dd, J = 1.1, 4.7 Hz, 1H), 7.68 (dt, J = 1.9, 7.9 Hz, 1H), 7.22 (ddd, J = 0.4, 4.7, 7.9 Hz, 1 H), 
6.24 (q, J = 2.1 Hz, 1H), 4.25 (quin, J = 5.7 Hz, 1H), 3.32–3.38 (m, 1H),  3.01–3.07 (ddt, J = 2.1, 9.3, 16.2 
Hz, 1H), 2.83–2.90 (tquin, J = 2.4, 9.0 Hz, 1H), 2.62–2.67 (dq, J = 2.4, 16.2 Hz, 1H), 2.23 (m, 1H), 2.14 (m, 
1H), 1.75 (s, br, 1H), 1.52–1.62 ppm (m, 2H); 13C-NMR (125 MHz, CDCl3): δ = 148.1, 147.3, 137.3, 132.8, 
132.4, 132.0, 123.2, 74.6, 49.7, 43.9, 40.7, 38.5 ppm; IR: ν˜ = 3221, 2957, 2929, 1444, , 1344, 1088, 1041, 
810, 711, 629 cm–1; MS (ESI) m/z = 202 [M+H]+; HRMS: m/z [M+H]+ calcd for C13H16NO: 202.1232, found: 
202.1223. 
5-Pyridin-3-yl-octahydro-pentalen-2-ol (6): The title compound was synthesized according to Method D 
using 3 (40 mg, 0.22 mmol), sodium borohydride (15 mg, 0.40 mmol) in MeOH (5 mL) to give a pale yellow 
semisolid (30 mg, 74%) after purification by flash chromatography (MeOH/CH2Cl2, 1:30). Rf = 0.17 
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(MeOH/CH2Cl2, 1:20); 1H-NMR (500 MHz, CDCl3): δ = 8.47 (d, J = 2.3 Hz, 1H), 8.39 (dd, J = 1.6, 4.8 Hz, 
1 H), 7.55 (dt, J = 1.8, 7.9 Hz, 1H), 7.18 (dd, J = 4.8, 7.9 Hz, 1H), 4.38 (quin, J = 5.6 Hz, 1 H), 2.97–3.04 
(sept, J = 6.1 Hz,, 1H), 2.53–2.75 (m, 2 H), 2.27–2.35 (m, 2H), 2.18 (s, br, 1H), 2.03–2.09 (m, 2H), 1.61–
1.68 (m, 2H), 1.52–1.56 ppm (m, 2H); 13C-NMR (125 MHz, CDCl3): δ = 148.9, 147.2, 139.8, 134.3, 123.2, 
76.5, 45.9, 42.7, 42.0 ppm; IR: ν˜ = 3318, 2936, 1578, 1426, 1097, 1027, 983, 713, 625 cm–1; MS (ESI) m/z 
= 204 [M+H]+; HRMS: m/z [M+H]+ calcd for C13H18NO: 204.1388, found: 204.1379. 
5-Pyridin-3-yl-cyclooct-4-enone (7): The title compound was synthesized according to Method B using 
7a (103 mg, 0.38 mmol), pyridine-3-boronic acid (60 mg, 0.49 mmol), sodium carbonate (200 mg, 1.89 
mmol) and tetrakis(triphenylphosphine) palladium (0) (22 mg, 0.02 mmol) in dimethoxyethanol (6 mL) and 
water (2 mL) to give a pale yellow oil (50 mg, 65%) after purification by flash chromatography (EtOAc/n-
hexane,1:5). Rf = 0.21 (EtOAc/PE, 2:1); 1H-NMR (500 MHz, CDCl3): δ = 8.58 (d, J = 1. 7 Hz, 1H), 8.46 (d, 
J = 4.7 Hz, 1H), 7.60 (dt, J = 1.7, 7.9 Hz, 1H), 7.21 (dd, J = 4.7, 7.9 Hz, 1H) , 6.06 (m, 1H), 2.60–2.65 (m, 
6H), 2.51 (m, 2H), 1.71–1.76 ppm (m, 2H); 13C-NMR (125 MHz, CDCl3): δ = 212.3, 146.7, 145.9, 137.2, 
136.5, 131.7, 127.4, 121.6, 45.6, 38.7, 28.3, 21.9, 21.8 ppm; IR: ν˜ = 2934, 1703, 1471, 1412, 1337, 1110, 
892, 803, 712, 618 cm–1; MS (ESI) m/ = 202 [M+H]+; HRMS: m/z [M+H]+ calcd for C13H16NO: 202.1232, 
found: 202.1224. 
5-Pyridin-3-yl-cyclooctanone (8): The title compound was synthesized according to Method C using 7 
(87 mg, 0.43 mmol) and 5% Pd/C (13 mg) in methanol (10 mL) to give a colorless oil (60 mg, 69%) after 
purification by flash chromatography (EtOAc/n-hexane,1:2). Rf = 0.21 (EtOAc/PE, 2:1); 1H-NMR (500 MHz, 
CDCl3): δ = 8.40 (d, J = 4.7 Hz, 1H); 8.37 (s, 1H), 7.40(dt, J = 1.9, 7.9 Hz, 1H), 7.17 (dd, J = 4.7, 7.9 Hz, 
1H), 2.64–2.69 (m, 2H), 2.34–2.40 (m, 3H) , 2.13–2.21 (m, 2H), 1.81–1.90 ppm (m, 6H); 13C-NMR (125 
MHz, CDCl3): δ = 217.1, 148.5, 147.4, 144.6, 134.0, 123.4, 42.0, 40.7, 36.1, 25.2 ppm; IR: ν˜ = 2930, 2858, 
1696, 1446, 1258, 1209, 1024, 979, 849, 716 cm–1; MS (ESI) m/z =  204 [M+H]+; HRMS: m/z [M+H] calcd 
for C13H18NO: 204.1388, found: 204.1380. 
5-Pyridin-3-yl-cyclooct-4-enol (9): The title compound was synthesized according to Method D using 7 
(60 mg, 0.30 mmol), sodium borohydride (23 mg, 0.60 mmol) in MeOH (5 mL) to give a light yellow oil (30 
mg, 49%) after flash chromatography (MeOH/CH2Cl2, 1:30). Rf = 0.14 (MeOH/CH2Cl2,1:20); 1H-NMR (500 
MHz, CDCl3): δ = 8.61 (d, J = 2.2 Hz, 1H), 8.43 (dd, J = 1.5, 4.8 Hz, 1H), 7.64 (dt, J = 2.2, 7.9 Hz, 1H), 
7.21 (dd, J = 4.8, 7.9 Hz, 1H), 6.08 (t, J = 8.2 Hz, 1H), 3.81 (m, 1H), 2.60 (t, J = 6.3 Hz, 2H), 2.41–2.49 (m, 
1H), 2.24–2.30 (m, 1H), 1.98–2.04 (m, 1H), 1.92 (br, 1H), 1.82–1.87 (m, 1H), 1.74–1.79 (m, 2H), 1.59–1.70 
ppm (m, 2H); 13C-NMR (125 MHz, CDCl3): δ = 147.7, 147.1, 138.1, 137.0, 132.9, 129.3, 123.1, 72.8, 38.3, 
36.2, 28.6, 24.9, 24.2 ppm; IR: ν˜ = 3329, 2924, 2853, 1472, 1414, 1077, 1041, 1023, 965, 803, 709 cm–1; 
MS (ESI) m/z = 204 [M+H]+; HRMS: m/z [M+H]+ calcd for C13H18NO: 204.1388, found: 204.1380. 
(endo/exo)-5-Pyridin-3-yl-cyclooctanol (10): The title compound was synthesized according to Method 
D using 8 (96 mg, 0.47 mmol), sodium borohydride (36 mg, 0.95 mmol) in MeOH (5 mL) to give a colorless 
oil (72 mg, 75%) after flash chromatography (MeOH/ CH2Cl2, 1:30). Rf  = 0.24 (MeOH/ CH2Cl2, 1:20); 1H-
NMR (500 MHz, CDCl3): δ = 8.41 (m, 2H), 7.46 (m, 1H), 7.19 (m, 1H), 3.86–4.04 (m, 1H) , 2.66–2.83 (m, 
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1H), 1.90–2.01 (m, 4H), 1.79–1.87 (m, 3H), 1.69–1.77 ppm (m, 6H); 13C-NMR (125 MHz, CDCl3): δ = 
148.7, 147.1, 144.9, 134.1, 123.4, 71.7, 71.6, 41.6, 40.3, 35.6, 35.2, 34.3, 22.6, 21.7 ppm; IR: ν˜ = 3362, 
2923, 1577, 1425, 1053, 990, 796, 715, 624 cm–1; MS (ESI) m/z = 206 [[M+H]+; HRMS: m/z [[M+H]+ calcd 
for C13H20NO: 206.1545, found: 206.1536.  
3-Cyclooct-1-enyl-pyridine (11): The title compound was synthesized according to Method B using 11a 
(300 mg, 1.16 mmol), pyridine-3-boronic acid (186 mg, 1.51 mmol), sodium carbonate (614 mg, 5.81 mmol) 
and tetrakis(triphenylphosphine)palladium (0) (133 mg, 0. 11 mmol) in dimethoxyethanol (12 mL) and water 
(4 mL) to give a pale yellow oil (153 mg, 71%) after purification by flash chromatography (EtOAc/n-
hexane,1:5). Rf = 0.38 (EtOAc/ PE, 1:5); 1H-NMR (500 MHz, CDCl3): δ = 8.65 (d, J = 2.1 Hz, 1H), 8.43 (dd, 
J = 1.3, 4.7 Hz, 1H), 7.66 (dt, J = 2.1, 7.9 Hz, 1H), 7.20 (dd, J = 4.7, 7.9 Hz, 1H), 6.04 (t, J = 8.3 Hz, 1H), 
2.61 (t, J = 6.3 Hz, 2H), 2.30 (m, 2H), 1.57–1.66 (m, 4H),1.50–1.56 ppm (m, 4H); 13C-NMR (125 MHz, 
CDCl3): δ = 147.6, 147.4, 138.4, 137.4, 132.8, 129.8, 123.0, 29.8, 29.2, 28.2, 27.4, 26.8, 26.0 ppm; IR: ν˜ = 
2922, 2850, 1471, 1412, 1021, 802, 709, 626 cm–1; MS (ESI) m/z = 188 [M+H]+; HRMS: m/z [M+H]+ calcd 
for C13H18N: 188.1439, found: 188.1430. 
3-Cyclooctyl-pyridine (12): The title compound was synthesized according to Method C using 11 (160 
mg, 0.85 mmol) and 5% Pd/C (16 mg) in methanol (15 mL) to give a colorless oil (150 mg, 93%) after 
purification by flash chromatography (EtOAc/n-hexane,1:10). Rf = 0.22 (EtOAc/PE, 1:5); 1H-NMR (500 
MHz, CDCl3): δ = 8.45 (d, J = 1.8 Hz, 1H), 8.40 (dd, 1H, J = 1.5, 4.8 Hz, 1H), 7.48 (dt, J = 4.8, 7.8 Hz, 1H), 
7.18 (dd, J = 4.8, 7.8 Hz, 1H), 2.81–2.76(m, 1H), 1.73–1.86 (m, 6H), 1.58–1.68 ppm (m, 8H); 13C-NMR 
(125 MHz, CDCl3): δ = 149.0, 147.0, 145.1, 134.2, 123.3, 42.1, 34.2, 26.8, 26.2, 25.8 ppm; IR: ν˜ = 2920, 
2851, 1574, 1476, 1446, 1423, 793, 715, 640, 613 cm–1; MS (ESI) m/z = 190 [M+H]+; HRMS: m/z [M+H]+ 
calcd for C13H20N: 190.1596, found: 190.1587.  
3-Cyclodec-1-enyl-pyridine (13): The title compound was synthesized according to Method B using 13a 
(410 mg, 1.43 mmol), pyridine-3-boronic acid (228 mg, 1.86 mmol), sodium carbonate (758 mg, 7.15 mmol) 
and tetrakis (triphenylphosphine)palladium (0) (83 mg, 0. 07 mmol) in dimethoxyethanol (15 mL) and water 
(5 mL) to give a pale yellow oil (205 mg, 67%) after purification by flash chromatography (EtOAc/n-
hexane,1:20). Rf = 0.19 (EtOAc/PE,1:10); 1H-NMR (500 MHz, CDCl3): δ = 8.64 (d, J = 1.9 Hz, 1H), 8.46 
(dd, J = 1.4, 4.7 Hz, 1H), 7.64 (dt, J = 1.9, 7.9 Hz, 1H), 7.21 (dd, J = 4.7, 7.9 Hz, 1H) , 5.70 (t, J = 8.4 Hz, 
1H), 2.71 (t, J = 6.1 Hz, 2H) , 2.43 ( q, J = 6.7 Hz, 2H), 1.67 (m, 2H) , 1.47–1.40 (m, 8H), 1.22 ppm (m, 2H); 
13C-NMR (125 MHz, CDCl3): δ = 148.1, 147.8, 138.3, 136.8, 133.6, 131.5, 123.0, 27.6, 26.9, 26.6, 26.1, 
25.7, 24.7, 21.2, 20.4 ppm; IR: ν˜ = 2921, 2850, 1474, 1444, 1411, 1022, 885, 804, 757, 712, 625 cm–1; MS 
(ESI) m/z = 216 [M+H]+; HRMS: m/z [M+H]+ calcd for C15H22N: 216.1752, found: 216.1744. 
3-Cyclodecyl-pyridine (14): The title compound was synthesized according to Method C using 13 (63 mg, 
0.29 mmol) and 5% Pd/C (10 mg) in methanol (6 mL) to give a colorless oil (48 mg, 75%) after purification 
by flash chromatography (EtOAc/n-hexane,1:10). Rf = 0.14 (EtOAc/PE, 1:5); 1H-NMR (500 MHz, CDCl3): δ 
= 8.45 (d, J = 2.0 Hz, 1H), 8.40 (dd, J = 1.6, 4.8 Hz, 1H), 7.50 (dt, J = 2.0, 7.9 Hz, 1H), 7.19 (dd, J = 4.8, 7.9 
Hz, 1H), 2.97 (m, 1H),1.88–1.94 (m, 2H), 1.69–1.45 ppm (m, 16H); 13C-NMR (125 MHz, CDCl3): δ = 149.4, 
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147.2, 143.8, 134.6, 123.3, 39.6, 32.5, 25.1, 25.0, 23.9 ppm; IR: ν˜ = 2923, 2869, 1574, 1479, 1443, 1423, 
1024, 806, 715, 632, 615 cm–1; MS (ESI) m/z = 218 [M+H]+; HRMS: m/z [M+H]+ calcd for C15H24N: 
218.1909, found: 218.1900. 
3-Cyclododec-1-enyl-pyridine (15): The title compound was synthesized according to Method B using 
15a (300 mg, 0.95 mmol), pyridine-3-boronic acid (153 mg, 1.24 mmol), sodium carbonate (506 mg, 4.77 
mmol) and tetrakis(triphenylphosphine) palladium (0) (110 mg, 0. 09 mmol) in dimethoxyethanol (12 mL) 
and water (4 mL) to give a pale yellow oil (140 mg, 60%) after purification by flash chromatography 
(EtOAc/n-hexane,1:5). Rf = 0.38 (EtOAc/PE,1:5); 1H-NMR (500 MHz, CDCl3): δ = 8.54 (d, J = 2.1 Hz, 1H), 
8.48 (dd, J = 1.6, 4.8 Hz, 1H), 7.56 (dt, J = 2.1, 7.9 Hz, 1H), 7.26 (dd, J = 4.8, 7.9 Hz, 1H), 5.86 (t, J = 8.1 
Hz, 1H), 2.46 (t, J = 5.8 Hz, 2H), 2.00 (m, 2H),1.28–1.58 ppm (m, 16H); 13C-NMR (125 MHz, CDCl3): δ = 
149.3, 147.4, 136.0, 135.5, 134.7, 132.1, 122.8, 36.5, 28.8, 27.3, 26.9, 25.9, 25.8, 24.0, 23.7, 23.5, 23.0 ppm; 
IR: ν˜ = 2925, 2855, 1461, 1408, 1022, 814, 716, 622 cm–1; MS (ESI) m/z = 244 [M+H]+; HRMS: m/z 
[M+H]+ calcd for C17H26N: 244.2065, found: 244.2057. 
3-Cyclododecyl-pyridine (16): The title compound was synthesized according to Method C using 15 (30 
mg, 0.22 mmol) and 5% Pd/C (10 mg) in methanol (6 mL) to give a colorless oil (26 mg, 87%) after 
purification by flash chromatography (EtOAc/n-hexane,1:10). Rf = 0.22 (EtOAc/PE, 1:5); 1H-NMR (500 
MHz, CDCl3): δ = 8.43 (s, 1H)，8.41 (d, J = 4.7 Hz, 1H)，7.48 (d, J = 7.8, 1H), 7.19 (dd, J = 4.7, 7.8 Hz, 
1H), 2.76(quin, J = 6.3 Hz, 1H), 1.79–1.85 (m, 2H), 1.26–1.50 ppm (m, 20H); 13C-NMR (125 MHz, CDCl3): 
δ = 149.6, 147.2, 142.5, 134.7, 123.2, 37.3, 31.2, 23.8, 23.7, 23.3, 23.2, 22.5 ppm; IR: ν˜ = 2929, 2848, 1575, 
1469, 1424, 1026, 812, 733, 716, 609 cm–1; MS (ESI) m/z = 246 [M+H]+; HRMS: m/z [M+H]+ calcd for 
C17H28N: 246.2222, found: 246.2213. 
(±)-8a-Methyl-6-pyridin-3-yl-3,7,8,8a-tetrahydro-2H-naphthalen-1-one (17): The title compound was 
synthesized according to Method B using 17a (290 mg, 0.93 mmol), pyridine-3-boronic acid (149 mg, 1.21 
mmol), sodium carbonate (492 mg, 4.65 mmol) and tetrakis(triphenylphosphine)palladium (0) (54 mg, 0.05 
mmol) in dimethoxyethanol (12 mL) and water (4 mL) to give a pale yellow oil (200 mg, 90%) after 
purification by flash chromatography (EtOAc/n-hexane,1:2). Rf = 0.24 (EtOAc/PE,1:1); 1H-NMR (500 MHz, 
CDCl3): δ = 8.72 (d, J =1.8 Hz, 1H), 8.46 (dd, J = 1.0, 4.7 Hz, 1H), 7.72 (dt, J = 1.8, 8.0 Hz, 1H), 7.24 (dd, J 
= 4.7, 8.0 Hz, 1H), 6.54 (s, 1H), 5.86 (t, J = 4.4 Hz, 1H), 2.80 (ddd, J = 5.7, 7.2, 15.6 Hz, 1H), 2.66–2.73 (m, 
1H), 2.50–2.62 (m, 3H), 2.38–2.44 (m, 1H), 2.10–2.14 (ddd, J = 2.2, 4.6, 13.4 Hz, 1H),1.63–1.69 ppm (m, 
1H), 1.25 ppm (s, 3H); 13C-NMR (125 MHz, CDCl3): δ = 214.6, 148.2, 146.6, 139.8, 136.1, 132.5, 132.1, 
125.7, 125.0, 123.1, 44.8, 35.4, 28.8, 24.3, 23.7, 22.6 ppm; IR: ν˜ = 2925, 2358, 1706, 1446, 1414, 1094, 
1045, 896, 807, 707 cm–1; MS (ESI) m/z = 240 [M+H]+. 
3-Bicyclo[2.2.1]hept-2-en-2-yl-pyridine (18): The title compound was synthesized according to Method 
B using 18a (410 mg, 1.69 mmol), pyridine-3-boronic acid (270 mg, 2.20 mmol), sodium carbonate (896 mg, 
8.45 mmol) and tetrakis(triphenylphosphine)palladium (0) (98 mg, 0.08 mmol) in dimethoxyethanol (18 mL) 
and water (6 mL) to give a pale yellow oil (237 mg, 82%) after purification by flash chromatography 
(EtOAc/n-hexane,1:10). Rf = 0.21 (EtOAc/PE,1:5); 1H-NMR (500 MHz, CDCl3): δ = 8.66 (d, J = 2.1 Hz, 
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1H), 8.41 (d, J = 4.7 Hz, 1H), 7.65 (dt, J = 2.1, 7.9 Hz, 1H), 7.20 (dd, J = 4.7, 7.9 Hz, 1H) , 6.39 (d, J = 2.5 
Hz, 1H), 3.32 (s, 1H), 3.02 (s, 1H), 1.76–1.83 (m, 2H), 1.54 (dt, J = 1.9, 8.2 Hz, 1H), 1.27 (d, J = 8.2 Hz, 
1H), 1.09–1.18 ppm (m, 2H); 13C-NMR (125 MHz, CDCl3): δ = 146.7, 146.6, 144.8, 131.8, 131.8, 131.4, 
123.3, 48.0, 43.2, 43.0, 26.5, 24.7 ppm; IR: ν˜ = 2962, 2871, 1684, 1585, 1418, 1301, 1024, 873, 798, 707 
cm–1; MS (ESI) m/z = 172 [M+H]+. 
(endo/exo)-3-Bicyclo[2.2.1]hept-2-yl-pyridine (19): The title compound was synthesized according to 
Method C using 18 (190 mg, 0.22 mmol) and 5% Pd/C (30 mg) in methanol (10 mL) to give a colorless oil 
(171 mg, 90%) after purification by flash chromatography (EtOAc/n-hexane,1:10). Rf = 0.22 (EtOAc/PE, 
1:5); 1H-NMR (500 MHz, CDCl3): δ = 8.46 (d, J = 2.2 Hz, 1H), 8.40 (dd, J = 1.4, 4.7 Hz, 1H), 7.49 (d, J = 
7.8 Hz, 1H ), 7.20 (dd, J = 4.7, 7.8 Hz, 1H), 3.20 (m, 1H), 2.42 (t, J = 3.9 Hz, 1H), 2.35 (t, J = 4.3 Hz, 1H), 
1.97–2.04 (tt, J = 3.9, 12.1 Hz,1H), 1.53–1.60 (m, 2H), 1.46 (m, 1H), 1.40 (ddd, J = 2.3, 5.7, 12.5 Hz, 1H), 
1.28–1.34 (m, 1H), 1.18–1.24 ppm (m, 2H); 13C-NMR (125 MHz, CDCl3): δ = 150.1, 146.9, 138.8, 135.4, 
122.9, 43.6, 42.2, 40.5, 37.4, 34.0, 30.0, 22.7 ppm; IR: ν˜ = 2951, 2872, 1478, 1420, 1025, 802, 714, 615 cm–
1; MS (ESI) m/z = 174 [M+H]+; HRMS: m/z [M+H]+ calcd for C12H16N: 174.1283, found: 174.1273. 
8-Methyl-3-pyridin-3-yl-8-aza-bicyclo[3.2.1]oct-2-ene (20): The title compound was synthesized 
according to Method B using 18a (391 mg, 1.44 mmol), pyridine-3-boronic acid (230 mg, 1.87 mmol), 
sodium carbonate (763 mg, 7.2 mmol) and tetrakis(triphenylphosphine)palladium (0) (83 mg, 0.07 mmol) in 
dimethoxyethanol (18 mL) and water (6 mL) to give a pale yellow oil (201 mg, 70%) after purification by 
flash chromatography (EtOAc/n-hexane,1:10). Rf = 0.30 (CHCl2/MeOH/Et3N,100:10:1); 1H-NMR (500 MHz, 
CDCl3): δ = 8.63 (d, J = 1.9 Hz, 1H), 8.48 (dd, J = 1.3, 4.7 Hz, 1H), 7.64 (dt, J = 1.9, 7.9 Hz, 1H), 7.24 (dd, J 
= 4.7, 7.9 Hz, 1H), 6.32 (dt, J = 1.5, 5.6 Hz, 1H), 3.66 (tt, J = 5.8, 17.6 Hz, 2H), 2.98 (dd, J = 3.9, 17.6 Hz, 
1H), 2.55 (s, 3H), 2.28–2.35 (m, 1H) , 2.18–2.25 (m, 2H), 2.02 (m, 1H), 1.72 ppm (m, 1H); 13C-NMR (125 
MHz, CDCl3): δ = 148.6, 146.4, 134.6, 132.1, 130.5, 127.1, 123.2, 59.8, 58.4, 36.3, 33.1, 29.6, 29.1 ppm; IR: 
ν˜ = 2941, 1415, 1260, 1156, 1030, 802, 708, 638 cm–1; MS (ESI) m/z = 200 [M]+. 
(endo/exo)-8-Methyl-3-pyridin-3-yl-8-aza-bicyclo[3.2.1]octane (21): The title compound was 
synthesized according to Method C using 20 (100 mg, 0.50 mmol) and 5% Pd/C (15 mg) in methanol (10 
mL) to give a colorless oil (92 mg, 91%) after purification by flash chromatography 
(CHCl2/MeOH/Et3N,100:10:1). Rf = 0.18 (CHCl2/MeOH/Et3N, 100:10:1); 1H-NMR (500 MHz, CDCl3): δ = 
8.55 (d, J = 2.0 Hz, 1H), 8.40 (dd, J = 1.5, 4.7 Hz, 1H), 7.56 (dt, J = 1.7, 7.9 Hz, 1H), 7.18(dd, J = 4.7, 7.9 Hz, 
1H), 3.20–3.27 (m, 2H), 3.07 (quin, J = 8.0 Hz, 1H), 2.43 (m, 2H), 2.24 (s, 3H), 2.03–2.12 (m, 2H), 1.57 
(ddd, J = 1.3, 8.4, 13.9 Hz, 2H), 1.43 ppm (m, 2H); 13C-NMR (125 MHz, CDCl3): δ = 149.2, 147.1, 141.4, 
134.5, 123.0, 59.5, 40.6, 38.3, 30.3, 28.1 ppm; IR: ν˜ = 2935, 1575, 1478, 1451, 1332, 1024, 799, 714, 623 
cm–1; MS (ESI) m/z = 202 [M]+ 
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Supporting Information 
1. The synthetic procedures and characterization of all intermediates. 
Method A: Triflation 
To a solution of 2,6-di-tert-butyl-4-methylpyridine (7.23 mmol) and the corresponding ketone (6.57 mmol) 
in CH2Cl2 (20 mL) was added trifluoromethanesulfonic anhydride (7.16 mmol) dropwise at 0 °C under 
nitrogen. A white precipitate was formed soon. The reaction mixture was warmed to room temperature and 
further stirred for 4 h. The solvent was removed in vacuo, and the resulting residue was diluted with 
petroleum ether (20 mL). After removal of the solid by filtration, the filtrate was concentrated in vacuo to 
give a crude product which was used in the next step without further purification. 
Method B: Suzuki coupling 
A suspension of enol triflate (4.56 mmol), pyridine-3-boronic acid (5.92 mmol), sodium carbonate (22. 8 
mmol) and tetrakis(triphenylphosphine)palladium (0) (0.23 mmol) in dimethoxyethanol (45 mL) and water 
(15 mL) was stirred at 90 °C under nitrogen for 2 h. The reaction mixture was cooled to room temperature 
naturally and diluted with water (10 mL). The aqueous layer was extracted with ethyl acetate (2 x 30 mL) 
and the combined organic layers were washed with brine twice and dried over MgSO4. After evaporation in 
vacuo, the resulting residue was purified by flash chromatography to afford the corresponding product. 
Trifluoro-methanesulfonic acid 3,4,4a,5,6,7,8,8a-octahydro-naphthalen-2-yl ester (1b): The title 
compound was synthesized according to Method A using a mixture of cis and trans of 2-decalone (1.00 g, 
6.57 mmol), trifluoromethanesulfonic anhydride (1.20 mL, 7.16 mmol) and 2, 6-di-tert-butyl-4-
methylpyridine (1.48 g, 7.23 mmol) in CH2Cl2 (20 mL) to give a yellow oil (1.30 g). 
A isomer mixture of 3-(3,4,4a,5,6,7,8,8a-octahydro-naphthalen-2-yl)-pyridine and 3-
(1,4,4a,5,6,7,8,8a-octahydro-naphthalen-2-yl)-pyridine (1a): The title compound was synthesized 
according to Method B using 1b (1.29 g, 4.54 mmol ), pyridine-3-boronic acid (0.73 g, 5.92 mmol), sodium 
carbonate (2.41 g, 22.8 mmol) and tetrakis (triphenylphosphine)palladium (0) (0.24 g, 0.21 mmol) in 
dimethoxyethanol  (45 mL) and water (15 mL) to give a pale yellow oil (0.86 mg, 88%) after purification by 
flash chromatography (EtOAc / n-hexane,1:10): Rf = 0.45 (EtOAc/PE,1:5); MS (ESI) m/z = 214 [M+H]+. 
cis-Trifluoro-methanesulfonic acid 5-oxo-1,3a,4,5,6,6a-hexahydro-pentalen-2-yl ester (2a): The title 
compound was synthesized according to Method A using cis-tetrahydropentalene-2,5(1H,3H)-dione (300 mg, 
2.17 mmol), trifluoromethanesulfonic anhydride (0.36 mL, 2.17 mmol) and 2, 6-di-tert-butyl-4-
methylpyridine (455 mg, 2.21 mmol) in CH2Cl2 (15 mL) to give a yellow oil (290 mg). 
Cyclooctane-1,5-diol (7b): A solution of BH3-THF complex in THF (1.0 M, 10 mL, 10.0 mmol) was 
stirred at 0 °C under N2. A solution of 1,5-cyclooctadiene (1.00 g, 9.24 mmol) in THF (2 mL) was added 
slowly, and the resulting mixture was refluxed for 1 h. Upon cooling to room temperature, to the reaction 
mixture was added 3 M NaOH (2 mL), followed by 35% H2O2 (1.7 mL), which was added dropwise at a rate 
which caused the solution to reflux gently. The resulting mixture was allowed to cool for 30 min and 
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saturated with K2CO3. After separation, the aqueous layer was extracted with diethyl ether (2 × 8 mL). The 
combined organic layers were dried over MgSO4 and concentrated in vacuo to give a colorless tar. The tar 
was dissolved in CH2Cl2 (60 mL), and PCC (9.24 g, 42.9 mmol) was added in three portions. The reaction 
mixture was refluxed for 2 d, and an additional PCC (4.70 g, 21.8 mmol) was added. After refluxing for 6 h, 
the reaction was cooled to room temperature and poured to a silica column, which was eluted with 1:1 
diethyl ether/n-hexane. An offwhite semisolid (1.07 g, 82%) was obtained. 1H-NMR (500 MHz, CDCl3): δ = 
2.49 (m, 8H), 2.13 ppm (m, 4H); 13C-NMR (125 MHz, CDCl3): δ = 213.0, 42.2, 22.1 ppm. 
Trifluoro-methanesulfonic acid cyclooct-1-enyl ester (11a): The title compound was synthesized 
according to Method A using cyclooctanone (1.00 g, 7.87 mmol), trifluoromethanesulfonic anhydride (1.45 
mL, 8.57 mmol) and 2, 6-di-tert-butyl-4-methylpyridine (1.78 g, 8.64 mmol) in CH2Cl2 (20 mL) to give a 
yellow oil (1.60 g). 
Trifluoro-methanesulfonic acid cyclodec-1-enyl ester (13a): The title compound was synthesized 
according to Method A using cyclodecanone (300 mg, 1.94 mmol), trifluoromethanesulfonic anhydride (0.33 
mL, 1.94 mmol) and 2, 6-di-tert-butyl-4-methylpyridine (407 mg, 1.98 mmol) in CH2Cl2 (15 mL) to give a 
yellow oil (410 mg). 
Trifluoro-methanesulfonic acid cyclododec-1-enyl ester (15a): The title compound was synthesized 
according to Method A using cyclododecanone (1.00 g, 5.49 mmol), trifluoromethanesulfonic anhydride 
(1.01 mL, 5.98 mmol) and 2, 6-di-tert-butyl-4-methylpyridine (1.24 g, 6.03 mmol) in CH2Cl2 (20 mL) to 
give a yellow oil (1.71 g). 
Trifluoro-methanesulfonic acid 4a-methyl-5-oxo-3,4,4a,5,6,7-hexahydro-naphthalen-2-yl ester (17a): 
The title compound was synthesized according to Method A using Wieland-Miescher ketone (200 mg, 1.12 
mmol), trifluoromethanesulfonic anhydride (0.36 mL, 2.15 mmol) and 2, 6-di-tert-butyl-4-methylpyridine 
(481 mg, 2.34 mmol) in CH2Cl2 (8 mL) to give a yellow oil (294 mg). 
Trifluoro-methanesulfonic acid bicyclo[2.2.1]hept-2-en-2-yl ester (18a): The title compound was 
synthesized according to Method A using norcamphor (500 mg, 4.54 mmol), trifluoromethanesulfonic 
anhydride (0.83 mL, 4.95 mmol) and 2, 6-di-tert-butyl-4-methylpyridine (1.03 g, 5.00 mmol) in CH2Cl2 (20 
mL) to give a yellow oil (410 mg). 
Trifluoro-methanesulfonic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-2-en-3-yl ester (20a): To a solution 
of tropinone (500 mg, 4.54 mmol) in THF (20 mL) was added a solution of lithium hexamethyldisilazide in 
THF (1.0 M, 4.3 mL, 4.30 mmol) dropwise at –78 °C. The resulting mixture was stirred at the temperature 
for 30 min, and then was warmed to 0 °C. A solution of PhNTf2 (1.54 g, 4.30 mmol) in THF (2 mL) was 
added. The reaction was stirred for 1 h at 0 °C, and subsequently stirred overnight at room temperature An 
aqueous solution of NH4Cl (10 mL ) was added to quench and the resulting mixture was separated. The 
aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with 
brine (3 x 30 mL), dried over MgSO4 and concentrated in vacuo to give a red oil (391 mg), which was 
directly used for next step. 
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2. HPLC purity control of all final compounds. 
The Surveyor®-LC-system consisted of a pump, an autosampler, and a PDA detector. Mass spectrometry 
was performed on a TSQ® Quantum (Thermo Electron Corporation, Dreieich, Germany). The triple 
quadrupole mass spectrometer was equipped with an electrospray interface (ESI). The system was operated 
by the standard software Xcalibur®. 
A RP C18 NUCLEODUR® 100-5 (125 × 3 mm) column (Macherey-Nagel GmbH, Duehren, Germany) 
was used as stationary phase. All solvents were HPLC grade. 
In a gradient run the percentage of acetonitrile (containing 0.1 % triflouro-acetic acid) in water was 
increased from an initial concentration of 3% at 0 min to 100% at 15 min and kept at 100% for 3 min. 
The injection volume was 10 µl and flow rate was set to 350 µl/min. MS analysis was carried out at a 
spray voltage of 3800 V, a capillary temperature of 350 °C and a source CID of 10 V. Spectra were acquired 
in positive mode from 100 to 1000 m/z and full scan UV-mode. In some cases APC ionization had to be 
applied. 
Compd RT (min) Purity [%] 
1 7.98 99.9% 
2 4.45 99.1% 
3 3.55 99.1% 
4 7.86 99.9% 
5 5.10 98.1 % 
6 5.14 99.3 % 
7 4.46 99.0% 
8 4.56 99.0% 
9 7.72 99.9% 
10 4.61 98.7% 
11 7.81 98.4% 
12 8.07 99.9% 
13 9.01 98.0 % 
14 9.31 99.3% 
15 9.03 99.4% 
16 8.99 99.9% 
17 5.29 98.1% 
18 5.04 99.9% 
19 5.62 99.0% 
20 8.81 98.3% 
21 8.79 99.3% 
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3.II. Novel Pyridyl or Isoquinolinyl Substituted Indolines 
and Indoles as Potent and Selective CYP11B2 
Inhibitors 
 
Introduction 
Aldosterone is the important mineralocorticoid and regulates electrolyte and volume homeostasis after 
binding to mineralocorticoid receptors (MR). Normally, its secretion is controlled by the renin-angiotensin-
aldosterone system (RAAS), adrenocorticotropic hormone (ACTH) and potassium concentration. However, 
in some pathological circumstances, the aldosterone levels are abnormally elevated. It has been demonstrated 
that high aldosterone levels are associated with severe cardiovascular diseases such as congestive heart 
failure, myocardial fibrosis, and certain forms of hypertension,1 which can thereby lead to sudden death.  
Aldosterone is biosynthesized from 11-deoxycorticosterone via three consecutive steps catalyzed by 
aldosterone synthase (CYP11B2), which is a mitochondrial cytochrome P450 enzyme located in the outer 
layer of adrenal cortex.2 Therefore, it is rational to reduce high aldosterone levels through inhibition of 
CYP11B2, which has been proposed as a novel strategy for the treatment of aldosterone related heart 
diseases over a decade ago.3 This therapy is believed to be superior to the treatment with angiotensin-
converting-enzyme (ACE) inhibitors (such as enalapril, Chart 1) and MR antagonists (such as spironolactone, 
Chart 1) that are currently in clinical use. The reason for this is the “aldosterone escape” for ACE inhibitors4 
as a result of their long-term application and the outage of MR blockage at high aldosterone levels.5 Recently, 
an in vivo study in rats has demonstrated that CYP11B2 inhibitors are effective in decreasing plasma 
aldosterone levels.6 Experiments in rat heart failure models indicated that long-term administration of  
FAD286 (Chart 1), the R-enantiomer of fadrozole - a nonselective aromatase inhibitor also showing potent 
inhibition of CYP11B2 - improved both cardiac hemodynamics and cardiac function, which was more 
pronounced than that achieved by spironolactone.7  
Chart 1. Structures of ACE inhibitor Enalapril, MR antagonist Spironolactone and aromatase inhibitor 
Fadrozole (R-enantiomer: FAD 286). 
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In the last few years, several classes of CYP11B2 inhibitors have been designed by our group8 and others.9 
The same inhibitory mechanism as for aromatase (CYP19)10, 17α-hydroxylase-17,20-lyase (CYP17) 11 and 
11ß-hydroxylase (CYP11B1) inhibitors12 - a sp2 hybrid N reversibly coordinating to the heme iron - is 
employed in the design strategy. This is quite different from the inhibition mechanism of 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) inhibitors13 and 5α-reductase inhibitors,14 whose targets are also 
important enzymes in the steroid biosynthesis. This design strategy led to some extremely potent CYP11B2 
inhibitors with IC50 values in a sub-nanomolar range.8b,d,e It is crucial that inhibition of other steroidogenic 
CYP enzymes should be avoided because they are essential for the biosynthesis of some vital steroid 
hormones, for example, CYP17 and CYP11A1 for androgens, CYP19 and CYP11A1 for estrogens, and 
CYP11B1, CYP21 and CYP11A1 for glucocorticoids. Inhibition of these enzymes will cause severe side 
effects. Due to the identical catalytic mechanism and the homology throughout the steroidogenic CYP 
enzyme family, especially to 11β-hydroxylase (CYP11B1), which shares more than 93% homology with 
CYP11B2, the selectivity is a real challenge. Nevertheless, it is possible to design highly selective 
compounds as it is shown by some CYP1711e and CYP11B28h,i inhibitors. Often the key to high selectivity 
resides in small structural differences which can be caused by single small substituents,11e as it has been 
demonstrated in the design of dual inhibitors of CYP enzymes.11d 
Chart 2. Inhibitor design concept. 
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Results and Discussion 
Chemistry  
The synthetic routes are depicted in Schemes 1–3. Two consecutive key steps were employed for the 
synthesis of compounds 1–13, 21 and 22, which include Suzuki coupling with pyridin-3-yl boronic acid or  
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Scheme 1a 
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a Reagents and conditions: (i) Boc2O, NaHCO3, THF, H2O, 0 °C to room temp; (ii) Method A:  Pyridin-3-ylboronic acid or 
isoquinolin-4-ylboronic acid, Ph(PPh3)4, Na2CO3, DME, H2O, 90 °C; (iii) Method B: CF3COOH, CH2Cl2, 0 °C to room temp; (iv) 
Method C: RCOCl, Pyridine, THF, 0 °C to room temp. 
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 a Reagents and conditions: (i) Method C: CH3COCl, Pyridine, THF, 0 °C to room temp; (ii) Bis(pinacolato)diboron, Pd(dppf)2Cl2, 
KOAc, dioxane, 105 °C; (iii) Method A: R substituted 3-bromopyridine, Ph(PPh3)4, Na2CO3, DME, H2O, 90 °C; (iv) NaBH4, MeOH, 
0 °C. 
 
 
 
Scheme 3a 
N
H
Br
N
O
N
N
H
N
i ii
21a,22a 21 3-Py22 Isoquinolinyl  
a Reagents and conditions: (i) Method A: Pyridin-3-yl boronic acid or isoquinolin-4-yl boronic acid, Ph(PPh3)4, Na2CO3, DME, H2O, 
90 °C; (ii) Method D: Ac2O, Et3N, DMAP, CH2Cl2, 60 °C. 
isoquinolin-4-yl boronic acid to introduce the N-containing heterocycle and acylation in order to furnish 
various substituents on the indoline or indole core (Scheme 1 and 3). For the indoline analogues 1–13, the 
amino group was primarily protected with Boc to ensure high yields in the Suzuki coupling, and was 
subsequently cleaved using trifluoroacetic acid before acylation was performed as the last step (Scheme 1). 
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With regard to the compounds with different substituents on the pyridyl moiety (14–20), boride 14a was 
used as a common building block to achieve the last-stage diversification via Suzuki coupling with various 
substituted bromo-3-pyridines (Scheme 2). Compound 14a was prepared by acetylation of 5-bromoindoline, 
and subsequent borylation with bis(pinacolato)diboron catalyzed by Pd(dppf)2Cl2.15 A simple stoichiometric 
reduction of the ketone to the alcohol with sodium borohydride was performed to convert compound 17 into 
18. 
Inhibition of CYP11B2 and CYP11B1. The synthesized compounds were evaluated for their inhibitory 
potencies using V79 MZh cells expressing either human CYP11B1 or CYP11B2.16 The results are presented 
with fadrozole as reference in tables 1–2. 
After various acyl rests with different bulkiness and electrostatic potential were introduced into the 
indoline core (Table 1), steric hindrance was identified to be very detrimental for CYP11B2 inhibition. The 
Me compound 1 exhibited strong inhibition of CYP11B2 with an IC50 value of 60 nM and a good selectivity 
factor of 47. However, the ethyl analogue 2 showed a decrease in potency and selectivity (IC50 = 228 nM and 
SF = 21). Along with the increase in bulkiness of substituent R, the inhibitory potency of the corresponding 
compounds dropped dramatically to less than 30% at an inhibitor concentration of 500 nM (compounds 3–9). 
Lipophilic or electronic properties of R as well as the existence of π-electron exerted only little effect. 
Intriguingly, benzyl substitution on the amido moiety led to a preference for CYP11B1 inhibition (9, 2.2 and 
26% inhibition of CYP11B2 and CYP11B1, respectively). 
The modifications of the nitrogen-containing heterocycle were performed for improving inhibitory 
potency and selectivity. Positions adjacent to the N were left unsubstituted to avoid any obstacles for the N 
atom to coordinate with the heme iron. The 3-pyridyl moiety was fused with an additional benzene nucleus 
leading to an isoquinolinyl substituent. The resulting compounds 10–13, which were furnished with methyl, 
ethyl, cyclopropyl or isopropyl at the amido moiety, exhibited substantial improvement regarding inhibitory 
activity and selectivity compared with the corresponding 3-pyridyl analogues (Table 1). It is obvious that the 
replacement of pyridyl by isoquinolinyl elevated the inhibitory potency by approximate 80-fold for the 
methyl (10) and ethyl (11) analogues to 0.7 and 2.8 nM, respectively. The inhibition of CYP11B2 by the 
cyclopropyl or isopropyl compounds 12 and 13 was also increased to 30 and 152 nM. Among these potent 
inhibitors, compounds 11 and 12 exhibited excellent selectivity over CYP11B1 with selectivity factors 
around 150. As expected, the influence of steric bulkiness was once again clearly observed in this series of 
compounds. With the increase in the substituents size from methyl and ethyl to cyclopropyl and isopropyl, 
the IC50 values rise from 0.7 nM to 152 nM.  
Since methyl was discovered to be the most suitable group on the amido moiety, it was conserved when 
further substituents were introduced onto the 3-pyridyl ring. A wide range of the substituents were exploited 
for this further optimization, including electron donating (Me, MeO, and 1-OH-Et), electron withdrawing (F, 
CN, and Acetyl), and bulky aromatic (Ph) groups. In most cases, the resulting compounds exhibited 
significant amelioration of both potency and selectivity in comparison to the non-substituted pyridyl 
compound 1 (Table 2). It is apparent that electron withdrawing substituents cannot really improve the 
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Table 1. Inhibition of CYP11B1 and CYP11B2 by compounds 1–13. 
N
N
O
R
1 - 9
N
N
O
R
10 - 13
5
7
 
Inh.% @ 500 nMc  IC50 [nM]d 
Compd R 
11B2a 11B1b 11B2a 11B1b 
SFe 
1 Me 87 14 60 2848 47 
2 Et 66 0.8 228 4737 21 
3 ClCH2CH2 7.0 6.0 n.d. n.d.  
4 i-Propyl 7.3 11 n.d. n.d.  
5 c-Propyl 28 26 n.d. n.d.  
6 4-F Ph 15 2.1 n.d. n.d.  
7 4-MeO Ph 26 1.6 n.d. n.d.  
8 2-Thiophenyl 14 4.9 n.d. n.d.  
9 Bn 2.2 26 n.d. n.d.  
10 Me 100 92 0.7 52 74 
11 Et 100 39 2.8 516 184 
12 c-Propyl 98 29 30 3723 124 
13 i-Propyl 90 11 152 6093 40 
Fadrozole -   0.8 6.3 7.9 
a Hamster fibroblasts expressing human CYP11B2; substrate: deoxycorticosterone, 100 nM. b Hamster fibroblasts expressing 
human CYP11B1; substrate: deoxycorticosterone, 100 nM. c Mean value of at least three experiments, standard deviation usually less 
than 10%. d Mean value of at least three experiments, relative standard deviation usually less than 25%. e SF (selectivity factor) = 
IC50 CYP11B2 / IC50 CYP11B1; n.d. = not determined. 
inhibitory activity. When F was substituted at the 5-position of the pyridyl, the resulting compound 14 
showed an IC50 value of 61 nM - a similar potency as the non-substituted analogue 1 - and an increase in 
selectivity by nearly 3-fold to 112. Whereas compound 17, also with an electron withdrawing acetyl, 
exhibited an improved inhibitory activity of 36 nM, cyano substitution led to a loss of potency (compound 
15). The electron donating OMe group significantly increased CYP11B2 inhibition (16, 16 nM), and the 1-
OH-Et compound (18) rendered similar potency as 1 (IC50 = 55 nM). Methyl substituted at the 4-position 
elevated the CYP11B2 inhibition to 2.2 nM (20), and also led to an excellent selectivity over CYP11B1 (SF 
= 166). It is interesting to observe that the bulky electron donating phenyl group increased inhibitory potency 
to 3 nM (19). This finding might be indicative of an additional hydrophobic pocket near the heme, which can 
be exploited to improve inhibitory activity. 
Furthermore, dehydrogenation of the indoline core resulting in the indole analogues 21 and 22 (Table 2) 
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showed an elevation of inhibitoty potency to 23 and 0.6 nM, respectively. However, no improvement of 
selectivity was observed (SFs around 60). 
Table 2. Inhibition of CYP11B1 and CYP11B2 by compounds 14–22. 
N
N
O
14 - 20
N
N
O
22
R
N
N
O
21
3
4
5
 
Inh.% @ 500 nMc  IC50 [nM]d 
Compd R 
11B2a 11B1b 11B2a 11B1b 
SFe 
14 5-F 93 11 61 6812 112 
15 5-CN 54 7.3 n.d. n.d.  
16 5-MeO 100 48 16 803 50 
17 5-Ac 97 24 36 3125 87 
18 5-(1-OH-Et) 99 8.7 55 3756 68 
19 5-Ph 100 74 3.0 160 53 
20 4-Me 100 70 2.2 366 166 
21  98 25 23 1379 60 
22  100 97 0.6 34 57 
Fadrozole -   0.8 6.3 7.9 
a Hamster fibroblasts expressing human CYP11B2; substrate: deoxycorticosterone, 100 nM. b Hamster fibroblasts expressing human 
CYP11B1; substrate: deoxycorticosterone, 100 nM. c Mean value of at least three experiments, standard deviation usually less than 
10%. d Mean value of at least three experiments, relative standard deviation usually less than 25%. e SF (selectivity factor) = IC50 
CYP11B2 / IC50 CYP11B1; n.d. = not determined. 
Inhibition of Human CYP17 and CYP19. To investigate the selectivity profiles of this series of 
compounds, potent inhibitors (IC50 < 100 nM) were selected for further evaluation against CYP17 and 
CYP19. Inhibitory activity toward CYP17 was tested using the 50,000 sediments of E.coli homogenates 
coexpressing human CYP17 and cytochrome P450 reductase with an inhibitor concentration of 2 µM.17a As 
for CYP19 inhibition, microsomal preparations of human placenta were used with an inhibitor concentration 
of 500 nM.18 All compounds exhibited no inhibition of CYP17 and CYP19 (data not shown).  
Conclusion 
A series of pyridyl or isoquinolinyl substituted indolines and indoles were designed by ligand-based 
approach: cleaving of the lactam ring and introduction of various substituents to the amido moiety resulted in 
very potent and selective CYP11B2 inhibitors, which might be promising for the treatment of aldosterone 
dependent cardiovascular diseases. It has been found that too bulky substituents at the amido group had a 
negative effect on inhibitory potency. The methyl group turned out to be the most suitable substituent. 
Modifications on the pyridyl by furnishing electron donating groups, such as methyl, methoxy and phenyl, 
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led to a significant increase of CYP11B2 inhibition. Interestingly, the highly potent inhibition exhibited by 
the phenyl substituted compound is indicative of an additional hydrophobic pocket near the heme. Another 
structure modification, the dehydrogenation of the indoline core also resulted in improved CYP11B2 
inhibition, but had no real influence on selectivity. These novel potent CYP11B2 inhibitors exhibited no 
inhibition of other steroidogenic CYP enzymes, such as CYP17 and CYP19, indicating that the application 
of these compounds as CYP11B2 inhibitors can be expected to be safe regarding inhibition of other 
steroidogentic enzymes. 
After a series of optimizations, highly potent and selective CYP11B2 inhibitors were identified especially 
compounds 11 and 20 (IC50 values around 2 nM and SFs around 170). These compounds can be considered 
as candidates for further evaluation in vivo. 
Experimental Section 
Biology 
Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human CYP11B1 or CYP11B2 were incubated with [1,2-3H]-11-
deoxycorticosterone as substrate and the inhibitor at different concentrations.. The assay was performed as 
previously described.16 
CYP17 preparation and assay 
Human CYP17 was used as 50,000 sediments of E.coli17a homogenates coexpressing the human enzyme 
and NADPH-P450 reductase, and the assay was performed using the method previously described, with 
progesterone as substrate and NADPH as cofactor.17b 
CYP19 preparation and assay 
Human CYP19 was obtained from microsomal preparations of human placenta and the assay was 
performed using the 3H2O-method as previously described and [1β-3H]androstenedione as the substrate.18 
Chemistry 
General Method 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. 1H-NMR 
spectra were measured on a Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million 
(ppm), and TMS was used as an internal standard for spectra obtained. All coupling constants (J) are given 
in Hz. ESI (electrospray ionization) mass spectra were determined on a TSQ quantum (Thermo Electron 
Corporation) instrument. The purities of the final compounds were controlled by Surveyor-LC-system. 
Purities were greater than 95%. Column chromatography was performed using silica-gel 60 (50–200 µm), 
and reaction progress was determined by TLC analysis on Alugram SIL G/UV254 (Macherey-Nagel). 
Reagents and solvents were used as obtained from commercial suppliers without further purification.  
Method A: Suzuki coupling 
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A suspension of bromo compound (1.0 equiv), boride (0.8–1.2 equiv), sodium carbonate (4.1–5.0 mmol) 
and tetrakis(triphenylphosphine)palladium (0) (0.05 equiv) in dimethoxyethane/water (3:1) was stirred at 90 
°C under nitrogen for 2 h. The reaction mixture was cooled to room temperature slowly and then diluted with 
water. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with 
brine twice and dried over MgSO4. After evaporation in vacuo, the resulting residue was purified by flash 
chromatography to afford the corresponding product. 
Method B: N-Boc Deprotection 
Trifluoroacetic acid (9.0 equiv) was added to a solution of Boc-protected indoline (1.0 equiv) in anhydrous 
dichloromethane (25 mL) at 0 °C. The reaction was warmed to room temperature and stirred overnight. 
Subsequently, the reaction mixture was poured into a solution of saturated aqueous NaHCO3 (25 mL). The 
resulting mixture was separated and the aqueous layer was extracted with dichloromethane (2 x 15 mL). The 
combined organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo. The residue 
was purified by flash chromatography on silica gel (EtOAc/n-hexane, 1:50 to 1:1) to yield the deprotected 
product. 
Method C: Acylation of Indoline 
Acyl chloride (1.2 equiv) was added dropwise to a solution of substituted indoline (1.0 equiv) and pyridine 
(1.5 equiv) in anhydrous THF at 0 °C. The reaction was warmed to room temperature and stirred overnight. 
After water (5 mL) was added for quenching, the resulting mixture was separated. The aqueous layer was 
extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine, dried over MgSO4 
and concentrated in vacuo. The resulting crude product was purified by flash chromatography on silica gel 
(EtOAc/n-hexane, 1:50 to 1:2). 
Method D: Acetylation of Indole 
To a stirred solution of 3-pyridinyl or isoquinolinyl substituted indole (1.0 equiv) in 1,2-dichloroethane (6 
mL) was added triethylamine (1.5 equiv), acetic anhydride (3.9 equiv) and DMAP (0.2 equiv) in sequence 
under N2. The solution was heated to 60 °C for 8h. Upon cooling to ambient temperature, the reaction was 
diluted with EtOAc (6 mL) and washed with a saturated solution of ammonium chloride, and the aqueous 
layer was extracted with EtOAc (3 x 10 mL).The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel 
(EtOAc/n-hexane, 1:50 to 1:2). 
5-Pyridin-3-yl-2,3-dihydro-1H-indole (1a). The title compound was synthesized according to Method B 
using crude 1b (1.40 g, 4.73 mmol) and trifluoroacetic acid (3.26 mL, 42.5 mmol) as a brown solid (0.93 g, 
100%). 1H-NMR (500 MHz, CDCl3): δ 3.11 (t, J = 8.4 Hz, 2H), 3.64 (t, J = 8.4 Hz, 2H), 6.71 (d, J = 8.1 Hz, 
1H), 7.25 (m, 1H), 7.29 (ddd, J = 0.8, 4.9, 7.9 Hz, 1H), 7.35 (d, J = 1.2 Hz, 1H), 7.80 (dt, J = 2.1, 7.9 Hz, 
1H), 8.49  (dd, J = 1.6, 4.8 Hz, 1H), 8.79 (dd, J = 0.6, 2.3 Hz, 1H). 
1-Acetyl-5-pyridin-3-yl-2,3-dihydro-1H-indole (1). The title compound was synthesized according to 
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Method C using 1a (80 mg, 0.41 mmol), acyl chloride (28 µL, 0.49 mmol) and pyridine (50 µL, 0.62 mmol) 
in anhydrous THF (3 mL). After flash column chromatography, recrystallization from THF gave yellow 
crystals (93 mg, 95%). mp 125–127 °C, Rf = 0.05 (EtOAc/n-hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 
2.25 (s, 3H), 3.27 (t, J = 8.5 Hz, 2H), 4.12 (t, J = 8.5 Hz, 2H), 7.33 (dd, J = 4.8, 7.8 Hz, 1H), 7.42  (m, 2H), 
7.83 (dt, J = 1.9, 7.8 Hz, 1H), 8.29 (d, J = 8.3 Hz, 1H), 8.55 (d, J = 4.5 Hz, 1H), 8.81 (d, J = 1.9 Hz, 1H). 
13C-NMR (125 MHz, CDCl3): δ 24.2, 28.0, 49.0, 117.3, 123.1, 123.5, 126.6, 132.1, 133.2, 134.0, 136.3, 
143.0, 148.0, 148.1, 168.8. MS (ESI) m/z = 239 [M+H] +. 
1-Propanoyl-5-pyridin-3-yl-2,3-dihydro-1H-indole (2). The title compound was synthesized according 
to Method C using 1a (200 mg, 1.02 mmol), propanoyl chloride (0.11 mL, 1.22 mmol) and pyridine (0.12 
mL, 1.53 mmol) in anhydrous THF (3 mL). After flash column chromatography, recrystallization from THF 
gave offwhite needles (220 mg, 86%). mp 155–157 °C, Rf = 0.06 (EtOAc/n-hexane, 1:1). 1H-NMR (500 
MHz, CDCl3): δ 1.26 (t, J = 7.3 Hz, 3H), 2.48 (q, J = 7.3 Hz, 2H), 3.28 (t, J = 8.3 Hz, 2H), 4.11 (t, J = 8.3 
Hz, 2H), 7.33 (dd, J = 4.9, 7.8 Hz, 1H), 7.41  (d, J = 3.4 Hz, 1H), 7.42 (s, 1H), 7.84 (dt, J = 2.0, 7.8 Hz, 1H), 
8.34 (d, J = 8.0 Hz, 1H), 8.55 (d, J = 4.0 Hz,1H), 8.82 (d, J = 2.2 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ 
8.7, 28.0, 29.1, 48.0, 117.3, 123.1, 123.5, 126.7, 132.0, 133.0, 133.9, 136.3, 143.3,143.4,  148.0, 172.1. MS 
(ESI) m/z = 253 [M+H] +. 
4-(2,3-Dihydro-1H-indol-5-yl)isoquinoline (10a). The title compound was synthesized according to 
Method B using crude 10b (1.97 g) and trifluoroacetic acid (2.43 mL, 31.8 mmol) and was obtained as 
yellow oil (0.58 g, 67% for three steps). 1H-NMR (500 MHz, CDCl3): δ 3.14 (t, J = 8.4 Hz, 2H), 3.67 (t, J = 
8.4 Hz, 2H), 6.78 (d, J = 7.9 Hz, 1H), 7.17 (dd, J = 1.7, 7.9 Hz, 1H), 7.27 (m, 1H), 7.61 (m, 1H), 7.66 (m, 
1H),  8.01 (dd, J = 1.0, 8.4 Hz, 2H), 8.46 (s, 1H), 9.19 (s, 1H). 
4-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)isoquinoline (10). The title compound was synthesized according 
to Method C using 10a (100 mg, 0.41 mmol), acetyl chloride (28 µL, 0.49 mmol) and pyridine (49 µL, 0.61 
mmol) in anhydrous THF (5 mL). Purification by flash column chromatography twice gave a pale yellow 
solid (78 mg, 66%). mp 170–172 °C, Rf = 0.05 (EtOAc/n-hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.28 
(s, 3H), 3.30 (t, J = 8.4 Hz, 2H), 4.16 (t, J = 8.4 Hz, 2H), 7.32 (s, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.62 (t, J = 
7.4 Hz, 1H), 7.67 (t, J = 7.4 Hz, 1H), 7.93 (d,3J = 8.4 Hz, 1H), 8.03 (d, J = 7.9 Hz, 1H), 8.35 (d, J = 8.2 Hz, 
1H), 8.46 (s, 1H), 9.24 (s, 1H).13C-NMR (125 MHz, CDCl3): δ 24.2, 28.0, 49.0, 116.9, 124.8, 126.1, 127.2, 
127.9, 128.4, 129.6, 130.6, 131.7, 132.2, 133.2, 134.4, 142.6, 142.9, 151.6, 168.8. MS (ESI) m/z = 289 
[M+H] +. 
4-(1-Propanoyl-2,3-dihydro-1H-indol-5-yl)isoquinoline (11). The title compound was synthesized 
according to Method C using 10a (80 mg, 0.32 mmol), propanoyl chloride (34 µL, 0.39 mmol) and pyridine 
(39 µL, 0.49 mmol) in anhydrous THF (3 mL). Purification by flash column chromatography was performed 
twice and gave a pale yellow solid (65 mg, 67%). mp 153–155 °C, Rf = 0.12 (EtOAc/n-hexane, 1:1). 1H-
NMR (500 MHz, CDCl3): δ 1.28 (t, J = 7.3 Hz, 3H), 2.51 (q, J = 7.3 Hz, 2H), 3.30 (t, J = 8.4 Hz, 2H), 4.14 
(t, J = 8.4 Hz, 2H), 7.32 (s, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.62 (t, J = 7.3 Hz, 1H), 7.67 (t, J = 7.3 Hz, 1H), 
7.93 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 8.39 (t, J = 8.1 Hz, 1H), 8.46 (s, 1H), 9.23 (s, 1H).13C-
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NMR (125 MHz, CDCl3): δ 8.7, 28.1, 29.2, 48.1, 116.8, 124.8, 126.1, 127.1, 127.9, 128.4, 129.6, 130.5, 
131.5, 132.1, 133.1, 134.3, 136.3, 143.1, 151.7, 172.2. MS (ESI) m/z = 303 [M+H] +. 
4-[1-(Cyclopropylcarbonyl)-2,3-dihydro-1H-indol-5-yl]isoquinoline (12). The title compound was 
synthesized according to Method C using 10a (80 mg, 0.32 mmol), cyclopropanecarbonyl chloride (36 µL, 
0.40 mmol) and pyridine (39 µL, 0.49 mmol) in anhydrous THF (3 mL). Purification by flash column 
chromatography was performed twice and gave a pale yellow solid (77 mg, 76%). mp 159–162 °C, Rf = 0.11 
(EtOAc/n-nexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 0.93 (m, 2H), 1.17 (m, 2H), 1.81 (s, br, 1H), 3.33 (s, 
br, 2H), 4.37 (s, br, 2H), 7.34 (m, 2H), 7.62–7.70 (m, 2H), 7.94 (d, J = 8.1 Hz, 1H), 8.04 (d, J = 7.7 Hz, 1H), 
8.32 (s, br, 1H), 8.47 (s, 1H), 9.24 (s, 1H).13C-NMR (125 MHz, CDCl3): δ 8.3, 13.7, 27.9, 48.3, 116.8, 124.8, 
126.1, 127.2, 127.9, 128.4, 129.6, 130.6, 131.7, 131.9, 133.3, 134.4, 142.4, 143.2, 151.5, 172. MS (ESI) m/z 
= 315 [M+H] +. 
4-[1-(2-Methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]isoquinoline (13). The title compound was 
synthesized according to Method C using 10a (80 mg, 0.32 mmol), isobutyryl chloride (36 µL, 0.40 mmol) 
and pyridine (39 µL, 0.49 mmol) in anhydrous THF (3 mL). Purification by flash column chromatography 
was performed twice and gave a pale yellow solid (70 mg, 69 %). mp 149–151 °C, Rf = 0.12 (EtOAc/n-
hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 1.28 (d, J = 6.7 Hz, 6H), 2.84 (m, 1H), 3.31 (t, J = 7.9 Hz, 2H), 
4.24 (t, J = 8.5 Hz, 2H), 7.35 (m, 2H), 7.66 (m, 1H), 7.72 (m, 1H), 7.97 (d, J = 8.1 Hz, 1H), 8.07 (d, J = 7.8 
Hz, 1H), 8.42 (s, J = 7.8 Hz, 1H), 8.47 (s, 1H), 9.26 (s, 1H).13C-NMR (125 MHz, CDCl3): δ 19.2, 28.1, 33.5. 
48.1, 117.2, 124.8, 126.0, 127.1, 127.9, 128.4, 129.6, 130.5, 131.8, 132.2, 133.1, 134.3, 142.8, 143.2, 151.7, 
175.8. MS (ESI) m/z = 317 [M+H] +. 
1-[5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-indol-1-yl]-ethanone (14a). To a 
solution of 14b (1.86 g, 7.75 mmol) in dioxane (31 mL) was added bis(pinacolato)diboron (3.93 g, 15.5 
mmol), Pd(dPPf)2Cl2 (0.57 g, 0.78 mmol) and anhydrous potassium acetate (3.80 g, 38.7 mmol) under N2. 
The reaction was heated at 105 °C for 2 h. Upon cooling to room temperature, water (20 mL) was added and 
the resulting mixture was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with 
brine, dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (EtOAc/n-hexane, 1:50 to 1:2) to yield a pale yellow solid (2.08 g, 94%). 1H-
NMR (500 MHz, CDCl3): δ 1.34 (s, 12H), 2.32 (s, 3H), 3.18 (t, J = 8.4 Hz, 2H), 4.05 (t, J = 8.5 Hz, 2H), 
7.62 (s, 1H), 7.67 (d, J = 8.0 Hz, 1H), 8.19 (d, J = 8.1 Hz, 1H). 
1-Acetyl-5-(5-fluoropyridin-3-yl)-2,3-dihydro-1H-indole (14). The title compound was synthesized 
according to Method A using 14a (150 mg, 0.52 mmol), 3-bromo-5-fluoropyridine (111 mg, 0.63 mmol), 
sodium carbonate (277 mg, 2.61 mmol) and tetrakis(triphenylphosphine)palladium (0) (30 mg, 0. 03 mmol) 
in dimethoxyethane (9 mL) and water (3 mL). The crude product was purified by flash column 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 2%) and crystallization from acetone to yield colorless 
crystals (108 mg, 81%). mp 178–180 °C, Rf = 0.26 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 MHz, CDCl3): δ 
2.26 (s, 3H), 3.28 (t, J = 8.4 Hz, 2H), 4.13 (t, J = 8.5 Hz, 2H), 7.40 (m, 2H), 7.56 (dt, J = 2.0, 9.6 Hz, 1H), 
8.30 (d, J = 8.2 Hz,1H), 8.41 (d, J = 1.8 Hz,1H), 8.64 (s, 1H).13C-NMR (125 MHz, CDCl3): δ 24.2, 27.9, 
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49.0, 117.4, 118.1, 120.7 (d, 2JC,F = 18.6 Hz), 123.2, 126.8, 131.5, 132.3, 136.0 (d, 2JC,F = 23.3 Hz), 138.1 (d, 
4JC,F = 3.6 Hz), 143.6 (d, 4JC,F = 3.2 Hz), 159.7 (d, 1JC,F = 257 Hz), 168.9. MS (ESI) m/z = 257 [M+H] +. 
5-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)pyridine-3-carbonitrile (15). The title compound was 
synthesized according to Method A using 14a (150 mg, 0.52 mmol), 5-bromonicotinonitrile (118 mg, 0.63 
mmol), sodium carbonate (277 mg, 2.61 mmol) and tetrakis(triphenylphosphine)palladium (0) (30 mg, 0. 03 
mmol) in dimethoxyethane (9 mL) and water (3 mL). The crude product was purified by flash column 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 2%) and crystallization from acetone to yield a white 
solid (123 mg, 90%). mp 206–207 °C, Rf = 0.31 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 MHz, CDCl3): δ 2.27 
(s, 3H), 3.30 (t, J = 8.4 Hz, 2H), 4.15 (t, J = 8.5 Hz, 2H), 7.40 (m, 2H), 8.10 (t, J = 2.1 Hz, 1H), 8.34 (d, J = 
8.3 Hz, 1H), 8.80 (d, J = 1.5 Hz, 1H), 9.00 (d, J = 2.2 Hz, 1H).13C-NMR (125 MHz, CDCl3): δ 24.2, 27.9, 
49.0, 110.1, 116.5, 117.6, 123.1, 126.9, 130.4, 132.7, 136.8, 136.9, 144.1, 150.0, 151.0, 169.0. MS (ESI) m/z 
= 264 [M+H] +. 
1-Acetyl-5-(5-methoxypyridin-3-yl)-2,3-dihydro-1H-indole (16). The title compound was synthesized 
according to Method A using 14a (150 mg, 0.52 mmol), 3-bromo-5-methoxypyridine (122 mg, 0.63 mmol), 
sodium carbonate (277 mg, 2.61 mmol) and tetrakis(triphenylphosphine) palladium (0) (30 mg, 0. 03 mmol) 
in dimethoxyethane (9 mL) and water (3 mL). The crude product was purified by flash column 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 2%) and crystallization from acetone to yield colorless 
crystals (99 mg, 71%). mp 166–168 °C, Rf = 0.22 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 MHz, CDCl3): δ 
2.25 (s, 3H), 3.27 (t, J = 8.5 Hz, 2H), 3.92 (s, 3H), 4.12 (t, J = 8.5 Hz, 2H), 7.35 (t, J = 2.1 Hz,1H), 7.40 (m, 
2H), 8.26 (d, J = 2.6 Hz,1H), 8.29 (d, J = 8.3 Hz,1H), 8.43 (d, J = 1.8 Hz,1H).13C-NMR (125 MHz, CDCl3): 
δ 24.2, 28.0, 49.0, 55.7, 117.3, 119.1, 123.2, 126.8, 132.1, 132.8, 135.2, 137.3, 140.0, 143.2, 155.9, 168.8. 
MS (ESI) m/z = 269 [M+H] +. 
1-[5-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)pyridin-3-yl]ethanone (17). The title compound was 
synthesized according to Method A using 14a (300 mg, 1.04 mmol), 3-acetyl-5-bromopyridine (259 mg, 
1.26 mmol), sodium carbonate (551 mg, 5.20 mmol) and tetrakis(triphenylphosphine)palladium (0) (60 mg, 
0. 05 mmol) in dimethoxyethane (15 mL) and water (5 mL). The crude product was purified by flash column 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 1:50) and crystallization from acetone to yield colorless 
crystals (250 mg, 86%). mp 152–154 °C, Rf = 0.23 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 MHz, CDCl3): δ 
2.26 (s, 3H), 2.69 (s, 3H), 3.29 (t, J = 8.5 Hz, 2H), 4.13 (t, J = 8.5 Hz, 2H), 7.45 (m, 2H), 8.32 (t, J = 8.3 
Hz,1H), 8.38 (t, J = 2.1 Hz,1H), 8.98 (d, J = 2.0 Hz,1H), 9.01 (s, 1H).13C-NMR (125 MHz, CDCl3): δ 24.2, 
26.9, 27.9, 49.0, 117.4, 123.2, 126.7, 131.8, 132.3, 132.4, 133.2, 136.6, 143.6, 147.8, 151.4, 168.9, 196.7. 
MS (ESI) m/z = 281 [M+H] +. 
1-[5-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)pyridin-3-yl]ethanol (18). To a solution of 17 (120 mg, 0.43 
mmol) in methanol (5 mL) was added sodium borohydride (32 mg, 0.86 mmol) at 0 °C. The mixture was 
stirred at the same temperature for 1 h before removal of the solvent. The residue was diluted with water (5 
ml) and then extracted with EtOAc (2 × 5 mL). The combined organic layers were washed with brine, dried 
over MgSO4 and concentrated in vacuo.The residue was purified by flash column chromatography on silica 
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gel (MeOH/CH2Cl2, 0 to 5%) and crystallization from acetone to yield a pale yellow solid (120 mg, 98%). 
mp 179–181 °C, Rf = 0.06 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 MHz,  MeOD-d4): δ 1.53 (s, J = 6.5 Hz, 
3H), 2.67 (s, 3H), 3.29 (d, J = 5.3 Hz, 2H), 4.19 (d, J = 3.8 Hz, 2H), 4.98 (q, J = 6.5 Hz, 1H), 7.49 (s, 1H), 
7.55 (s, 1H), 8.05 (s, 1H), 8.20 (s, 1H), 8.49 (s, 1H), 8.66 (s, 1H).13C-NMR (125 MHz,  MeOD-d4): δ 24.0, 
25.5, 28.8, 50.3, 68.5, 118.4, 124.5, 127.3, 133.2, 134.4, 134.8, 138.0, 143.9, 144.3, 146.1, 146.8, 171.7. MS 
(ESI) m/z = 283 [M+H] +. 
1-Acetyl-5-(5-phenylpyridin-3-yl)-2,3-dihydro-1H-indole (19). The title compound was synthesized 
according to Method A using 14a (150 mg, 0.52 mmol), 3-bromo-5-phenylpyridine (153 mg, 0.63 mmol), 
sodium carbonate (277 mg, 2.61 mmol) and tetrakis(triphenylphosphine)palladium (0) (30 mg, 0. 03 mmol) 
in dimethoxyethane (9 mL) and water (3 mL). The crude product was purified by flash column 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 2%) and crystallization from acetone to yield pale yellow 
crystals (137 mg, 84%). mp 168–170 °C, Rf = 0.24 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 MHz, CDCl3): δ 
2.26 (s, 3H), 3.29 (t, J = 8.4 Hz, 2H), 4.13 (t, J = 8.4 Hz, 2H), 7.42–7.52 (m, 5H), 7.64 (m, 2H), 8.03 (d, J = 
2.0 Hz,1H), 8.32 (d, J = 8.3 Hz,1H), 8.79 (m, 2H).13C-NMR (125 MHz, CDCl3): δ 24.2, 28.0, 49.0, 117.4, 
123.2, 126.8, 127.2, 128.3, 129.1, 132.2, 132.8, 132.9, 136.5, 136.8, 137.6, 143.3, 146.2, 146.3, 168.8. MS 
(ESI) m/z = 315 [M+H] +. 
1-Acetyl-5-(4-methylpyridin-3-yl)-2,3-dihydro-1H-indole (20). The title compound was synthesized 
according to Method A using 14a (150 mg, 0.52 mmol), 3-bromo-4-methylpyridine (70 µL, 0.63 mmol), 
sodium carbonate (277 mg, 2.61 mmol) and tetrakis(triphenylphosphine)palladium (0) (30 mg, 0. 03 mmol) 
in dimethoxyethane (9 mL) and water (3 mL). The crude product was purified by flash column 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 2%) and crystallization from acetone to yield pale yellow 
crystals (85 mg, 65%). mp 180–182 °C, Rf = 0.50 (MeOH/CH2Cl2 1:20). 1H-NMR (500 MHz, CDCl3): δ 
2.25 (s, 3H), 2.29 (s, 3H), 3.26 (t, J = 8.5 Hz, 2H), 4.12 (t, J = 8.5 Hz, 2H), 7.12–7.18 (m, 3H), 8.27 (d, J = 
8.2 Hz,1H), 8.41 (m, 2H).13C-NMR (125 MHz, CDCl3): δ 19.9, 24.1, 28.0, 48.9, 116.7, 125.2, 125.3, 128.8, 
131.5, 133.1, 137.6, 142.5, 144.8, 147.8, 149.7, 168.8. MS (ESI) m/z = 253 [M+H] +. 
5-Pyridin-3-yl-1H-indole (21a). The title compound was synthesized according to Method A using crude 
5-bromoindole (250 mg, 1.26 mmol), pyridin-3-ylboronic acid (186 mg, 1.51 mmol), sodium carbonate (667 
mg, 6.30 mmol) and tetrakis(triphenylphosphine)palladium (0) (73 mg, 0.06 mmol) in dimethoxyethane (30 
mL) and water (10 mL). The crude product was purified by flash column chromatography on silica gel 
(EtOAc/n-hexane, 1:100 to 1:2) to yield a pale yellow solid (202 mg, 82%). 1H-NMR (500 MHz, CDCl3): δ 
7.37 (ddd, J = 0.8, 4.8, 7.9 Hz, 1H), 7.41 (m, 1H), 7.49 (m, 2H), 7.59 (m, 2H), 7.88 (dt, J = 2.0, 7.9 Hz, 1H), 
8.60 (dd, J = 1.6, 4.8 Hz, 1H), 8.86 (dd, J = 0.6, 2.4 Hz, 1H). 
1-Acetyl-5-pyridin-3-yl-1H-indole (21). The title compound was synthesized according to Method D 
using 21a (163 mg, 0.84 mmo), triethylamine (0.17 ml, 1.26 mmol), acetic anhydride (0.30 ml, 3.28 mmol) 
and DMAP (20 mg, 0.16 mmol) and was obtained as pale yellow crystals (100 mg, 50%). mp 138–140 °C, Rf 
= 0.16 (EtOAc/n-hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.67 (s, 3H), 6.71 (d, J = 3.8 Hz, 1H), 7.38  
(dd, J = 4.8, 7.9 Hz, 1H), 7.48 (d, J = 3.7 Hz, 1H), 7.57 (dd, J = 1.8, 8.5 Hz, 1H), 7.77 (d, J = 1.7 Hz, 1H), 
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7.93 (dt, J = 1.8, 7.9 Hz, 1H), 8.54 (d, J = 8.5 Hz, 1H), 8.59 (dd, J = 1.5, 4.8 Hz, 1H), 8.90 (d, J = 1.8 Hz, 
1H). 13C-NMR (125 MHz, CDCl3): δ 23.9, 109.2, 117.1, 119.4, 123.6, 124.4, 126.1, 131.1, 133.4, 134.7, 
135.4, 137.0, 148.0, 148.3, 168.5. MS (ESI) m/z = 237 [M+H] +. 
4-(1H-indol-5-yl)isoquinoline (22a). The title compound was synthesized according to Method A using 
crude 5-bromoindole (250 mg, 1.26 mmol), isoquinoline-4-ylboronic acid (240 mg, 1.39 mmol), sodium 
carbonate (667 mg, 6.30 mmol) and tetrakis(triphenylphosphine)palladium (0) (73 mg, 0.06 mmol) in 
dimethoxyethane (12 mL) and water (4 mL). The crude product was purified by flash column 
chromatography on silica gel (EtOAc/n-hexane, 1:100 to 1:2) to yield a yellow solid (190 mg, 62%).  
4-(1-Acetyl-1H-indol-5-yl)isoquinoline (22). The title compound was synthesized according to Method D 
using 22a (190 mg, 0.78 mmol), triethylamine (0.16 mL, 1.17 mmol), acetic anhydride (0.28 mL, 3.03 mmol) 
and DMAP (27 mg, 0.22 mmol) and obtained as a pale yellow solid (130 mg, 58%). mp 120–122 °C, Rf = 
0.18 (EtOAc/n-hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.70 (s, 3H), 6.73 (d, J = 3.7 Hz, 1H), 7.51 (dd, 
J = 1.7, 8.5 Hz, 1H), 7.53  (d, J = 3.7 Hz, 1H), 7.66 (m, 2H), 7.70 (d, J = 1.4 Hz, 1H), 7.94 (d, J = 8.4 Hz, 
1H), 8.06 (dd, J = 1.3, 7.4 Hz, 1H), 8.54 (s, 1H), 8.59 (d, J = 8.4 Hz, 1H), 9.28 (s, 1H). 13C-NMR (125 MHz, 
CDCl3): δ 24.0, 109.2, 116.2, 122.3, 125.0, 126.0, 127.2, 127.3, 127.9, 128.4, 130.7, 130.8, 132.4, 133.6, 
134.6, 135.2, 142.7, 151.6, 168.6. MS (ESI) m/z = 287 [M+H] +. 
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Supporting Information 
1. The synthetic procedures and characterization of intermediates 1c, 1b, 10b and 14b as well as final 
compounds 3–9. 
tert-Butyl 5-bromo-2,3-dihydro-1H-indole-1-carboxylate (1c). To a solution of 5-bromoindoline (1.20 g, 
6.10 mmol) in anhydrous THF (20 mL) and water (20 mL) was added NaHCO3 (1.53g, 18.2 mmol). After 
being cooled down to 0 °C, to the reaction mixture was added Boc2O (2.59 mL, 12.1 mmol) dropwise, and 
stirred at the same temperature for 30 min. Afterwards, the reaction was warmed to room temperature and 
stirred for additional 5 h. The resulting mixture was separated and the aqueous layer was extracted with 
EtOAc (3 x 20 mL), dried over MgSO4 and concentrated in vacuo to give a grey solid (2.85 g), which was 
directly used in next step without further purification. 
tert-Butyl 5-pyridin-3-yl-2,3-dihydro-1H-indole-1-carboxylate (1b). The title compound were 
synthesized according to Method A using crude 1c (2.85 g), pyridin-3-ylboronic acid (0.98 g, 7.93 mmol), 
sodium carbonate (3.23 g, 30.5 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.35 g, 0.30 mmol) in 
dimethoxyethane (30 mL) and water (10 mL). The crude product was purified by flash column 
chromatography on silica gel (EtOAc/n-hexane, 1:100 to 1:2) to yield colorless crystals (1.42 g, 78% for two 
steps). 1H-NMR (500 MHz, CDCl3): δ 1.58 (s, 9H), 3.16 (t, J = 8.7 Hz, 2H), 4.04 (t, J = 7.9 Hz, 2H), 7.32 
(dd, J = 4.9, 7.9 Hz, 1H), 7.38 (m, 2H),7.74 (s, 1H), 7.83 (dt, J = 2.0, 7.9 Hz, 1H), 8.54  (dd, J = 1.5, 4.8 Hz, 
1H), 8.81 (d, J = 2.2 Hz, 1H). 
tert-Butyl 5-isoquinolin-4-yl-2,3-dihydro-1H-indole-1-carboxylate (10b). The title compound were 
synthesized according to Method A using crude 10c (1.61 g), isoquinoline-4-ylboronic acid (0.73 g, 4.24 
mmol), sodium carbonate (1.87 g, 17.6 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.20 g, 0.18 
mmol) in dimethoxyethane (30 mL) and water (10 mL). The crude product was used directly to next step 
without further purification as brown solids (1.97 g). 
1-Acetyl-5-bromo-2,3-dihydro-1H-indole (14b). The title compound were synthesized according to 
Method C using 5-bromoindoline (1.80 g, 9.09 mmol), acyl chloride (0.62 mL, 10.9 mmol), pyridine (1.10 
mL, 13.6 mmol) and anhydrous THF (35 mL) to yield the crude product as grey solids (1.92 g) without 
further purification. 
1-(3-Chloropropanoyl)-5-pyridin-3-yl-2,3-dihydro-1H-indole (3). The title compound was synthesized 
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according to Method C using 1a (80 mg, 0.41 mmol), 3-chloropropanoyl chloride (48 µL, 0.49 mmol) and 
pyridine (50 µL, 0.62 mmol) in anhydrous THF (3 mL). After flash column chromatography, 
recrystallization from THF gave pale yellow needles (95 mg, 81%). mp 157–159 °C, Rf = 0.10 (EtOAc/n-
hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.95 (t, J = 6.8 Hz, 2H), 3.30 (t, J = 8.5 Hz, 2H), 3.93 (t, J = 6.8 
Hz, 2H), 4.15 (t, J = 8.5 Hz, 2H), 7.34 (dd, J = 4.8, 7.8 Hz, 1H), 7.44  (m, 2H), 7.84 (dt, J = 1.9, 7.8 Hz, 1H), 
8.31 (d, J = 8.2 Hz, 1H), 8.56 (d, J = 4.5 Hz,1H), 8.82 (d, J = 1.9 Hz, 1H).13C-NMR (125 MHz, CDCl3): δ 
28.0, 38.7, 39.2, 48.2, 117.5, 123.2, 123.5, 126.7, 132.2, 133.6, 134.0, 136.2, 142.7, 148.1, 148.2, 168.9. MS 
(ESI) m/z = 287 M +. 
1-(2-Methylpropanoyl)-5-pyridin-3-yl-2,3-dihydro-1H-indole (4). The title compound was synthesized 
according to Method C using 1a (100 mg, 0.51 mmol), isobutyryl chloride (64 µL, 0.61 mmol) and pyridine 
(62 µL, 0.77 mmol) in anhydrous THF (5 mL). The crude product underwent flash column chromatography 
twice gave pale yellow crystals (90 mg, 66%). mp 135–137 °C, Rf = 0.08 (EtOAc/n-hexane, 1:1). 1H-NMR 
(500 MHz, CDCl3): δ 1.25 (d, J = 6.7 Hz, 6H), 2.80 (m, 1H), 3.27 (t, J = 7.8 Hz, 2H), 4.19 (t, J = 8.5 Hz, 
2H), 7.34 (dd, J = 4.9, 7.7 Hz,  1H), 7.42  (m, 2H), 7.85 (dt, J = 2.0, 7.9 Hz, 1H), 8.36 (d, J = 7.5 Hz, 1H), 
8.55 (dd, J = 0.9, 4.5 Hz, 1H), 8.82 (d, J = 1.9 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ 19.1, 28.0, 33.5, 
48.1, 117.7, 123.0, 123.5, 126.6, 132.3, 132.3, 133.0, 134.1, 136.4, 143.5, 147.9, 175.8. MS (ESI) m/z = 267 
[M+H] +. 
1-(Cyclopropylcarbonyl)-5-pyridin-3-yl-2,3-dihydro-1H-indole (5). The title compound was 
synthesized according to Method C using 1a (100 mg, 0.51 mmol), cyclopropanecarbonyl chloride (56 µL, 
0.61 mmol) and pyridine (62 µL, 0.77 mmol) in anhydrous THF (5 mL). The crude product underwent flash 
column chromatography twice gave pale yellow crystals (103 mg, 76%). mp 158–161 °C, Rf = 0.07 
(EtOAc/n-hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 0.91 (m, 2H), 1.15 (m, 2H), 1.78 (s, br, 1H), 3.30 (t, 
J = 8.3 Hz, 2H), 4.33 (t, J = 8.3 Hz, 2H), 7.34 (dd, J = 4.8, 7.8 Hz, 1H), 7.40  (m, 2H), 7.85 (dt, J = 2.0, 7.8 
Hz, 1H), 8.26 (s, br, 1H), 8.55 (d, J = 4.6 Hz,1H), 8.82 (d, J = 1.8 Hz, 1H).13C-NMR (125 MHz, CDCl3): δ 
8.3, 13.6, 27.9, 48.3, 117.3, 123.1, 123.5, 126.6, 132.2, 132.8, 134.1, 136.4, 143.4, 147.8, 171.9. MS (ESI) 
m/z = 265 [M+H] +. 
1-[(4-Fluorophenyl)carbonyl]-5-pyridin-3-yl-2,3-dihydro-1H-indole (6). The title compound was 
synthesized according to Method C using 1a (80 mg, 0.41 mmol), 4-fluorobenzoyl chloride (60 µL, 0.49 
mmol) and pyridine (50 µL, 0.62 mmol) in anhydrous THF (3 mL). After flash column chromatography, 
recrystallization from THF gave pale yellow crystals (102 mg, 78%). mp 161–162 °C, Rf = 0.09 (EtOAc/n-
hexane, 1:1). 1H-NMR (500 MHz, DMSO-d6, 300K): δ 3.16 (t, J = 8.3 Hz, 2H), 4.07 (t, J = 8.3 Hz, 2H), 7.34 
(m, 2H), 7.46 (dd, J = 4.8, 8.0 Hz, 1H), 7.56 (s, br, 1H), 7.67 (d, J = 0.9 Hz,1H), 7.70 (m, 2H ), 8.05 (d, J = 
8.0 Hz, 1H), 8.53 (dd, J = 1.5, 4.7 Hz, 1H), 8.87 (d, J = 1.8 Hz,1H). 1H-NMR (500 MHz, DMSO-d6, 373K): 
δ 3.19 (t, J = 8.3 Hz, 2H), 4.08 (t, J = 8.3 Hz, 2H), 7.31 (m, 2H), 7.43 (dd, J = 4.7, 7.9 Hz, 1H), 7.51 (d, J = 
8.3 Hz, 1H), 7.63 (s, 1H), 7.68 (m, 2H ), 7.73 (s, br, 1H), 8.01 (dt, J = 1.9, 7.9 Hz, 1H), 8.53 (dd, J = 1.4, 4.7 
Hz, 1H), 8.85 (d, J = 2.0 Hz, 1H). 13C-NMR (125 MHz, DMSO-d6): δ 27.7, 50.5, 115.5 (d, 2JC,F = 22.0 Hz), 
116.8, 123.4, 123.8, 125.6, 129.7 (d, 3JC,F = 8.8 Hz), 132.5, 133.3, 133.6, 133.9, 135.2, 142.7, 147.3, 148.0, 
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163.0 (d, 1JC,F = 247 Hz), 167.2. MS (ESI) m/z = 319 [M+H] +. 
1-[(4-Methoxyphenyl)carbonyl]-5-pyridin-3-yl-2,3-dihydro-1H-indole (7). The title compound was 
synthesized according to Method C using 1a (80 mg, 0.41 mmol), 4-methoxybenzoyl chloride (70 µL, 0.49 
mmol) and pyridine (50 µL, 0.62 mmol) in anhydrous THF (3 mL). After flash column chromatography 
(MeOH/CH2Cl2, 0 to 1:100), recrystallization from THF gave colorless crystals (106 mg, 78%). mp 177–179 
°C, Rf = 0.07 (EtOAc/n-hexane, 1:1). 1H-NMR (500 MHz, DMSO-d6, 300K): δ 3.16 (t, J = 8.3 Hz, 2H), 3.83 
(s, 3H), 4.11 (t, J = 8.3 Hz, 2H), 7.04 (m, 2H), 7.45 (dd, J = 4.8, 7.9 Hz, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.60 
(m, 2H), 7.66 (s, 1H), 8.04 (dt, J = 2.0, 8.0 Hz, 1H), 8.52 (dd, J = 1.5, 4.7 Hz, 1H), 8.87 (d, J = 2.0 Hz, 1H). 
1H-NMR (500 MHz, DMSO-d6, 373K): δ 3.18 (t, J = 8.3 Hz, 2H), 3.86 (s, 3H), 4.12 (t, J = 8.3 Hz, 2H), 7.04 
(m, 2H), 7.42 (dd, J = 4.7, 7.9 Hz, 1H), 7.47 (dd, J = 1.7, 8.3 Hz, 1H), 7.57 (m, 2H), 7.60 (d, J = 0.9 Hz, 1H), 
7.67 (d, J = 8.4 Hz, 1H), 8.98 (dt, J = 2.0, 7.9 Hz, 1H), 8.52 (dd, J = 1.5, 4.7 Hz, 1H), 8.84 (d, J = 2.4 Hz, 
1H).13C-NMR (125 MHz, CDCl3): δ 28.2, 50.9, 55.4, 113.8, 117.2, 123.5, 126.3, 128.8, 129.4, 132.1, 133.3, 
133.5, 133.9, 136.3, 143.1, 148.1, 148.2, 161.5, 168.9. MS (ESI) m/z = 331 [M+H] +. 
5-Pyridin-3-yl-1-(thiophen-2-ylcarbonyl)-2,3-dihydro-1H-indole (8). The title compound was 
synthesized according to Method C using 1a (80 mg, 0.41 mmol), thiophene-2-carbonyl chloride (50 µL, 
0.49 mmol) and pyridine (50 µL, 0.62 mmol) in anhydrous THF (3 mL). Purification by flash column 
chromatography (MeOH/CH2Cl2, 0 to 1:100) gave pale yellow solids (101 mg, 80%). mp 160–162 °C, Rf = 
0.08 (EtOAc/n-hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 3.30 (t, J = 8.3 Hz, 2H), 4.45 (t, J = 8.3 Hz, 
2H), 7.13 (t, J = 8.3 Hz, 1H), 7.34 (dd, J = 4.8, 7.9 Hz, 1H), 7.44  (m, 2H), 7.56 (dd, J = 0.9, 5.0 Hz, 1H), 
7.62 (dd, J = 0.8, 3.7 Hz, 1H), 7.83 (dt, J = 2.0, 7.9 Hz, 1H), 8.18 (s, br, 1H), 8.56 (dd, J = 1.5, 4.8 Hz, 1H), 
8.83 (d, J = 2.0 Hz, 1H).13C-NMR (125 MHz, CDCl3): δ 28.7, 50.8, 118.2, 123.2, 123.5, 126.6, 127.3, 130.0, 
130.4, 132.9, 133.8, 134.0, 136.2, 139.2, 143.3, 148.1, 148.2, 161.5. MS (ESI) m/z = 307 [M+H] +. 
1-(Penylacetyl)-5-pyridin-3-yl-2,3-dihydro-1H-indole (9). The title compound was synthesized 
according to Method C using 1a (80 mg, 0.41 mmol), phenylacetyl chloride (70 µL, 0.49 mmol) and pyridine 
(50 µL, 0.62 mmol) in anhydrous THF (3 mL). After flash column chromatography (MeOH/CH2Cl2, 0 to 
1:100), recrystallization from THF gave pale yellow crystals (110 mg, 85%). mp 125–127 °C, Rf = 0.08 
(EtOAc/n-hexane, 1:1). 1H-NMR (500 MHz, CDCl3): δ 3.24 (t, J = 8.5 Hz, 2H), 3.84 (s, 2H), 4.13 (t, J = 8.5 
Hz, 2H), 7.28  (m, 1H), 7.34 (m, 5H), 7.39 (s, 1H), 7.42 (d, J = 8.5 Hz,1H), 7.83 (dt, J = 1.8, 7.9 Hz, 1H), 
8.36 (d, J = 8.4 Hz, 1H), 8.55 (d, J = 1.3, 4.7 Hz, 1H), 8.81 (d, J = 2.1 Hz, 1H).13C-NMR (125 MHz, CDCl3): 
δ 28.0, 43.5, 48.4, 117.6, 123.1, 123.5, 126.7, 127.1, 128.8, 129.0, 132.2, 133.4, 134.0, 134.0, 136.3, 143.2, 
148.0, 148.1, 169.2. MS (ESI) m/z = 315 [M+H] +. 
 
2. X-ray crystal structure data of compound 6 and 7. 
Compound 6: 
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Crystal data and structure refinement. 
Empirical formula  C20H15FN2O 
Formula weight  318.34 
Temperature  153(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.3874(5) Å 　 α = 101.696(3)°. 
 b = 11.5729(6) Å 　 β = 102.001(3)°. 
 c = 16.2624(11) Å 　 γ = 111.851(2)°. 
Volume 1525.71(15) Å3 
Z 4 
Density (calculated) 1.386 mg/m3 
Absorption coefficient 0.095 mm-1 
F(000) 664 
Crystal size 0.43 x 0.38 x 0.25 mm3 
Theta range for data collection 1.35 to 27.37°. 
Index ranges -12<=h<=12, -14<=k<=14, -19<=l<=20 
Reflections collected 24262 
Independent reflections 6722 [R(int) = 0.0407] 
Completeness to theta = 27.37° 97.4 %  
Absorption correction Multiscan 
Max. and min. transmission 0.9768 and 0.9600 
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Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6722 / 0 / 553 
Goodness-of-fit on F2 1.067 
Final R indices [I>2sigma(I)] R1 = 0.0505, wR2 = 0.1410 
R indices (all data) R1 = 0.0687, wR2 = 0.1547 
Largest diff. peak and hole 0.332 and -0.276 e.Å-3 
 
Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 x 103) for Compound 6. U(eq) is 
defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N(1) 4623(2) 6365(1) 1256(1) 27(1) 
N(2) 6959(2) 488(2) 933(1) 35(1) 
O(1) 1972(2) 5173(1) 1066(1) 37(1) 
F(1) 1461(2) 10378(1) 948(1) 44(1) 
C(1) 6629(2) 5696(2) 1180(1) 26(1) 
C(2) 7356(2) 4860(2) 1197(1) 29(1) 
C(3) 6564(2) 3647(2) 1326(1) 27(1) 
C(4) 5040(2) 3331(2) 1443(1) 30(1) 
C(5) 4300(2) 4162(2) 1436(1) 30(1) 
C(6) 5109(2) 5352(2) 1297(1) 26(1) 
C(7) 5994(3) 7516(2) 1214(2) 38(1) 
C(8) 7195(2) 7000(2) 1016(2) 33(1) 
C(9) 7307(2) 2728(2) 1340(1) 28(1) 
C(10) 8952(2) 3148(2) 1755(1) 32(1) 
C(11) 9571(3) 2242(2) 1763(1) 36(1) 
C(12) 8537(3) 927(2) 1355(2) 35(1) 
C(13) 6382(2) 1381(2) 931(1) 30(1) 
C(14) 3077(2) 6224(2) 1132(1) 27(1) 
C(15) 2732(2) 7371(2) 1090(1) 26(1) 
C(16) 1287(2) 7138(2) 478(1) 29(1) 
C(17) 848(2) 8136(2) 425(1) 31(1) 
C(18) 1867(2) 9384(2) 1001(1) 31(1) 
C(19) 3264(2) 9647(2) 1631(1) 30(1) 
C(20) 3706(2) 8641(2) 1673(1) 28(1) 
N(3) 3263(2) 5050(2) 3730(1) 26(1) 
N(4) 6053(2) -466(2) 4145(1) 37(1) 
O(2) 975(2) 4146(1) 4091(1) 35(1) 
F(2) 157(2) 9095(2) 3526(1) 60(1) 
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C(21) 5390(2) 4486(2) 3809(1) 25(1) 
C(22) 6131(2) 3664(2) 3813(1) 26(1) 
C(23) 5251(2) 2355(2) 3762(1) 25(1) 
C(24) 3615(2) 1931(2) 3712(1) 28(1) 
C(25) 2853(2) 2750(2) 3709(1) 28(1) 
C(26) 3763(2) 4043(2) 3755(1) 25(1) 
C(27) 4599(2) 6193(2) 3651(2) 33(1) 
C(28) 6085(2) 5919(2) 3874(1) 30(1) 
C(29) 6001(2) 1435(2) 3757(1) 25(1) 
C(30) 7244(2) 1514(2) 3395(1) 29(1) 
C(31) 7867(2) 610(2) 3413(1) 32(1) 
C(32) 7237(3) -364(2) 3788(1) 34(1) 
C(33) 5470(2) 420(2) 4126(1) 31(1) 
C(34) 1881(2) 5042(2) 3884(1) 26(1) 
C(35) 1474(2) 6149(2) 3780(1) 27(1) 
C(36) 805(2) 6622(2) 4378(1) 30(1) 
C(37) 365(2) 7618(2) 4301(2) 35(1) 
C(38) 578(2) 8106(2) 3605(2) 38(1) 
C(39) 1161(2) 7628(2) 2982(2) 38(1) 
C(40) 1631(2) 6651(2) 3076(1) 31(1) 
________________________________________________________________________________  
Bond lengths [Å] and angles [°] for Compound 6. 
_____________________________________________________  
N(1)-C(14)  1.364(2) 
N(1)-C(6)  1.416(2) 
N(1)-C(7)  1.495(2) 
N(2)-C(13)  1.333(3) 
N(2)-C(12)  1.342(3) 
O(1)-C(14)  1.236(2) 
F(1)-C(18)  1.353(2) 
C(1)-C(2)  1.377(3) 
C(1)-C(6)  1.396(3) 
C(1)-C(8)  1.502(3) 
C(2)-C(3)  1.404(3) 
C(3)-C(4)  1.403(3) 
C(3)-C(9)  1.474(3) 
C(4)-C(5)  1.381(3) 
C(5)-C(6)  1.394(2) 
C(7)-C(8)  1.519(3) 
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C(9)-C(10)  1.397(3) 
C(9)-C(13)  1.400(3) 
C(10)-C(11)  1.375(3) 
C(11)-C(12)  1.386(3) 
C(14)-C(15)  1.491(3) 
C(15)-C(16)  1.400(3) 
C(15)-C(20)  1.403(3) 
C(16)-C(17)  1.376(3) 
C(17)-C(18)  1.389(3) 
C(18)-C(19)  1.372(3) 
C(19)-C(20)  1.383(3) 
N(3)-C(34)  1.369(2) 
N(3)-C(26)  1.414(2) 
N(3)-C(27)  1.497(2) 
N(4)-C(33)  1.332(3) 
N(4)-C(32)  1.335(3) 
O(2)-C(34)  1.231(2) 
F(2)-C(38)  1.363(2) 
C(21)-C(22)  1.372(3) 
C(21)-C(26)  1.395(2) 
C(21)-C(28)  1.510(2) 
C(22)-C(23)  1.405(2) 
C(23)-C(24)  1.406(3) 
C(23)-C(29)  1.478(3) 
C(24)-C(25)  1.384(3) 
C(25)-C(26)  1.397(2) 
C(27)-C(28)  1.532(3) 
C(29)-C(30)  1.394(3) 
C(29)-C(33)  1.402(3) 
C(30)-C(31)  1.377(3) 
C(31)-C(32)  1.387(3) 
C(34)-C(35)  1.496(3) 
C(35)-C(36)  1.391(3) 
C(35)-C(40)  1.394(3) 
C(36)-C(37)  1.381(3) 
C(37)-C(38)  1.381(3) 
C(38)-C(39)  1.364(3) 
C(39)-C(40)  1.382(3) 
C(14)-N(1)-C(6) 124.57(15) 
C(14)-N(1)-C(7) 125.66(16) 
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C(6)-N(1)-C(7) 109.00(15) 
C(13)-N(2)-C(12) 116.98(18) 
C(2)-C(1)-C(6) 120.45(16) 
C(2)-C(1)-C(8) 129.73(17) 
C(6)-C(1)-C(8) 109.78(17) 
C(1)-C(2)-C(3) 120.02(17) 
C(4)-C(3)-C(2) 118.19(18) 
C(4)-C(3)-C(9) 120.56(16) 
C(2)-C(3)-C(9) 121.25(17) 
C(5)-C(4)-C(3) 122.55(17) 
C(4)-C(5)-C(6) 117.87(18) 
C(5)-C(6)-C(1) 120.90(18) 
C(5)-C(6)-N(1) 129.16(17) 
C(1)-C(6)-N(1) 109.94(15) 
N(1)-C(7)-C(8) 104.94(16) 
C(1)-C(8)-C(7) 104.40(16) 
C(10)-C(9)-C(13) 116.68(19) 
C(10)-C(9)-C(3) 122.29(17) 
C(13)-C(9)-C(3) 121.03(17) 
C(11)-C(10)-C(9) 119.69(19) 
C(10)-C(11)-C(12) 118.8(2) 
N(2)-C(12)-C(11) 123.3(2) 
N(2)-C(13)-C(9) 124.52(19) 
O(1)-C(14)-N(1) 121.32(18) 
O(1)-C(14)-C(15) 119.80(17) 
N(1)-C(14)-C(15) 118.87(15) 
C(16)-C(15)-C(20) 118.67(18) 
C(16)-C(15)-C(14) 117.52(17) 
C(20)-C(15)-C(14) 123.60(17) 
C(17)-C(16)-C(15) 121.03(18) 
C(16)-C(17)-C(18) 118.38(18) 
F(1)-C(18)-C(19) 118.55(18) 
F(1)-C(18)-C(17) 118.98(18) 
C(19)-C(18)-C(17) 122.47(19) 
C(18)-C(19)-C(20) 118.77(18) 
C(19)-C(20)-C(15) 120.62(18) 
C(34)-N(3)-C(26) 124.77(15) 
C(34)-N(3)-C(27) 125.69(16) 
C(26)-N(3)-C(27) 108.89(15) 
C(33)-N(4)-C(32) 116.96(17) 
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C(22)-C(21)-C(26) 120.94(16) 
C(22)-C(21)-C(28) 129.56(17) 
C(26)-C(21)-C(28) 109.48(16) 
C(21)-C(22)-C(23) 120.07(17) 
C(22)-C(23)-C(24) 118.01(17) 
C(22)-C(23)-C(29) 121.73(16) 
C(24)-C(23)-C(29) 120.26(16) 
C(25)-C(24)-C(23) 122.54(17) 
C(24)-C(25)-C(26) 117.86(17) 
C(21)-C(26)-C(25) 120.58(17) 
C(21)-C(26)-N(3) 110.51(15) 
C(25)-C(26)-N(3) 128.88(17) 
N(3)-C(27)-C(28) 104.69(15) 
C(21)-C(28)-C(27) 103.94(15) 
C(30)-C(29)-C(33) 116.46(18) 
C(30)-C(29)-C(23) 123.27(16) 
C(33)-C(29)-C(23) 120.27(17) 
C(31)-C(30)-C(29) 119.49(17) 
C(30)-C(31)-C(32) 119.14(19) 
N(4)-C(32)-C(31) 123.1(2) 
N(4)-C(33)-C(29) 124.83(19) 
O(2)-C(34)-N(3) 121.54(18) 
O(2)-C(34)-C(35) 120.30(17) 
N(3)-C(34)-C(35) 118.14(15) 
C(36)-C(35)-C(40) 119.28(19) 
C(36)-C(35)-C(34) 117.87(17) 
C(40)-C(35)-C(34) 122.68(17) 
C(37)-C(36)-C(35) 120.55(19) 
C(36)-C(37)-C(38) 118.1(2) 
F(2)-C(38)-C(39) 118.3(2) 
F(2)-C(38)-C(37) 118.5(2) 
C(39)-C(38)-C(37) 123.1(2) 
C(38)-C(39)-C(40) 118.3(2) 
C(39)-C(40)-C(35) 120.6(2) 
_____________________________________________________________  
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Compound 7: 
 
Crystal data and structure refinement. 
Empirical formula  C21H18N2O2 
Formula weight  330.37 
Temperature  153(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 19.5025(4) Å α = 90°. 
 b = 11.0639(2) Å β = 109.506(2)°. 
 c = 15.5364(4) Å γ = 90°. 
Volume 3159.94(12) Å3 
Z 8 
Density (calculated) 1.389 mg/m3 
Absorption coefficient 0.090 mm-1 
F(000) 1392 
Crystal size 0.30 x 0.25 x 0.13 mm3 
Theta range for data collection 2.15 to 27.90°. 
Index ranges -18<=h<=25, -14<=k<=14, -20<=l<=20 
Reflections collected 15711 
Independent reflections 3782 [R(int) = 0.0356] 
Completeness to theta = 27.90° 99.8 %  
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Absorption correction Multiscan 
Max. and min. transmission 0.9883 and 0.9731 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3782 / 0 / 298 
Goodness-of-fit on F2 1.029 
Final R indices [I>2sigma(I)] R1 = 0.0377, wR2 = 0.0887 
R indices (all data) R1 = 0.0547, wR2 = 0.0973 
Largest diff. peak and hole 0.255 and -0.200 e.Å-3 
 
Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 x 103) for Compound 7. U(eq) is 
defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N(1) 4633(1) 9286(1) 3532(1) 22(1) 
N(2) 8676(1) 11194(1) 5779(1) 29(1) 
O(1) 4446(1) 7294(1) 3703(1) 34(1) 
O(2) 1150(1) 8388(1) 1616(1) 29(1) 
C(1) 5388(1) 9273(1) 4038(1) 20(1) 
C(2) 5856(1) 8296(1) 4337(1) 23(1) 
C(3) 6576(1) 8530(1) 4856(1) 22(1) 
C(4) 6842(1) 9706(1) 5066(1) 20(1) 
C(5) 6360(1) 10674(1) 4748(1) 21(1) 
C(6) 5640(1) 10454(1) 4246(1) 20(1) 
C(7) 5028(1) 11342(1) 3895(1) 23(1) 
C(8) 4386(1) 10561(1) 3327(1) 25(1) 
C(9) 7619(1) 9933(1) 5585(1) 21(1) 
C(10) 8033(1) 9186(1) 6292(1) 25(1) 
C(11) 8758(1) 9456(1) 6732(1) 29(1) 
C(12) 9055(1) 10457(1) 6455(1) 31(1) 
C(13) 7977(1) 10918(1) 5368(1) 24(1) 
C(14) 4194(1) 8286(1) 3401(1) 23(1) 
C(15) 3397(1) 8411(1) 2902(1) 22(1) 
C(16) 3085(1) 9146(1) 2147(1) 24(1) 
C(17) 2338(1) 9163(1) 1699(1) 25(1) 
C(18) 1887(1) 8434(1) 2005(1) 23(1) 
C(19) 2194(1) 7672(1) 2753(1) 25(1) 
C(20) 2936(1) 7656(1) 3184(1) 24(1) 
C(21) 819(1) 9208(1) 877(1) 33(1) 
________________________________________________________________________________  
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Bond lengths [Å] and angles [°] for Compound 7. 
_____________________________________________________  
N(1)-C(14)  1.3726(15) 
N(1)-C(1)  1.4184(15) 
N(1)-C(8)  1.4907(15) 
N(2)-C(13)  1.3343(16) 
N(2)-C(12)  1.3394(18) 
O(1)-C(14)  1.2295(15) 
O(2)-C(18)  1.3614(15) 
O(2)-C(21)  1.4360(17) 
C(1)-C(2)  1.3906(17) 
C(1)-C(6)  1.3953(16) 
C(2)-C(3)  1.3905(18) 
C(3)-C(4)  1.3986(17) 
C(4)-C(5)  1.4022(17) 
C(4)-C(9)  1.4808(17) 
C(5)-C(6)  1.3796(17) 
C(6)-C(7)  1.5018(17) 
C(7)-C(8)  1.5337(18) 
C(9)-C(13)  1.3944(17) 
C(9)-C(10)  1.3952(17) 
C(10)-C(11)  1.3817(18) 
C(11)-C(12)  1.384(2) 
C(14)-C(15)  1.4939(17) 
C(15)-C(16)  1.3890(17) 
C(15)-C(20)  1.3999(17) 
C(16)-C(17)  1.3885(18) 
C(17)-C(18)  1.3895(18) 
C(18)-C(19)  1.3981(18) 
C(19)-C(20)  1.3773(18) 
C(14)-N(1)-C(1) 123.70(10) 
C(14)-N(1)-C(8) 126.22(10) 
C(1)-N(1)-C(8) 109.19(9) 
C(13)-N(2)-C(12) 116.34(12) 
C(18)-O(2)-C(21) 117.26(10) 
C(2)-C(1)-C(6) 120.55(11) 
C(2)-C(1)-N(1) 129.54(11) 
C(6)-C(1)-N(1) 109.89(10) 
C(3)-C(2)-C(1) 118.17(11) 
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C(2)-C(3)-C(4) 122.24(11) 
C(3)-C(4)-C(5) 118.30(11) 
C(3)-C(4)-C(9) 121.16(11) 
C(5)-C(4)-C(9) 120.51(11) 
C(6)-C(5)-C(4) 120.05(11) 
C(5)-C(6)-C(1) 120.67(11) 
C(5)-C(6)-C(7) 128.68(11) 
C(1)-C(6)-C(7) 110.58(11) 
C(6)-C(7)-C(8) 103.75(10) 
N(1)-C(8)-C(7) 105.50(10) 
C(13)-C(9)-C(10) 116.65(11) 
C(13)-C(9)-C(4) 120.23(11) 
C(10)-C(9)-C(4) 123.11(11) 
C(11)-C(10)-C(9) 119.30(12) 
C(10)-C(11)-C(12) 118.92(12) 
N(2)-C(12)-C(11) 123.57(13) 
N(2)-C(13)-C(9) 125.22(12) 
O(1)-C(14)-N(1) 120.81(11) 
O(1)-C(14)-C(15) 119.73(11) 
N(1)-C(14)-C(15) 119.45(11) 
C(16)-C(15)-C(20) 117.90(11) 
C(16)-C(15)-C(14) 125.38(11) 
C(20)-C(15)-C(14) 116.54(11) 
C(17)-C(16)-C(15) 121.43(12) 
C(16)-C(17)-C(18) 119.88(12) 
O(2)-C(18)-C(17) 124.38(11) 
O(2)-C(18)-C(19) 116.24(11) 
C(17)-C(18)-C(19) 119.38(12) 
C(20)-C(19)-C(18) 120.02(12) 
C(19)-C(20)-C(15) 121.34(12) 
_____________________________________________________________  
Acknowledgements. The authors appreciate Dr. Volker Huch for the determination and analysis of X-ray 
crystal structure. 
 
3. HPLC purity control of all final compounds. 
The Surveyor®-LC-system consisted of a pump, an autosampler, and a PDA detector. Mass spectrometry 
was performed on a TSQ® Quantum (Thermo Electron Corporation, Dreieich, Germany). The triple 
quadrupole mass spectrometer was equipped with an electrospray interface (ESI). The system was operated 
by the standard software Xcalibur®. 
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A RP C18 NUCLEODUR® 100-5 (125 × 3 mm) column (Macherey-Nagel GmbH, Duehren, Germany) 
was used as stationary phase. All solvents were HPLC grade. 
In a gradient run the percentage of acetonitrile (containing 0.1% triflouro-acetic acid) in water was 
increased from an initial concentration of 3% at 0 min to 100% at 15 min and kept at 100% for 3 min. 
The injection volume was 10 µl and flow rate was set to 350 µl/min. MS analysis was carried out at a 
spray voltage of 3800 V, a capillary temperature of 350 °C and a source CID of 10 V. Spectra were acquired 
in positive mode from 100 to 1000 m/z and full scan UV-mode. In some cases APC ionization had to be 
applied. 
Compd. RT (min) Purity [%] 
1 9.08 99.7% 
2 7.79 99.9% 
3 10.86 99.6% 
4 8.93 99.9% 
5 8.64 99.9% 
6 10.33 99.9% 
7 9.92 99.9% 
8 9.71 99.9% 
9 10.44 99.9% 
10 9.03 99.7% 
11 12.26 99.7% 
12 10.36 99.7% 
13 10.61 99.9% 
14 11.17 99.9% 
15 11.24 99.9% 
16 8.35 99.4% 
17 9.70 99.9% 
18 7.60 99.9% 
19 11.05 99.7% 
20 7.43 99.9% 
21 8.16 98.5% 
22 10.09 99.7% 
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3.III. Novel Pyridinylmethyl Substituted 1,2,5,6-
Tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones Type 
Dual  CYP19 / CYP11B2 Inhibitors as Adjuvant 
Therapy for Post-Menopausal Breast Cancer 
Patients with Elevated Risk  for Cardiovascular 
Complications 
 
Introduction 
Estrogens not only act physiologically as important sexual hormones to promote the development of 
female secondary sexual characteristics and to maintain the normal functions of the reproductive system, but 
also exhibit dichotomous impacts on human health under some pathological circumstances. On one hand, 
estrogens stimulate the proliferation of breast cancer (BC) cells which express estrogen receptors (ER) and / 
or progesterone receptors (PgR).1 Estrogen deprivation is therefore a rational treatment for BC. Two 
approaches have been implemented in clinic: selective estrogen receptor modulators (SERMs),2 and 
aromatase inhibitors (AIs),3 such as letrozole and vorozole (Chart 1). Since AIs show fewer side effects 
compared to SERMs especially in long-term applications, they are first choice nowadays as adjuvant 
therapeutics for postmenopausal women, the majority of breast cancer patients. On the other hand, estrogen 
deficiency is closely correlated with cardiovascular diseases (CVD), which has been demonstrated by the 
fact that the incidences of CVD in post-menopausal women triple those of premenopausal women at the 
same age.4 It has been elucidated that estrogens exhibit some protective effects on heart5 and kidney.6 The 
administration of estrogen prevents the development of heart failure post-myocardial infarction7 and 
attenuates ventricular hypertrophy and remodelling.8 As for BC patients, menopause and the application of 
AIs decrease the estrogen concentrations below undetectable levels,9 which leads  to even higher risk of 
CVD.  
It is believed that the high CVD risk results from estrogen depletion and is mediated to a great extent by 
the increase of aldosterone levels. Estrogen deficiency not only directly promotes aldosterone secretion, but 
also upregulates other renin–angiotensin–aldosterone system (RAAS) components, such as rennin, 
angiotensin II (Ang II), angiotensin converting enzyme (ACE), and angiotensin II type 1 receptor (AT1R), 
which further elevate aldosterone biosynthesis.10 The abnormally high concentration of aldosterone retains 
sodium and water leading to an increase of blood volume and the subsequent elevation of blood pressure.11 It 
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also promotes the influx of calcium into vascular smooth muscle cells12 and the expression of 
adrenomedullin and regulator of G protein signaling-2 (RGS2)13 leading to vasoconstriction, which together 
with the increase of blood volume results in chronic hypertension. Moreover, excessive aldosterone acts as a 
pro-inflammation factor14, and it induces the production of reactive oxygen species (ROS)15 as well. 
Inflammation and ROS formation lead to cardiac myocyte necrosis, collagen synthesis and fibroblast 
proliferation thus resulting in cardiac and vascular fibrosis and an increase in myocardial stiffness.16 
Subsequently, cardiac hypertrophy and ventricular remodelling occure as further structural deterioration with 
functional degradation.17 The ventricular remodeling causes diastolic dysfunction, diminishes contractile 
capability, reduces stroke volume and ultimately results in heart failure, often leading to sudden death. 
Aldosterone synthase (CYP11B2) is the crucial enzyme catalyzing the conversion of 11-
deoxycorticosterone to aldosterone. Its inhibition leading to a reduction of aldosterone levels would be 
beneficial for post-menopausal BC patients under AI treatment. For pursuing this goal, the dual inhibitors of 
CYP19 and CYP11B2 would be advantageous for reasons of a better compliance and to decrease side effects. 
Besides, application of this kind of a dual-target-directed agents18 could also avoid possible drug-drug 
interactions often observed after of administration of two drugs. Accordingly, in this paper we like to 
develop dual inhibitors of both enzymes as a novel innovative therapeutic approach for the treatment of BC.  
For this, important structural features of CYP11B2 inhibitors and CYP19 inhibitors were combined in a 
common structural template and a series of pyridinylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-
ij]quinolin-4-ones 1–26 were synthesized. The inhibition of CYP11B2 and CYP19 by these compounds is 
presented in comparison with fadrozole (Chart 1), which is a potent CYP19 inhibitor showing unselective 
inhibition of 11β-hydroxylase (CYP11B1) and CYP11B2. Accordingly, the selectivity of the new 
compounds against CYP11B1 and 17α-hydroxylase-17,20-lyase (CYP17), which are the crucial enzymes in 
the biosyntheses of glucocorticoids and androgens, respectively, were also determined as safety criteria. 
Dual Inhibitors Design Concept 
All cytochrome P450s are cysteinato-heme enzymes, and the iron in the protoporphyrin acts as the reactive 
centre to activate oxygen which is required for the oxidation of the substrate. Therefore, reversible 
competitive inhibition via the coordination of this Fe by sp2 hybrid N is a common inhibitory mechanism for 
most of the CYP enzymes inhibitors. It was first identified for CYP19 inhibitors,19a but was soon 
successfully applied to the inhibitors of CYP17,20 CYP11B1,21 and CYP11B2.22 Despite poor sequence 
identity of less than 20% across the whole CYP superfamily, CYP proteins share similar folding 
configurations and conserved substrate binding pockets. This makes it difficult to achieve selectivity, but 
could be advantageous to develop dual inhibitors. A simple design strategy was applied in this study: the 
combination of the important structural features of selective CYP19 and CYP11B2 inhibitors into one 
molecule. Plenty of CYP19 inhibitors19 have been designed and synthesized with letrozole and vorozole 
(Chart 1) as the representatives. It is obvious that three major structural features appear in these two 
compounds: triazole providing sp2 hybrid N, CH between N containing heterocycle and hydrophobic core, 
and two hydrophobic aryls. These two compounds showed potent inhibition of CYP19 and weak or no 
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intereference with CYP11B2. On the contrary, fadrozole (Chart 1), in which one aryl was replaced by alkyl 
fused onto the imidazole, was not selective toward CYP11B1 and CYP11B2 inhibition. Hence, the scaffold 
of arylmethyl substituted N containing heterocycle was considered to be crucial for strong CYP19 inhibition 
and modifications on aryl and N containing heterocycle were performed to tune the inhibition of CYP11B 
enzymes. As our efforts to develop selective CYP11B2 inhibitors had been successful and had led to 
reference compound I22h with 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one as hydrophobic core and 3-
pyridyl as N containing heterocycle. This core was considered to be important for a strong CYP11B2 
inhibition. It was therefore introduced into the CYP19 scaffold to achieve dual inhibition. Moreover, 3- or 4-
pyridinyl were employed as N-containing heterocycles while various substituents were furnished on the CH 
bridge leading to a series of pyridinylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones 
(Chart 1). 
Results and Discussion 
Chemistry.  The preparation of compounds 1–26 is illustrated in Scheme 1. The 1,2,5,6-tetrahydro-
pyrrolo[3,2,1-ij]quinolin-4-one core 5c was synthesized from indoline after amidation and Friedel-Crafts 
alkylation, and subsequently converted into the pyridinyl ketones 5b (3-py) and 13b (4-py) via Friedel-Crafts 
acylation with the corresponding nicotinoyl or isonicotinoyl chlorides in solid phase. The ketones were 
transformed into alcohols 5a–9a, 13a–15a, 17a–26a and 16 with various Grignard reagents, whose OH  
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1,104,15
5a-9a,13a-14a,16,18a-26a 5-9,13-14,17-265b,13b5c
 10   4-Py      -  
 11   4-Py      -
 12   4-Py      -     
 13   4-Py      i-Pr        
 14   4-Py     c-Hex     
 15   4-Py     OH
 16   4-Py     Ph, OH
 17   4-Py     Ph
 18   4-Py     2-MeO Ph
 19   4-Py     3-MeO Ph  
 20   4-Py     4-MeO Ph
 21   4-Py     3-F Ph     
 22   4-Py     4-F Ph         
 23   4-Py     3-Cl Ph     
 24   4-Py     4-Cl Ph
 25   4-Py     3-Me Ph
 26   4-Py     3,5-di CF3 Ph
 1   3-Py     -  
 2   3-Py     -
 3   3-Py     -     
 4   3-Py     -         
 5   3-Py     Ph     
 6   3-Py     2-MeO Ph
 7   3-Py     3-Me Ph
 8   3-Py     3-Cl Ph
 9   3-Py     4-F Ph
Het.      R                       Het.      R                         Het.      R
 
a Reagents and conditions: (i) Method A: Nicotinoyl or isonicotinoyl chloride hydrochloride, AlCl3, 140 oC; (ii) Method B: 
RMgX, THF, –78 oC to room temp.;  (iii) Method C: Et3SiH, TFA, CF3SO3H, CH2Cl2, 0 oC to room temp.; (iv) Method D: 
CH3PPh3Br, n-BuLi, THF, –78 oC to room temp.; (v) Method E: Pd/C, H2, MeOH, room temp.; (vi) Method F: NaBH4, MeOH, 0 oC. 
3 Results and Discussions 
Lina Yin Dissertation 
- 71 -
groups were then removed using triethylsilane under acidic conditions to afford compounds 5–9, 13–15, 17–
26 with various substituents at the CH bridge. On the contrary, reduction of ketones by sodium borohydride 
followed by triethylsilane treatment led to non-substituted analogues 1 and 10. Moreover, methylene group 
was introduced onto the CH bridge via Wittig reaction (compounds 3 and 12), which were further saturated 
by hydrogenation to yield 2 and 11.Our group has reported about several series of biphenyl methylene 
imidazoles13 as potent CYP17 inhibitors. All these compounds were designed based on the mechanism that 
the sp2 hybrid nitrogen can coordinate with the heme iron, which was first14a identified for aromatase 
(CYP19, estrogen synthase) inhibitors,14 and later was also proven to be valid for aldosterone synthase 
(CYP11B2)15 and CYP17 inhibitors.10, 12-13  
 
Biology. 
Inhibition of Human CYP19, CYP11B2 and CYP11B1. The synthesized compounds were investigated 
for their inhibitory activities against CYP19 with human placenta microsomal preparations23a as well as 
against CYP11B1 and CYP11B2 in V79 MZh cells expressing the corresponding enzymes.23b,c IC50 values 
are presented in comparison to lead compounds fadrozole and letrozol. 
It is obvious that when 3-pyridinyl was employed as heterocycle to provide the sp2 hybrid N, the resulting 
compounds 1–8 showed weak to no inhibition of CYP19 regardless of the substituents on the CH bridge 
(Table 1). Exception was compound 9 with 4-F Ph at the CH bridge exhibiting potent inhibition with an IC50 
value of 140 nM. On the contrary, some compounds were much more potent toward CYP11B2. Analogues 
with no (1) or methyl (2) substituents on the CH bridge were strong CYP11B2 inhibitors with IC50 values of 
74 and 37 nM, respectively. Introduction of an unsaturated methylene group (3) decreased the inhibitory 
activity to 468 nM, probably due to the rigidification limiting the flexibility. The total loss of potency 
rendered by OH (4) leads to the conclusion that hydrophilicity is not tolerated in this area. Moreover, strict 
steric limitation was observed for compounds 5–9. When substituted with a phenyl (5), the compound turned 
out to be potent (IC50 = 132 nM). However, further introduction of methoxy (6), methyl (7) and chloro (8) 
substituents into the phenyl at the 2- or 3- positions led to total loss of inhibitory potency (IC50 > 5000 nM). 
Although small groups like 4-F (9) also reduced the potency, it was less pronounced (IC50 = 587 nM). After 
complexing the metal ion by the perpendicular interaction between N and Fe, it is difficult for the substituted 
phenyl groups to fit into the hydrophobic pocket. 
Interestingly, all the 3-pyridyl analogues showed preference for CYP11B1 with selectivity factors (SF = 
IC50 CYP11B1 / IC50 CYP11B2) less than 0.1.  
As for 4-pyridyl analogues, much more potent inhibitors of CYP19 and CYP11B2 were obtained (Table 2). 
When alkyl groups were introduced to the CH bridge, completely opposite SARs were observed for the 
inhibition of CYP19 or CYP11B2. As the bulkiness of the substituents increased from H (10) to methyl (11), 
isopropyl (13) and cyclohexyl (14), the inhibitory potency toward CYP19 increased from 2130 nM, 1500 nM, 
889 nM to 74 nM, respectively. However, this enhancement of bulkiness resulted in the reduction of 
CYP11B2 inhibition from 204 nM (10, H) to 1290 nM (14, cyclohexyl). Among these compounds, methyl  
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Table 1. Inhibition of CYP19, CYP11B1, CYP11B2, and CYP17 by 3-pyridinyl compounds 1–9. 
1-9
NO
R
N
 
IC50a nM 
Compd R 
IC50a nM 
CYP19c CYP11B2d CYP11B1e 
SFf 
Inhib.% b 
CYP17g 
1 H 3340 74 16 0.2 0.5 
2 Me > 5000 37 4 0.1 0.4 
3 =CH2 > 5000 468 41 0.1 3.1 
4 OH > 5000 > 5000 750 < 0.1 n.d.i 
5 Ph 2130 132 68 0.1 n.d.i 
6 2-MeO Ph 3660 > 5000 2270 < 0.3 n.d.i 
7 3-Me Ph > 5000 > 5000 1220 < 0.2 n.d.i 
8 3-Cl Ph 1350 > 5000 36 < 0.1 n.d.i 
9 4-F Ph 140 587 78 0.1 n.d.i 
I  18%h 1.1 715 650 6 
Fadrozole  41 0.8 6.3 7.9 0 
Letrozole  36 1420 2620 1.8 6.8 
a Mean value of at least three experiments, relative standard deviation usually less than 25%. b Mean value of at least two 
experiments, standard deviation usually less than 10%; inhibitor concentration, 500 nM. c Human placental CYP19; substrate 
androstenedione, 500 nM, inhibitor concentration 500 nM; fadrozole, IC50 = 41 nM; d Hamster fibroblasts expressing human 
CYP11B2; substrate deoxycorticosterone, 100 nM. e Hamster fibroblasts expressing human CYP11B1; substrate deoxycorticosterone, 
100 nM. f SF = IC50 CYP11B1 / IC50 CYP11B2. g E. coli expressinghuman CYP17; substrate progesterone, 25 μM; inhibitor concentration 
2.0 μM; ketoconazole, IC50 = 3.5 μM. h Inhibition percentage at inhibitor concentration of 500 nM. i n.d.: not determined. 
derivative 11 as an exception increased in the potency (IC50 = 74 nM), probably caused by the hydrophobic 
interaction between methyl and the small pocket which it fits in. Although potent inhibitors for CYP19 or 
CYP11B2 were identified respectively, no compromise of the contradictory SARs can be achieved to afford 
potent dual inhibitors. Moreover, these compounds exhibited no or little selectivity with SF ranging from 1 
to 4. Nevertheless, compound 12 with methylene at the CH bridge showed good selectivity over CYP11B1 
(SF = 13). This compounds also exhibited potent inhibition of CYP11B2 (IC50 = 96 nM) and modest 
inhibition of CYP19 (IC50 = 565 nM). Similar as observed for 3-pyridinyl analogues, OH (15 and 17) 
significantly decreased the inhibitory potency of both enzymes. 
Furthermore, bulky phenyl substitution on the CH bridge led to potent dual inhibitors. Consistent with the 
SAR observed above for CYP19, the increase in bulkiness leading to substituted phenyl resulted in strong 
inhibition of CYP19 with IC50 values ranging from 19 nM to 124 nM. Interestingly, the phenyl group also 
rendered potent CYP11B2 inhibition with IC50 values between 32 nM and 139 nM. This is in contrast to the 
low inhibition of analogues with other bulky groups, such as isopropyl (13, IC50 = 750 nM) and cyclohexyl 
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(14, IC50 = 1290 nM). This intriguing finding implies that the hydrophobic pocket in CYP11B2 might be 
narrow and rather flat so that the isopropyl or cyclohexyl group cannot fit in well. Possible π-π interactions 
between phenyl and some amino acid residues in the pocket might be responsible for this difference as well. 
Contrary influences on the inhibition of CYP19 and CYP11B2 were observed for the H-bond acceptors 
(OMe and F) on the phenyl ring. Regarding CYP19, the 2- and 3-methoxy substituted compounds 18 and 19 
showed elevated inhibition compared to non-substituted 16 (IC50 = 105 nM) with IC50 values of 81 and 59 
nM, respectively, whereas the 4-MeO analogue 20 exhibited slightly decreased inhibitory activity (IC50 = 124 
nM). On the contrary, as for CYP11B2 inhibition, the 2- or 3-MeO Ph substitution led to slight reduction of 
CYP11B2 inhibition (IC50 values around 130 nM) compared to 16 (IC50 = 85 nM), while the 4-MeO Ph 
compound 20 are more potent (IC50 = 52 nM). Similar observations were also made for F analogues 21 and 
22: when the compound showed improved inhibition toward one enzyme, the inhibitory potency toward the 
other enzyme was reduced and vice versa. Nonetheless, the substitution of chloro (23 and 24) and methyl (25) 
on the phenyl moiety significantly increased the inhibitory potency toward both enzymes regardless of the 
substitution positions leading to potent dual inhibitors of CYP19 and CYP11B2 (IC50 values less than 50 nM 
for both enzymes). Although 24 with 4-Cl Ph substitution exhibited poor selectivity (SF = 2.9) between 
CYP11B2 and CYP11B1, the other two compounds 23 (3-Cl Ph) and 25 (3-CH3 Ph) showed good selectivity 
with SFs of 13 and 33, respectively. Especially, compound 25 appeared to be superior to the lead compounds 
fadrozle and letrozole when taking into consideration the inhibitory potency towards both CYP19 and 
CYP11B2 as well as the selectivity between CYP11B2 and CYP11B1. It is interesting to observe that 
compounds with 3-substituted Ph moiety are always more selective than the corresponding 4-substituted Ph 
analogues (19 & 20, 21 & 22 and 23 & 24). Also, 3-substituted Ph compounds are more potent toward 
CYP19, whereas 4-substituted Ph derivatives inhibit CYP11B2 in a strong way. Furthermore, the total loss 
of CYP11B2 inhibition for compound 26, substituted with two trifluoromethyl groups at the m-positions, is a 
further indication of the tightness of the pocket. 
The potent (IC50 CYP19 = 124 nM and IC50 CYP11B2 = 52 nM) and selective (regarding CYP11B1, SF = 16) 
dual inhibitor 20 was resolved into pure enantiomers to examine the influence of the chiral center on 
biological activity. One enantiomer 20-1 showed enhanced CYP11B2 inhibition (IC50 = 46 nM) and 
selectivity (SF = 37), however, the CYP19 inhibitory activity was reduced (IC50 = 273 nM). Contrarily, the 
other enantiomer 20-2 exhibited stronger inhibition of CYP19 (IC50 = 92 nM), and CYP11B2 inhibition (IC50 
= 74 nM) and selectivity (SF = 7) were decreased. Since it is the aim to achieve potent dual inhibition, the 
racemate is considered to optimal. 
Inhibition of Human CYP17. The inhibition of CYP17 by the synthesized compounds was evaluated due 
to its important role in the biosynthesis of androgens. The percent inhibition values were obtained using the 
50,000 g sediment of E.coli coexpressing human CYP17 and cytochrome P450 reductase at an inhibitor 
concentration of 2 µM.23d,e The potent dual inhibitors 16, 18–25 showed weak inhibition (around 50 % at 2 
µM) toward CYP17, which is tolerable regarding their potency against CYP19 and CYP11B2 (IC50 values 
ranging from 19 to 139 nM). 
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Table 2. Inhibition of CYP19, CYP11B1, CYP11B2, and CYP17 by 4-pyridinyl compounds 10–26. 
NO
R
N
10-26  
IC50a nM 
Compd R 
IC50a nM 
CYP19c CYP11B2d CYP11B1e 
SFf 
Inhib.% b 
CYP17g 
10 H 2130 204 224 1.1 8.2 
11 Me 1500 74 140 1.9 n.d.i 
12 =CH2 565 96 1230 13 17 
13 i-Pr 889 750 1420 1.9 n.d.i 
14 c-Hex 74 1290 > 5000 > 4 n.d.i 
15 OH > 5000 563 347 1.6 0.6 
16 Ph 105 85 745 8.8 43 
17 Ph, OH 880 390 5399 14 n.d.i 
18 2-MeO Ph 81 128 276 2.2 33 
19 3-MeO Ph 59 139 2539 18 50 
20 4-MeO Ph 124 52 810 16 53 
20-1 4-MeO Ph 273 46 1688 37 n.d.i 
20-2 4-MeO Ph 92 74 511 6.9 n.d.i 
21 3-F Ph 74 88 532 6.0 n.d.i 
22 4-F Ph 116 56 88 1.6 55 
23 3-Cl Ph 19 51 646 13 58 
24 4-Cl Ph 55 32 92 2.9 60 
25 3-CH3 Ph 32 41 1336 33 46 
26 3,5-diCF3 Ph 246 1580 > 5000 > 3 n.d.i 
I  18% h 1.1 715 650 6 
Fadrozole  41 0.8 6.3 7.9 0 
Letrozole  36 1420 2620 1.8 6.8 
a Mean value of at least three experiments, relative standard deviation usually less than 25%. b Mean value of at least two 
experiments, standard deviation usually less than 10%; inhibitor concentration, 500 nM. c Human placental CYP19; substrate 
androstenedione, 500 nM, inhibitor concentration 500 nM; fadrozole, IC50 = 41 nM; d Hamster fibroblasts expressing human 
CYP11B2; substrate deoxycorticosterone, 100 nM. e Hamster fibroblasts expressing human CYP11B1; substrate deoxycorticosterone, 
100 nM. f SF = IC50 CYP11B1 / IC50 CYP11B2. g E. coli expressinghuman CYP17; substrate progesterone, 25 μM; inhibitor concentration 
2.0 μM; ketoconazole, IC50 = 3.5 μM. h Inhibition percentage at inhibitor concentration of 500 nM. i n.d.: not determined. 
Conclusion 
Estrogen deficiency has been observed to be closely correlated with CVD, which is believed to be 
mediated to a large extent by abnormally high concentration of aldosterone. The application of AIs to post-
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menopausal BC patients reduces estrogens to undetectable levels leading to high risk of CVD. Since AIs as 
adjuvant therapy have to be applied for more than five years, it is rational to design dual inhibitors of CYP19 
and CYP11B2 to reduce CVD risk. 
By integrating the 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one core from CYP11B2 inhibitors into 
the CYP19 inhibitor template of arylmethyl substituted N containing heterocycles, a series of potent dual 
inhibitors were designed and synthesized. It has been found that 3-pyridinyl was not suitable for this purpose, 
whereas 4-pyridinyl led to potent dual inhibitors. The substituents on the CH bridge showed significant 
influence on the inhibitory activity, in which opposite SARs were commonly observed for the inhibition of 
these two enzymes. When alkyl groups were furnished, the enhancement of bulkiness increased CYP19 
inhibition, but reduced that of CYP11B2. When substituted phenyl groups were introduced, the resulting 
compounds exhibited strong inhibition toward both enzymes. Depending on the substitution position,  H-
bond acceptors, such as methoxy and fluoro at the phenyl moiety, resulted in different inhibitory potencies. 
Opposite SARs were observed: the shifting of methoxy or fluoro from 2- or 3-position to 4-position 
decreased CYP19 inhibition, but elevated potency toward CYP11B2. Contrarily, chloro and methyl 
substitution led to potent dual inhibitors of CYP19 and CYP11B2 regardless their positions on the phenyl 
ring. It is interesting that 3-substituted Ph compounds are more potent toward CYP19, whereas 4-substituted 
Ph derivatives show a stronger inhibition of CYP11B2, and compounds with 3-substitution Ph are more 
selective than the corresponding 4-substituted Ph analogues. Moreover, the resolution of a racemic mixture 
led to an increase in CYP19 inhibition but to a reduction of CYP11B2 inhibition and selectivity regarding 
CYP11B1 for one enantiomer; while for the other one opposite results were observed. The compromise of 
these conflicts led to compounds 19, 20, 23 and 25 as potent and selective dual inhibitors of CYP19 and 
CYP11B2, especially compound 25, which exhibited IC50 values of 32 and 41 nM for CYP19 and CYP11B2, 
respectively, and a SF of 33 over CYP11B1. This compound is deemed to be superior to the leads fadrozole 
and letrozole, and could be a drug candidate after further evaluation in vivo. 
Experimental Section 
Biology 
CYP19 preparation and assay 
Human CYP19 was obtained from microsomal preparations of human placenta and the assay was 
performed using the 3H2O-method as previously described and [1β-3H] androstenedione as substrate.23a 
Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human CYP11B1 or CYP11B2 were incubated with [1,2-3H]-11-
deoxycorticosterone as substrate and the inhibitor at different concentrations. The assay was performed as 
previously described.23b,c 
CYP17 preparation and assay 
Human CYP17 was expressed in E. coli23d (coexpressing human CYP17 and NADPH-P450 reductase), 
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and the assay was performed using method as previously described, progesterone as substrate and NADPH 
as cofactor.23e 
Chemistry 
General Method 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. 1H-NMR 
spectra were measured on a Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million 
(ppm), and TMS was used as an internal standard for spectra obtained. All coupling constants (J) are given 
in Hz. ESI (electrospray ionization) mass spectra were determined on a TSQ quantum (Thermo Electron 
Corporation) instrument. The purities of the final compounds were controlled by Surveyor-LC-system. 
Purities were greater than 95%. Column chromatography was performed using silica-gel 60 (50–200 µm), 
and reaction progress was determined by TLC analysis on Alugram SIL G/UV254 (Macherey-Nagel). 
Reagents and solvents were used as obtained from commercial suppliers without further purification. 
Resolution of Racemate. Enantiomers were separated via preparative HPLC on a Agilent Technologies 
1200 series system (quaternary pump, MWD, fraction collector) using a NucleoCel Delta column, 0.8 cm × 
25 cm. Retention times (tR) were determined with an analytical column using 0.3 mL/min and UV detection 
(254 nm). The ee values were measured on a Merck-Hitachi LaChrome D-7000 System (isocratic pump 
L7100, diode array detector L7455, autosampler L-7200) using a Chiracel OD-H column, 0.46 cm × 25 cm. 
Method A: Friedel-Crafts Acylation 
1,2,5,6-Tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (1.0 equiv), nicotinoyl chloride hydrochloride or 
isonicotinoyl chloride hydrochloride (1.5 equiv) and AlCl3 (5.0 equiv) were melted at 140 °C for 4 h 
followed by being cooled to 0 °C. A mixture of ice/water was added to decompose the excessive AlCl3, and 
the resulting mixture was stirred at ambient temperature for 1 h. Extraction with CHCl3 (3 x 20 mL) gave the 
organic layers, which were combined and dried over MgSO4. After removal of solvent in vacuo, the residue 
was purified by flash chromatography on silica gel to yield the corresponding ketones. 
8-(Pyridin-3-ylcarbonyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (5b). The title 
compound was obtained according to Method A using 1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
(0.50 g, 2.89 mmol), nicotinoyl chloride hydrochloride (0.77 g, 4.33 mmol) and AlCl3 (2.60 g,19.5 mmol). 
The crude product was purified by flash chromatography column on silica gel (methanol/dichloromethane, 
1/100, Rf = 0.07) to give yellow solids (0.69 g, 86%), mp 135–137 °C. 1H-NMR (500 MHz, CDCl3): δ 2.72 
(t, J = 7.8 Hz, 2H), 3.03 (t, J = 7.8 Hz, 2H), 3.25 (t, J = 8.5 Hz, 2H), 4.16 (t, J = 8.5 Hz, 2H), 7.45 (ddd, J = 
0.8, 4.9, 7.9 Hz, 1H), 7.54 (s, 1H), 7.59 (s, 1H), 8.08 (dt, J = 2.0, 7.9 Hz, 1H), 8.80 (dd, J = 1.7, 4.7 Hz, 1H), 
8.94 (dd, J = 0.8, 2.2 Hz, 1H). MS (ESI) m/z = 279 [M+H] +. 
8-(Pyridin-4-ylcarbonyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (13b). The title 
compound was obtained according to Method A using 1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
(5c, 1.00 g, 5.77 mmol), isonicotinoyl chloride hydrochloride (1.54 g, 8.65 mmol) and AlCl3 (3.85 g, 28.9 
mmol). The crude product was purified by flash chromatography column on silica gel 
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(methanol/dichloromethane, 1/100, Rf = 0.05) to give yellow solids (1.15 g, 72%), mp 171–173 °C. 1H-NMR 
(500 MHz, CDCl3): δ 2.74 (t, J = 7.8 Hz, 2H), 3.03 (t, J = 7.9 Hz, 2H), 3.24 (t, J = 8.5 Hz, 2H), 4.16 (t, J = 
8.5 Hz, 2H), 7.52 (dd, J = 1.6, 4.4 Hz, 2H), 7.53 (s, 1H), 7.58 (s, 1H), 8.80 (dd, J = 1.6, 4.4 Hz, 2H). MS 
(ESI) m/z = 279 [M+H] +. 
Method B: Grignard Addition 
To a solution of a ketone (1.0 equiv) in anhydrous THF was added dropwise a solution of an appropriate 
Grignard reagent (2.0–3.0 equiv) under an atmosphere of nitrogene at –78 °C. The reaction was stirred at the 
same temperature for another 1h, and subsequently warmed to room temperature. After being stirred for 15 h, 
the reaction was quenched with saturated aqueous NHCl4 (5 mL), extracted with ethyl acetate (3 x 10 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatograph on silica gel 
(methanol/dichloromethane, 0 to 1:30) to yield the corresponding alcohol. 
Method C: Triethylsilane Reduction 
To an alcohol (1.0 equiv) in anhydrous dichloromethane was added in sequence by syringe trifluoroacetic 
acid (10 equiv), triethylsilane (3.0 equiv) and trifluoromethanesulfuric acid (0.1 equivalent) under an 
atmosphere of nitrogen at 0 °C. The resulting solution was stirred at room temperature for 18–48 h. 
Afterwards, the reaction mixture was separated, and the queous layer was extracted with dichloromethane (2 
x 10 mL). The combined organic layers were washed with aqueous NaHCO3 and brine, dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatograph on silica gel 
(methanol/dichloromethane, 0 to 1:40) to yield the corresponding dehydoxyl product. 
8-(Pyridin-3-ylmethyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (1). The title compound 
was obtained according to Method C using 4 (70 mg, 0.25 mmol), trifluoroacetic acid (0.19 mL, 2.50 mmol), 
triethylsilane (0.12 mL, 0.75 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 mmol) in anhydrous 
CH2Cl2 (5 mL) as white solids (44 mg, 67%), mp 108–110 °C. 1H-NMR (500 MHz, CDCl3): δ 2.65 (t, J = 
7.7 Hz, 2H), 2.92 (t, J = 7.7 Hz, 2H), 3.14 (t, J = 8.5 Hz, 2H), 3.90 (s, 2H), 4.06 (t, J = 8.5 Hz, 2H), 6.80 (s, 
1H), 6.88 (s, 1H), 7.20 (dd, J = 4.8, 7.7 Hz, 1H), 8.46 (d, J = 7.8 Hz, 1H), 8.46 (dd, J = 1.1, 7.8 Hz, 1H), 8.49 
(d, J = 1.3 Hz, 1H). MS (ESI) m/z = 265 [M+H] +. 
8-[Phenyl(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (5). The title 
compound was obtained according to Method C using 5a (60 mg, 0.17 mmol), trifluoroacetic acid (0.13 mL, 
1.68 mmol), triethylsilane (82 µL, 0.51 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 mmol) in 
anhydrous CH2Cl2 (3 mL) as pale yellow solids (46 mg, 81%), mp 142–144 °C. 1H-NMR (500 MHz, 
CDCl3): δ 2.65 (t, J = 7.7 Hz, 2H), 2.89 (t, J = 7.7 Hz, 2H), 3.12 (t, J = 8.4 Hz, 2H), 4.06 (t, J = 8.4 Hz, 2H), 
5.49 (s, 1H), 6.74 (s, 1H), 6.80 (s, 1H), 7.10 (m, 2H), 7.22 (dd, J = 4.7, 7.9 Hz, 1H), 7.24 (m, 1H), 7.31 (m, 
2H), 7.40 (dt, J = 1.7, 7.9 Hz, 1H), 8.42 (d, J = 2.0 Hz, 1H), 8.48 (dd, J = 1.4, 4.7 Hz, 1H). MS (ESI) m/z = 
341 [M+H] +. 
8-[(2-Methoxyphenyl)(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (6). 
The title compound was obtained according to Method C using 6a (57 mg, 0.15 mmol), trifluoroacetic acid 
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(0.11 mL, 1.48 mmol), triethylsilane (71 µL, 0.44 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 mmol) 
in anhydrous CH2Cl2 (4 mL) as pale yellow solids (31 mg, 56%), mp 65–68 °C. 1H-NMR (500 MHz, 
CDCl3): δ 2.65 (t, J = 7.7 Hz, 2H), 2.89 (t, J = 7.7 Hz, 2H), 3.12 (t, J = 8.5 Hz, 2H), 3.74 (s, 3H), 4.06 (t, J = 
8.5 Hz, 2H), 5.85 (s, 1H), 6.71 (s, 1H), 6.78 (s, 1H), 6.84–6.91 (m, 3H), 7.20 (dd, J = 4.8, 7.8 Hz, 1H), 7.25 
(m, 1H), 7.36 (dt, J = 1.7, 7.8 Hz, 1H), 8.38 (d, J = 2.1 Hz, 1H), 8.45 (dd, J = 1.5, 4.8 Hz, 1H). MS (ESI) m/z 
= 371 [M+H] +. 
8-[(3-Methylphenyl)(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (7). 
The title compound was obtained according to Method C using 7a (62 mg, 0.17 mmol), trifluoroacetic acid 
(0.13 mL, 1.67 mmol), triethylsilane (0.81 µL, 0.50 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 
mmol) in anhydrous CH2Cl2 (4 mL) as pale yellow solids (30 mg, 50%), mp 164–166 °C. 1H-NMR (500 
MHz, CDCl3): δ 2.31 (s, 3H), 2.65 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.12 (t, J = 8.4 Hz, 2H), 4.06 
(t, J = 8.4 Hz, 2H), 5.44 (s, 1H), 6.73 (s, 1H), 6.80 (s, 1H),  6.88 (d, J = 7.6 Hz, 1H), 6.92 (s, 1H), 7.06 (d, J = 
7.5 Hz, 1H), 7.18–7.23 (m, 2H), 7.40 (dd, J = 1.8, 7.9 Hz, 1H), 8.41 (d, J = 1.6 Hz, 1H), 8.47 (dd, J = 1.2, 4.7 
Hz, 1H). MS (ESI) m/z = 355 [M+H] +. 
8-[(3-Chlorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (8). 
The title compound was obtained according to Method C using 8a (72 mg, 0.18 mmol), trifluoroacetic acid 
(0.14 mL, 1.84 mmol), triethylsilane (0.89 µL, 0.55 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 
mmol) in anhydrous CH2Cl2 (4 mL) as to give pale yellow solids (36 mg, 53 %), mp 129–131 °C. 1H-NMR 
(500 MHz, CDCl3): δ 2.68 (t, J = 7.7 Hz, 2H), 2.93 (t, J = 7.7 Hz, 2H), 3.16 (t, J = 8.4 Hz, 2H), 4.10 (t, J = 
8.4 Hz, 2H), 5.48 (s, 1H), 6.73 (s, 1H), 6.80 (s, 1H), 7.01 (m, 1H), 7.10 (s, 1H), 7.27 (m, 3H), 7.41 (d, J = 7.9 
Hz, 1H), 8.43 (d, J = 1.9 Hz, 1H), 8.52 (dd, J = 1.3, 4.7 Hz, 1H). MS (ESI) m/z = 375 [M+H] +. 
8-[(4-Fluorophenyl)(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (9). 
The title compound was obtained according to Method C using 9a (90 mg, 0.24 mmol), trifluoroacetic acid 
(0.18 mL, 2.40 mmol), triethylsilane (0.12 mL, 0.72 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 
mmol) in anhydrous CH2Cl2 (5 mL) as pale yellow solids (50 mg, 58%), mp 175–177 °C. 1H-NMR (500 
MHz, CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.13 (t, J = 8.4 Hz, 2H), 4.07 (t, J = 8.4 Hz, 
2H), 5.47 (s, 1H), 6.71 (s, 1H), 6.78 (s, 1H), 7.00 (m, 2H), 7.05 (m, 2H), 7.24 (dd, J = 4.8, 7.9 Hz, 1H), 7.38 
(dt, J = 1.7, 7.9 Hz, 1H), 8.40 (d, J = 1.0 Hz, 1H), 8.49 (dd, J = 1.4, 4.7 Hz, 1H). MS (ESI) m/z = 359 [M+H] 
+. 
8-(Pyridin-4-ylmethyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (10). The title compound 
was obtained according to Method C using 15 (125 mg, 0.45 mmol), trifluoroacetic acid (0.34 mL, 4.46 
mmol), triethylsilane (0.22 mL, 1.34 mmol) and trifluoromethanesulfuric acid (4 µL, 0.04 mmol) in 
anhydrous CH2Cl2 (5 mL) as pale yellow solids (65 mg, 55%), mp 199–200 °C. 1H-NMR (500 MHz, 
CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.93 (t, J = 7.7 Hz, 2H), 3.15 (t, J = 8.5 Hz, 2H), 3.89 (s, 2H), 4.07 (t, J = 
8.5 Hz, 2H), 6.80 (s, 1H), 6.88 (s, 1H), 7.09 (dd, J = 1.4, 4.5 Hz, 2H), 8.50 (dd, J =1.4, 4.5 Hz, 2H). MS 
(ESI) m/z = 265 [M+H] +. 
8-(2-Methyl-1-pyridin-4-ylpropyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (13). The 
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title compound was obtained according to Method C using 13a (167 mg, 0.52 mmol), trifluoroacetic acid 
(0.40 mL, 5.18 mmol), triethylsilane (0.25 mL, 1.55 mmol) and trifluoromethanesulfuric acid (5 µL, 0.05 
mmol) in anhydrous CH2Cl2 (8 mL) as white solids (105 mg, 66 %), mp 137–139 °C. 1H-NMR (500 MHz, 
CDCl3): δ 0.88 (q, J = 6.5 Hz, 6H), 2.40–2.47 (m, 1H), 2.64 (t, J = 7.7 Hz, 2H), 2.92 (t, J = 7.7 Hz, 2H), 3.14 
(t, J = 8.4 Hz, 2H), 3.32 (d, J = 10.9 Hz, 1H), 4.04 (t, J = 8.4 Hz, 2H), 6.86 (s, 1H), 6.96 (s, 1H), 7.18 (dd, J = 
1.4, 4.6 Hz, 2H), 8.47 (dd, J = 1.4, 4.6 Hz, 2H). MS (ESI) m/z = 307 [M+H] +. 
8-[Cyclohexyl(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (14). The 
title compound was obtained according to Method C using 14a (150 mg, 0.41 mmol), trifluoroacetic acid 
(0.32 mL, 4.14 mmol), triethylsilane (0.20 mL, 1.24 mmol) and trifluoromethanesulfuric acid (4 µL, 0.04 
mmol) in anhydrous CH2Cl2 (8 mL) as white crystals (80 mg, 54%), mp 83–85 °C. 1H-NMR (500 MHz, 
CDCl3): δ 0.86 (m, 2H), 1.14–1.26 (m, 3H), 1.62–1.70 (m, 5H), 2.05 (m, 1H), 2.64 (t, J = 7.7 Hz, 2H), 2.92 
(t, J = 7.7 Hz, 2H), 3.14 (t, J = 8.4 Hz, 2H), 3.40 (d, J = 10.9 Hz, 1H), 4.04 (t, J = 8.4 Hz, 2H), 6.85 (s, 1H), 
6.95 (s, 1H), 7.17 (dd, J = 1.4, 4.6 Hz, 2H), 8.46 (dd, J = 1.4, 4.6 Hz, 2H). MS (ESI) m/z = 347 [M+H] +. 
8-[Phenyl(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (17). The title 
compound was obtained according to Method C using 17a (70 mg, 0.20 mmol), trifluoroacetic acid (0.15 mL, 
1.96 mmol), triethylsilane (95 µL, 0.59 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 mmol) in 
anhydrous CH2Cl2 (5 mL) as pale yellow solids (48 mg, 72%), mp 168–169 °C. 1H-NMR (500 MHz, 
CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.13 (t, J = 8.4 Hz, 2H), 4.07 (t, J = 8.4 Hz, 2H), 
5.43 (s, 1H), 6.73 (s, 1H), 6.79 (s, 1H), 7.04 (d, J = 5.3 Hz, 2H), 7.08 (d, J = 7.2 Hz, 2H), 7.26 (m, 1H), 7.32 
(t, J = 7.4 Hz, 2H), 8.52 (d, J = 5.3 Hz, 2H). MS (ESI) m/z = 341 [M+H] +. 
8-[(2-Methoxyphenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
(18). The title compound was obtained according to Method C using 18a (77 mg, 0.20 mmol), trifluoroacetic 
acid (0.15 mL, 1.99 mmol), triethylsilane (97 µL, 0.60 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 
mmol) in anhydrous CH2Cl2 (4 mL) as pale yellow solids (55 mg, 75%), mp 70–72 °C. 1H-NMR (500 MHz, 
CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.12 (t, J = 8.5 Hz, 2H), 3.73 (s, 3H), 4.07 (t, J = 
8.5 Hz, 2H), 5.80 (s, 1H), 6.71 (s, 1H), 6.78 (s, 1H), 6.83 (m, 1H), 6.90 (m, 2H), 7.00 (d, J = 4.6 Hz, 2H), 
7.26 (m, 1H), 8.48 (d, J = 4.6 Hz, 2H). MS (ESI) m/z = 371 [M+H] +. 
8-[(3-Methoxyphenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
(19). The title compound was obtained according to Method C using 19a (102 mg, 0.26 mmol), 
trifluoroacetic acid (0.20 mL, 2.64 mmol), triethylsilane (0.13 mL, 0.79 mmol) and trifluoromethanesulfuric 
acid (2 µL, 0.03 mmol) in anhydrous CH2Cl2 (8 mL) as pale yellow solids (48 mg, 50%), mp 148–150 °C. 
1H-NMR (500 MHz, CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.12 (t, J = 8.4 Hz, 2H), 
4.06 (t, J = 8.4 Hz, 2H), 5.39 (s, 1H), 6.63 (m, 1H), 6.68 (d, J = 7.7 Hz, 1H), 6.72 (s, 1H), 6.80 (m, 2H), 7.04 
(d, J = 4.6 Hz, 2H), 7.24 (t, J = 8.0 Hz, 1H), 8.51 (d, J = 4.6 Hz, 2H). MS (ESI) m/z = 371 [M+H] +. 
8-[(4-Methoxyphenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
(20). The title compound was obtained according to Method C using 20a (102 mg, 0.26 mmol), 
trifluoroacetic acid (0.20 mL, 2.64 mmol), triethylsilane (0.13 mL, 0.79 mmol) and trifluoromethanesulfuric 
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acid (2 µL, 0.03 mmol) in anhydrous CH2Cl2 (8 mL) as pale yellow solids (83 mg, 86%), mp 71–73 °C. 1H-
NMR (500 MHz, CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.12 (t, J = 8.4 Hz, 2H), 3.80 (s, 
3H), 4.06 (t, J = 8.4 Hz, 2H), 5.38 (s, 1H), 6.71 (s, 1H), 6.78 (s, 1H), 6.85 (d, J = 8.7 Hz, 2H), 7.00 (d, J = 8.7 
Hz, 2H), 7.03 (d, J = 4.7 Hz, 2H), 8.51 (d, J = 4.7 Hz, 2H). MS (ESI) m/z = 371 [M+H] +. The racemate 20 
was separated by preparative HPLC on chiral stationary phase (NucleoCel Delta column, 0.8 cm × 25 cm, 
50% hexane/isopropanol, 1.0 mL/min) to yield 20-1 (100% ee and tR = 32.1 min by analytical HPLC) and 
20-2 (90.3% ee and tR = 38.2 min by analytical HPLC). 
8-[(3-Fluorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (21). 
The title compound was obtained according to Method C using 21a (96 mg, 0.26 mmol), trifluoroacetic acid 
(0.20 mL, 2.56 mmol), triethylsilane (0.13 mL, 0.78 mmol) and trifluoromethanesulfuric acid (2 µL, 0.03 
mmol) in anhydrous CH2Cl2 (6 mL) as pale yellow solids (40 mg, 43%), mp 162–165 °C. 1H-NMR (500 
MHz, CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.91 (t, J = 7.7 Hz, 2H), 3.14 (t, J = 8.4 Hz, 2H), 4.07 (t, J = 8.4 Hz, 
2H), 5.42 (s, 1H), 6.71 (s, 1H), 6.78 (m, 2H), 6.88 (d, J = 7.7 Hz, 1H), 6.96 (td, J = 2.2, 8.3 Hz, 1H),  7.03 (d, 
J = 4.6 Hz, 2H), 7.29 (m, 1H), 8.53 (d, J = 4.6 Hz, 2H). MS (ESI) m/z = 359 [M+H] +. 
8-[(4-Fluorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (22). 
The title compound was obtained according to Method C using 22a (65 mg, 0.17 mmol), trifluoroacetic acid 
(0.13 mL, 1.74 mmol), triethylsilane (80 µL, 0.52 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 mmol) 
in anhydrous CH2Cl2 (5 mL) as pale yellow solids (45 mg, 74%), mp 155–157 °C. 1H-NMR (500 MHz, 
CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.13 (t, J = 8.5 Hz, 2H), 4.07 (t, J = 8.5 Hz, 2H), 
5.41 (s, 1H), 6.70 (s, 1H), 6.77 (s, 1H), 6.99–7.06 (m, 6H), 8.53 (dd, J = 1.6， 4.5 Hz, 2H). MS (ESI) m/z = 
359 [M+H] +. 
8-[(3-Chlorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (23). 
The title compound was obtained according to Method C using 23a (85 mg, 0.22 mmol), trifluoroacetic acid 
(0.17 mL, 2.20 mmol), triethylsilane (0.11 mL, 0.65 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 
mmol) in anhydrous CH2Cl2 (5 mL) as pale yellow solids (42 mg, 51%), mp 163–165 °C. 1H-NMR (500 
MHz, CDCl3): δ  2.66 (t, J = 7.7 Hz, 2H), 2.91 (t, J = 7.7 Hz, 2H), 3.14 (t, J = 8.4 Hz, 2H), 4.08 (t, J = 8.4 
Hz, 2H), 5.40 (s, 1H), 6.70 (s, 1H), 6.77 (s, 1H), 6.98 (m, 1H), 7.02 (d, J = 4.6 Hz, 2H), 7.07 (s, 1H), 7.25 (m, 
2H),  8.54 (d, J = 4.6 Hz, 2H). MS (ESI) m/z = 375 M +. 
8-[(4-Chlorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (24). 
The title compound was obtained according to Method C using 24a (95 mg, 0.24 mmol), trifluoroacetic acid 
(0.19 mL, 2.43 mmol), triethylsilane (0.12 mL, 0.73 mmol) and trifluoromethanesulfuric acid (3 µL, 0.02 
mmol) in anhydrous CH2Cl2 (5 mL) as pale yellow solids (56 mg, 62%), mp 136–138 °C. 1H-NMR (500 
MHz, CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.13 (t, J = 8.4 Hz, 2H), 4.07 (t, J = 8.4 Hz, 
2H), 5.40 (s, 1H), 6.69 (s, 1H), 6.76 (s, 1H), 7.02 (m, 4H), 7.28 (d, J = 8.5 Hz, 2H), 8.53 (d, J = 4.6 Hz, 2H). 
MS (ESI) m/z = 375 M +. 
8-[(3-Methylphenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (25). 
The title compound was obtained according to Method C using 25a (65 mg, 0.18 mmol), trifluoroacetic acid 
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(0.14 mL, 1.80 mmol), triethylsilane (0.85 µL, 0.53 mmol) and trifluoromethanesulfuric acid (2 µL, 0.02 
mmol) in anhydrous CH2Cl2 (4 mL) as pale yellow solids (32 mg, 50%), mp 180–182 °C. 1H-NMR (500 
MHz, CDCl3): δ 2.31 (s, 3H), 2.66 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 3.13 (t, J = 8.4 Hz, 2H), 4.07 
(t, J = 8.4 Hz, 2H), 5.39 (s, 1H), 6.72 (s, 1H), 6.79 (s, 1H),  6.87 (d, J = 7.7 Hz, 1H), 6.91 (s, 1H), 7.04 (d, J = 
4.6 Hz, 2H), 7.07 (d, J = 7.5 Hz, 1H), 7.20 (t, J = 7.6 Hz, 1H), 8.51 (d, J = 4.6 Hz, 2H). MS (ESI) m/z = 355 
[M+H] +. 
8-[((3,5-Bis(trifluoromethyl)phenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-
ij]quinolin-4-one (26). The title compound was obtained according to Method C using 26a (95 mg, 0.19 
mmol), trifluoroacetic acid (0.15 mL, 1.93 mmol), triethylsilane (0.93 µL, 0.58 mmol) and 
trifluoromethanesulfuric acid (2 µL, 0.02 mmol) in anhydrous CH2Cl2 (6 mL) as pale yellow solids (38 mg, 
42%), mp 182–184 °C. 1H-NMR (500 MHz, CDCl3): δ 2.68 (t, J = 7.7 Hz, 2H), 2.92 (t, J = 7.7 Hz, 2H), 3.15 
(t, J = 8.4 Hz, 2H), 4.09 (t, J = 8.4 Hz, 2H), 5.55 (s, 1H), 6.68 (s, 1H), 6.75 (s, 1H), 7.00 (d, J = 4.6 Hz, 2H), 
7.54 (s, 2H), 7.80 (s, 1H), 8.58 (d, J = 4.6 Hz, 2H). MS (ESI) m/z = 477 [M+H] +. 
Method D: Wittig Reaction 
To a suspension of methyltriphenylphosphonium bromide (2.2 equiv) in anhydrous THF (5 mL) was 
added n-BuLi (2.0 equiv) slowly under an atmosphere of nitrogene at –78 °C. The reaction mixture was 
stirred at room temperature for 1 h, and then cooled to –78 °C again followed by addition of a solution of a 
ketone (1.0 equiv) in THF (5 mL). The resulting mixture was stirred at ambient temperature for 5 h, and 
subsequently quenched with aqueous NH4Cl, extracted with ethyl acetate (3 x 10 mL), dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatograph on silica gel to yield the 
corresponding methylene compound. 
8-(1-pyridin-3-ylvinyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (3). The title compound 
was obtained according to Method D using 5b (200 mg, 0.72 mmol), methyltriphenylphosphonium bromide 
(564 mg, 1.58 mmol), and n-BuLi (2.5 M in hexanes, 0.58 mL, 1.44 mmol). The crude product was purified 
by flash chromatography column on silica gel (methanol/dichloromethane, 0 to 1:70) to give offwhite solids 
(117 mg, 59%), mp 97–99 °C. 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.7 Hz, 2H), 2.95 (t, J = 7.7 Hz, 
2H), 3.17 (t, J = 8.5 Hz, 2H), 4.10 (t, J = 8.5 Hz, 2H), 5.40 (s, 1H), 5.48 (s, 1H), 6.95 (s, 1H), 7.03 (s, 1H), 
7.27 (dd, J = 4.9, 7.9 Hz, 1H), 7.61 (dt, J = 2.1, 7.9 Hz, 1H), 8.56 (dd, 3J = 1.6, 4.8 Hz, 1H), 8.60 (d, J = 1.6 
Hz, 1H). MS (ESI) m/z = 277 [M+H] +. 
8-(1-pyridin-4-ylvinyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (12). The title compound 
was obtained according to Method D using 13b (200 mg, 0.72 mmol), methyltriphenylphosphonium bromide 
(564 mg, 1.58 mmol), and n-BuLi (2.5 M in hexanes, 0.58 mL, 1.44 mmol). The crude product was purified 
by flash chromatography column on silica gel (methanol/dichloromethane, 0 to 1:50) to give pale yellow 
semisolids (115 mg, 58%). 1H-NMR (500 MHz, CDCl3): δ 2.69 (t, J = 7.7 Hz, 2H), 2.95 (t, J = 7.7 Hz, 2H), 
3.18 (t, J = 8.5 Hz, 2H), 4.10 (t, J = 8.5 Hz, 2H), 5.51 (d, J = 8.1 Hz, 2H), 6.93 (s, 1H), 7.00 (s, 1H), 7.23 
(dd, J = 1.6, 4.5 Hz, 2H), 8.58 (dd, J = 1.5, 4.6 Hz, 2H). MS (ESI) m/z = 277 [M+H] +. 
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Method E: Catalytic hydrogenation 
To a solution of a methylene compound (1 equiv) in methanol (8 mL) was added 5% Pd/C (15% weight). 
Subsequently, the reaction was stirred under a hydrogen atmosphere (maintained with balloons) for 10 h 
followed by filtration through a Celite cake and concentration in vacuo. The crude product was purified by 
flash chromatography on silica gel to yield the corresponding saturated product. 
8-(1-Pyridin-3-ylethyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (2). The title compound 
was obtained according to Method E using 3 (59 mg, 0.21 mmol), and 5% Pd/C (9 mg). The crude product 
was purified by flash chromatography column on silica gel (methanol/dichloromethane, 0 to 1:50) to give 
white solids (36 mg, 62%), 100–102 °C. 1H-NMR (500 MHz, CDCl3): δ 1.64 (d, J = 7.2 Hz, 3H), 2.65 (t, J = 
7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.14 (t, J = 8.4 Hz, 2H), 4.06 (t, J = 8.4 Hz, 2H), 4.11 (q, J = 7.2 Hz, 
1H), 6.83 (s, 1H), 6.91 (s, 1H), 7.21 (dd, J = 4.7, 7.9 Hz, 1H), 7.49 (dt, J = 1.8, 7.9 Hz, 1H), 8.44 (dd, J = 1.5, 
4.7 Hz, 1H), 8.51 (d, J = 2.2 Hz, 1H). MS (ESI) m/z = 279 [M+H] +. 
8-(1-Pyridin-4-ylethyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (11). The title compound 
was obtained according to Method E using 12 (115 mg, 0.38 mmol), and 5% Pd/C (16 mg). The crude 
product was purified by flash chromatography column on silica gel (methanol/dichloromethane, 0 to 1:50) to 
give offwhite solids (84 mg, 79%), 103–105 °C. 1H-NMR (500 MHz, CDCl3): δ 1.61 (d, J = 7.2 Hz, 3H), 
2.66 (t, J = 7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.14 (t, J = 8.4 Hz, 2H), 4.06 (m, 3H), 6.81 (s, 1H), 6.90 (s, 
1H), 7.13 (dd, J = 1.3, 4.8 Hz, 2H), 8.50 (dd, J = 1.3, 4.8 Hz, 2H). MS (ESI) m/z = 279 [M+H] +. 
Method F: Sodium Borohydride Reduction 
To a solution of a ketone (1.0 equiv) in methanol (8 mL) was added sodium borohydride (2.0 equiv) at 0 
°C. The mixture was stirred at the same temperature for 1 h before concentration in vacuo. The resulting 
solid was washed with water and diethylether in sequence to yield the corresponding alcohol. 
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Supporting Information 
1. The experimental details and characterization of compounds 4, 15 and 16 and intermediates 5a–
9a, 13a, 14a and 18a–26a, as well as the 13C-NMR of all final compounds. 
Method A: Friedel-Crafts Acylation 
1,2,5,6-Tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (1.0 equiv), nicotinoyl chloride hydrochloride or 
isonicotinoyl chloride hydrochloride (1.5 equiv) and AlCl3  (5.0 equiv) were melted at 140 °C for 4 h 
followed by being cooled to 0 °C. A mixture of ice/water was added to decompose the excessive AlCl3, and 
the resulting mixture was stirred at ambient temperature for 1 h. Extraction with CHCl3 (3 x 20 mL) gave the 
organic layers, which were combined and dried over MgSO4. After removal of solvent in vacuo, the residue 
was purified by flash chromatography on silica gel to yield the corresponding ketones. 
Method B: Grignard Addition 
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To a solution of a ketone (1.0 equiv) in anhydrous THF was added dropwise a solution of an appropriate 
Grignard reagent (2.0–3.0 equiv) under an atmosphere of nitrogene at –78 °C. The reaction was stirred at the 
same temperature for another 1h, and subsequently warmed to room temperature. After being stirred for 15 h, 
the reaction was quenched with saturated aqueous NHCl4 (5 mL), extracted with ethyl acetate (3 x 10 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatograph on silica gel  
(methanol/dichloromethane, 0 to 1:30) to yield the corresponding alcohol. 
8-[Hydroxy(phenyl)pyridin-4-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (16). 
The title compound was obtained according to Method B using 13b (200 mg, 0.72 mmol), phenylmagnesium 
bromide (1 M in THF, 2.16 mL, 2.16 mmol) in anhydrous THF (5 mL) as pale yellow solids (120 mg, 47%), 
mp 196–197 °C. 1H-NMR (500 MHz, CDCl3): δ 2.63 (t, J = 7.7 Hz, 2H), 2.88 (t, J = 7.7 Hz, 2H), 3.11 (t, J = 
8.3 Hz, 2H), 3.53 (s, br, 1H), 4.04 (t, J = 8.3 Hz, 2H), 6.88 (s, 1H), 6.93 (s, 1H), 7.25–7.33 (m, 7H), 8.49 (d, 
J = 3.2 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.4, 81.2, 119.5, 122.6, 123.1, 125.3, 
127.7, 127.8, 128.2, 128.7, 140.9, 141.4, 145.7, 149.4, 155.6, 167.6. MS (ESI) m/z = 357 [M+H] +. 
8-[Hydroxy(phenyl)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (5a). 
The title compound was obtained according to Method B using 5b (200 mg, 0.72 mmol), phenylmagnesium 
bromide (1 M in THF, 2.16 mL, 2.16 mmol) in anhydrous THF (5 mL) as yellow solids (60 mg, 23%). 1H-
NMR (500 MHz, CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.80 (s, 1H), 2.90 (t, J = 7.7 Hz, 2H), 3.13 (t, J = 8.5 Hz, 
2H), 4.08 (t, J = 8.5 Hz, 2H), 6.90 (s, 1H), 6.95 (s, 1H), 7.27 (m, 3H), 7.32–7.37 (m, 3H), 7.67 (dt, J = 2.0, 
8.0 Hz, 1H), 8.53 (dd, J = 1.6, 4.8 Hz, 1H), 8.55 (d, J = 2.3 Hz, 1H). 
8-[Hydroxy(2-methoxyphenyl)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (6a). The title compound was obtained according to Method B using 6b (200 mg, 0.72 mmol), 2-
methoxyphenylmagnesium bromide (1 M in THF, 1.44 mL, 1.44 mmol) in anhydrous THF (10 mL) as 
yellow solids (58 mg, 21%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 
3.13 (t, J = 8.4 Hz, 2H), 3.72 (s, 3H), 4.08 (t, J = 8.5 Hz, 2H), 5.33 (s, 1H), 6.55 (dd, J = 1.6, 7.6 Hz, 1H), 
6.88 (m, 2H), 6.90 (s, 1H), 6.98 (d, J = 8.0 Hz, 1H), 7.25 (m, 1H), 7.33 (m, 1H), 7.62 (dt, J = 1.9, 7.9 Hz, 
1H), 8.40 (d, J = 1.9 Hz, 1H), 8.53 (dd, J = 1.6, 4.7 Hz, 1H). 
8-[Hydroxy(3-methylphenyl)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (7a). The title compound was obtained according to Method B using 7b (200 mg, 0.72 mmol), m-
tolylmagnesium chloride (1 M in THF, 1.44 mL, 1.44 mmol) in anhydrous THF (10 mL) as yellow solids (62 
mg, 23%). 1H-NMR (500 MHz, CDCl3): δ 2.33 (s, 3H), 2.67 (t, J = 7.8 Hz, 2H), 2.77 (s, 1H), 2.91 (t, J = 7.8 
Hz, 2H), 3.13 (t, J = 8.4 Hz, 2H), 4.08 (t, J = 8.5 Hz, 2H), 6.90 (s, 1H), 6.94 (s, 1H), 7.00 (d, J = 7.9 Hz, 1H), 
7.10 (s, 1H), 7.13 (m, 1H), 7.22 (m , 1H), 7.27 (m, 1H), 7.67 (dt, J = 2.0, 8.0 Hz, 1H),  8.53 (dd, J = 1.5, 4.7 
Hz, 1H), 8.54 (d, J = 1.8 Hz, 1H). 
8-[(3-Chlorophenyl)(hydroxy)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (8a). The title compound was obtained according to Method B using 8b (200 mg, 0.72 mmol), 3-
chlorophenylmagnesium bromide (0.5 M in THF, 2.88 mL, 1.44 mmol) in anhydrous THF (10 mL) as 
yellow solids (72 mg, 26%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.82 (s, 1H), 2.91 (t, J 
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= 7.8 Hz, 2H), 3.14 (t, J = 8.5 Hz, 2H), 4.09 (t, J = 8.5 Hz, 2H), 6.86 (s, 1H), 6.92 (s, 1H), 7.15 (dt, J = 1.9, 
7.2 Hz, 1H),  7.29 (m , 3H), 7.34 (m, 1H), 7.65 (dt, J = 2.0, 8.0 Hz, 1H), 8.55 (m, 2H). 
8-[(4-Fluorophenyl)(hydroxy)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (9a). The title compound was obtained according to Method B using 9b (300 mg, 1.08 mmol), 4-
fluorophenylmagnesium bromide (0.8 M in THF, 2.69 mL, 2.16 mmol) in anhydrous THF (10 mL) as tan 
solids (128 mg, 34%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.78 (s, 1H), 2.91 (t, J = 7.7 
Hz, 2H), 3.14 (t, J = 8.5 Hz, 2H), 4.08 (t, J = 8.5 Hz, 2H), 6.87 (s, 1H), 6.92 (s, 1H),  7.03 (m, 2H), 7.24–
7.29 (m, 3H), 7.66 (dt, J = 2.0, 8.0 Hz, 1H), 8.54 (m, 2H). 
8-(1-Hydroxy-2-methyl-1-pyridin-3-ylpropyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1- ij]quinolin-
4-one (13a). The title compound was obtained according to Method B using 13b (150 mg, 0.54 mmol), 
isopropylmagnesium chloride (2.0 M in THF, 0.54 mL, 1.08 mmol) in anhydrous THF (10 mL) as yellow 
solids (124 mg, 36%). 1H-NMR (500 MHz, CDCl3): δ 0.85 (d, J = 6.7 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H), 2.05 
(s, 1H), 2.65 (t, J = 7.8 Hz, 2H), 2.83 (sept, 1H), 2.93 (t, J = 7.7 Hz, 2H), 3.15 (t, J = 8.4 Hz, 2H), 4.05 (t, J = 
8.5 Hz, 2H), 7.13 (s, 1H), 7.21 (s, 1H), 7.38 (dd, J = 1.6, 4.7 Hz, 2H), 8.51 (dd, J = 1.5, 4.7 Hz, 2H). 
8-[Cyclohexyl(hydroxy)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1- ij]quinolin-
4-one (14a). The title compound was obtained according to Method B using 13b (200 mg, 0.72 mmol), 
cyclohexylmagnesium chloride (1.3 M in THF/Toluene, 1.11 mL, 1.44 mmol) in anhydrous THF (10 mL) as 
pale yellow solids (150 mg, 56%). 1H-NMR (500 MHz, CDCl3): δ 1.06–1.16 (m, 3H), 1.25–1.36 (m, 2H), 
1.42 (m, 1H), 1.64–1.81 (m, 4H), 2.07 (s, 1H), 2.37 (m, 1H), 2.65 (t, J = 7.7 Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H), 
3.16 (t, J = 8.4 Hz, 2H), 4.05 (t, J = 8.4 Hz, 2H), 7.11 (s, 1H), 7.19 (s, 1H), 7.37 (dd, J = 1.6, 4.6 Hz, 2H), 
8.51 (dd, J = 1.5, 4.7 Hz, 2H). 
8-[Hydroxy(2-methoxyphenyl)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (18a). The title compound was obtained according to Method B using 18b (200 mg, 0.72 mmol), 2-
methoxyphenylmagnesium bromide (1.0 M in THF, 1.44 mL, 1.44 mmol) in anhydrous THF (10 mL) as tan 
solids (77 mg, 28%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.7 Hz, 2H), 2.90 (t, J = 7.8 Hz, 2H), 3.13 (t, 
J = 8.4 Hz, 2H), 3.69 (s, 3H), 4.08 (t, J = 8.5 Hz, 2H), 5.27 (s, 1H), 6.57 (dd, J = 1.6, 7.7 Hz, 1H), 6.88 (m, 
3H), 6.98 (d, J = 8.2 Hz, 1H), 7.18 (dd, J = 1.6, 4.6 Hz, 2H), 7.34 (m, 1H), 8.55 (dd, J = 1.5, 4.6 Hz, 2H). 
8-[Hydroxy(3-methoxyphenyl)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (19a). The title compound was obtained according to Method B using 19b (200 mg, 0.72 mmol), 3-
methoxyphenylmagnesium bromide (1.0 M in THF, 1.44 mL, 1.44 mmol) in anhydrous THF (10 mL) as 
yellow solids (145 mg, 52%). 1H-NMR (500 MHz, CDCl3): δ 2.66 (t, J = 7.7 Hz, 2H), 2.88 (s, 1H), 2.90 (t, J 
= 7.8 Hz, 2H), 3.13 (t, J = 8.5 Hz, 2H), 3.77 (s, 3H), 4.08 (t, J = 8.5 Hz, 2H), 6.81 (m, 1H), 6.85 (m, 2H), 
6.88 (s, 1H), 6.93 (s, 1H), 7.25 (m, 1H), 7.28 (dd, J = 1.6, 4.6 Hz, 2H), 8.56 (dd, J = 1.6, 4.6 Hz, 2H). 
8-[Hydroxy(4-methoxyphenyl)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (20a). The title compound was obtained according to Method B using 20b (200 mg, 0.72 mmol), 4-
methoxyphenylmagnesium bromide (1.0 M in THF, 1.44 mL, 1.44 mmol) in anhydrous THF (10 mL) as tan 
solids (102 mg, 36%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.7 Hz, 2H), 2.69 (s, 1H), 2.91 (t, J = 7.7 
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Hz, 2H), 3.13 (t, J = 8.5 Hz, 2H), 3.82 (s, 3H), 4.08 (t, J = 8.5 Hz, 2H), 6.86 (dd, J = 2.1, 6.8 Hz, 2H), 6.90 (s, 
1H), 6.94 (s, 1H), 7.15 (dd, J = 2.1, 6.8 Hz, 2H), 7.27 (dd, J = 1.7, 4.6 Hz, 2H), 8.57 (dd, J = 1.6, 4.6 Hz, 2H). 
8-[(3-Fluorophenyl)(hydroxy)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (21a). The title compound was obtained according to Method B using 21b (200 mg, 0.72 mmol), 3-
fluorophenylmagnesium bromide (1.0 M in THF, 1.44 mL, 1.44 mmol) in anhydrous THF (10 mL) as yellow 
solids (98 mg, 36%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.7 Hz, 2H), 2.77 (s, 1H), 2.91 (t, J = 7.7 Hz, 
2H), 3.14 (t, J = 8.4 Hz, 2H), 4.09 (t, J = 8.5 Hz, 2H), 6.86 (s, 1H), 6.91 (s, 1H), 7.02–7.06 (m, 3H), 7.27 (dd, 
J = 1.7, 4.6 Hz, 2H), 7.32 (m, 1H), 8.59 (d, J = 1.6, 4.6 Hz, 2H). 
8-[(4-Fluorophenyl)(hydroxy)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (22a). The title compound was obtained according to Method B using 22b (200 mg, 0.72 mmol), 4-
fluorophenylmagnesium bromide (0.8 M in THF, 2.7 mL, 2.16 mmol) in anhydrous THF (5 mL) as orange 
solids (66 mg, 24%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.77 (s, 1H), 2.90 (t, J = 7.8 Hz, 
2H), 3.14 (t, J = 8.5 Hz, 2H), 4.08 (t, J = 8.5 Hz, 2H), 6.86 (s, 1H), 6.91 (s, 1H), 7.03 (m, 2H), 7.24 (m, 4H), 
8.57 (d, J = 1.6, 4.6 Hz, 2H). 
8-[(3-Chlorophenyl)(hydroxy)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (23a). The title compound was obtained according to Method B using 23b (200 mg, 0.72 mmol), 3-
fluorophenylmagnesium bromide (0.5 M in THF, 2.88 mL, 1.44 mmol) in anhydrous THF (10 mL) as tan 
solids (85 mg, 30%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.80 (s, 1H), 2.91 (t, J = 7.8 Hz, 
2H), 3.14 (t, J = 8.5 Hz, 2H), 4.09 (t, J = 8.5 Hz, 2H), 6.84 (s, 1H), 6.90 (s, 1H), 7.15 (dt, J = 1.6, 7.3 Hz, 
1H), 7.29 (m, 5H), 8.59 (dd, J = 1.6, 4.7 Hz, 2H). 
8-[(4-Chlorophenyl)(hydroxy)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (24a). The title compound was obtained according to Method B using 24b (200 mg, 0.72 mmol), 3-
fluorophenylmagnesium bromide (0.5 M in THF, 2.88 mL, 1.44 mmol) in anhydrous THF (10 mL) as tan 
solids (85 mg, 30%). 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.74 (s, 1H), 2.91 (t, J = 7.8 Hz, 
2H), 3.14 (t, J = 8.5 Hz, 2H), 4.08 (t, J = 8.5 Hz, 2H), 6.85 (s, 1H), 6.90 (s, 1H), 7.22 (m, 2H), 7.25 (dd, J = 
1.6, 4.6 Hz, 2H), 7.32 (m, 2H), 8.58 (dd, J = 1.5, 4.6 Hz, 2H). 
8-[Hydroxy(3-methylphenyl)pyridin-3-ylmethyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-
one (25a). The title compound was obtained according to Method B using 25b (200 mg, 0.72 mmol), m-
tolylmagnesium chloride (1.0 M in THF, 1.44 mL, 1.44 mmol) in anhydrous THF (10 mL) as tan solids (65 
mg, 24%). 1H-NMR (500 MHz, CDCl3): δ 2.33 (s, 3H), 2.67 (t, J = 7.8 Hz, 2H), 2.74 (s, 1H), 2.91 (t, J = 7.7 
Hz, 2H), 3.14 (t, J = 8.4 Hz, 2H), 4.08 (t, J = 8.4 Hz, 2H), 6.89 (s, 1H), 6.94 (s, 1H), 7.00 (d, J = 7.6 Hz, 1H), 
7.09 (s, 1H), 7.14 (d, J = 7.3 Hz, 1H), 7.23 (t, J = 7.7 Hz, 1H), 7.27 (dd, J = 1.6, 4.6 Hz, 2H), 8.57 (dd, J = 
1.6, 4.6 Hz, 2H). 
8-{Hydroxy(pyridin-3-yl)[3,5-bis(trifluoromethyl)phenyl]methyl}-1,2,5,6-tetrahydro-4H-
pyrrolo[3,2,1-ij]quinolin-4-one (26a). The title compound was obtained according to Method B using 26b 
(200 mg, 0.72 mmol), 3,5-bis(trifluoromethyl)phenylmagnesium bromide (0.5 M in THF, 2.88 mL, 1.44 
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mmol) in anhydrous THF (12 mL) as yellow solids (96 mg, 27%). 1H-NMR (500 MHz, CDCl3): δ 2.68 (t, J 
= 7.8 Hz, 2H), 2.91 (t, J = 7.8 Hz, 2H), 2.99 (s, 1H),3.15 (t, J = 8.5 Hz, 2H), 4.10 (t, J = 8.5 Hz, 2H), 6.79 (s, 
1H), 6.84 (s, 1H), 7.25 (dd, J = 1.6, 4.6 Hz, 2H), 7.84 (s, 3H), 8.62 (dd, J = 1.6, 4.6 Hz, 2H). 
Method C: Triethylsilane Reduction 
To an alcohol (1.0 equiv) in anhydrous dichloromethane was added in sequence by syringe trifluoroacetic 
acid (10 equiv), triethylsilane (3.0 equiv) and trifluoromethanesulfuric acid (0.1 equivalent) under an 
atmosphere of nitrogen at 0 °C. The resulting solution was stirred at room temperature for 18–48 h. 
Afterwards, the reaction mixture was separated, and the queous layer was extracted with dichloromethane (2 
x 10 mL). The combined organic layers were washed with aqueous NaHCO3 and brine, dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatograph on silica gel 
(methanol/dichloromethane, 0 to 1:40) to yield the corresponding dehydoxyl product. 
8-(Pyridin-3-ylmethyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (1). 13C-NMR (125 
MHz, CDCl3): δ 24.4, 27.7, 31.6, 38.8, 45.3, 120.2, 123.4, 123.7, 125.9, 129.3, 135.2, 136.1, 136.7, 140.0, 
147.7, 150.1, 167.4. 
8-[Phenyl(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (5). 13C-NMR 
(125 MHz, CDCl3): δ 24.4, 27.7, 31.6, 45.3, 54.2, 120.1, 123.2, 124.2, 126.5, 126.7, 128.6, 129.2, 129.2, 
136.6, 138.2, 139.5, 140.2, 142.8, 147.8, 150.8, 167.5.  
8-[(2-Methoxyphenyl)(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (6). 
13C-NMR (125 MHz, CDCl3): δ 24.4, 27.8, 31.6, 45.3, 47.1, 55.5, 110.7, 119.9, 120.4, 123.1, 124.3, 126.5, 
128.0, 129.0, 130.0, 131.4, 136.5, 138.1, 139.6, 140.0, 147.4, 150.8, 156.8, 167.5.  
8-[(3-Methylphenyl)(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (7). 
13C-NMR (125 MHz, CDCl3): δ 21.5, 24.4, 27.7, 31.6, 45.3, 54.2, 120.0, 123.2, 124.2, 126.2, 126.5, 127.5, 
128.5, 129.2, 129.9, 136.6, 138.3, 138.4, 139.5, 140.1, 142.7, 147.7, 150.8, 167.5.  
8-[(3-Chlorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (8). 
13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.3, 53.9, 120.2, 123.4, 124.2, 126.4, 127.0, 127.4, 129.3, 
129.4, 129.8, 134.6, 136.5, 137.4, 138.7, 140.4, 144.9, 148.0, 150.7, 167.5.  
8-[(4-Fluorophenyl)(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (9). 
13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.3, 53.4, 115.4 (d, 2JC,F = 21.1 Hz), 120.2, 123.3, 124.1, 
126.4, 129.3, 130.6 (d, 3JC,F = 7.7 Hz), 136.5, 138.0, 138.5 (d, 4JC,F = 3.2 Hz), 139.3, 140.3, 147.9, 150.7, 
161.6 (d, 1JC,F = 246 Hz), 167.5.  
8-(Pyridin-4-ylmethyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (10). 13C-NMR (125 
MHz, CDCl3): δ 24.4, 27.7, 31.5, 41.0, 45.3, 120.3, 123.9, 124.0, 126.1, 129.4, 134.2, 140.1, 149.9, 150.2, 
167.4.  
8-(2-Methyl-1-pyridin-4-ylpropyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (13). 13C-
NMR (125 MHz, CDCl3): δ 21.6, 21.7, 24.5, 27.8, 31.5, 31.6, 45.3, 60.1, 120.1, 122.7, 123.2, 125.1, 129.3, 
3 Results and Discussions 
Lina Yin Dissertation 
- 89 -
138.6, 140.1, 149.9, 153.8, 167.4.  
8-[Cyclohexyl(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (14). 13C-
NMR (125 MHz, CDCl3): δ 24.4, 26.1, 26.2, 26.3, 27.7, 31.5, 31.7, 32.0, 40.8, 45.2, 58.7, 120.1, 122.8, 
123.3, 125.2, 129.2, 138.1, 140.0, 149.9, 153.4, 167.4.  
8-[Phenyl(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (17). 13C-NMR 
(125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.3, 56.1, 120.1, 124.3, 124.5, 126.5, 126.9, 128.6, 129.2, 129.2, 
137.6, 140.3, 142.2, 149.9, 152.9, 167.5.  
8-[(2-Methoxyphenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
(18). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.6, 45.3, 48.9, 55.5, 110.7, 119.9, 120.4, 124.4, 124.5, 
126.6, 128.2, 129.0, 130.2, 130.8, 137.4, 140.1, 149.6, 153.3, 156.9, 167.5.  
8-[(3-Methoxyphenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
(19). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.3, 55.2, 56.0, 111.6, 115.7, 120.1, 121.7, 124.2, 
124.5, 126.5, 129.2, 129.6, 137.4, 140.3, 143.8, 149.9, 152.7, 159.8, 167.5.  
8-[(4-Methoxyphenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
(20). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.3, 55.2, 55.2, 114.0, 120.1, 124.2, 124.4, 126.4, 
129.2, 130.2, 134.3, 138.0, 140.2, 149.8, 153.2, 158.4, 167.5. MS (ESI) m/z = 371 [M+H] +.  
8-[(3-Fluorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (21). 
13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.3, 55.7, 113.9 (d, 2JC,F = 21.1 Hz), 113.2 (d, 2JC,F = 21.9 
Hz), 120.2, 124.2, 124.4, 124.9 (d, 4JC,F = 2.6 Hz), 126.5, 129.4, 130.1 (d, 3JC,F = 8.2 Hz), 136.9, 140.5, 144.8 
(d, 3JC,F = 6.6 Hz), 150.0, 152.2, 163.0 (d, 1JC,F = 247 Hz), 167.5. MS (ESI) m/z = 359 [M+H] +. 
8-[(4-Fluorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (22). 
13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.3, 55.3, 115.5 (d, 2JC,F = 21.6 Hz), 120.2, 124.2, 124.4, 
126.4, 129.3, 130.7 (d, 3JC,F = 8.1 Hz), 137.4, 138.0 (d, 4JC,F = 3.0 Hz), 140.4, 150.0, 152.7, 161.7 (d, 1JC,F = 
246 Hz), 167.5.  
8-[(3-Chlorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (23). 
13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.4, 55.7, 120.3, 124.2, 124.4, 126.5, 127.2, 127.4, 129.3, 
129.4, 129.9, 134.6, 136.8, 140.6, 144.3, 150.0, 152.0, 167.5.  
8-[(4-Chlorophenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (24). 
13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.3, 55.4, 120.2, 124.2, 124.4, 126.4, 128.8, 129.4, 130.5, 
132.8, 137.1, 140.5, 140.8, 150.0, 152.3, 167.5. 
8-[(3-Methylphenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (25). 
13C-NMR (125 MHz, CDCl3): δ 21.5, 24.4, 27.7, 31.5, 45.3, 56.0, 120.1, 124.2, 124.5, 126.3, 126.5, 127.7, 
128.5, 129.2, 129.9, 137.7, 138.3, 140.3, 142.1, 149.8, 153.0, 167.5.  
8-[((3,5-Bis(trifluoromethyl)phenyl)(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-
ij]quinolin-4-one (26). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.4, 45.4, 55.6, 56.0, 120.6, 121.2 (t, 
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3JC,F = 3.64 Hz),  122.0, 124.2, 124.2, 125.3 (d, 1JC,F = 294 Hz), 129.2 (d, 4JC,F = 2.4 Hz), 129.9, 131.9 (q, 
2JC,F = 33.2 Hz), 135.5, 141.1, 145.0, 150.4, 150.8, 167.5.  
Method D: Wittig Reaction 
To a suspension of methyltriphenylphosphonium bromide (2.2 equiv) in anhydrous THF (5 mL) was 
added n-BuLi (2.0 equiv) slowly under an atmosphere of nitrogene at –78 °C. The reaction mixture was 
stirred at room temperature for 1 h, and then cooled to –78 °C again followed by addition of a solution of a 
ketone (1.0 equiv) in THF (5 mL). The resulting mixture was stirred at ambient temperature for 5 h, and 
subsequently quenched with aqueous NH4Cl, extracted with ethyl acetate (3 x 10 mL), dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatograph on silica gel to yield the 
corresponding methylene compound. 
8-(1-pyridin-3-ylvinyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (3). 13C-NMR (125 
MHz, CDCl3): δ 24.4, 27.6, 31.6, 45.4, 114.8, 119.9, 123.0, 123.2, 125.5, 129.1, 135.5, 136.1, 137.4, 141.5, 
146.9, 149.0, 149.3, 167.5.  
8-(1-pyridin-4-ylvinyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (12). 13C-NMR (125 
MHz, CDCl3): δ 24.3, 27.6, 31.6, 45.4, 115.9, 119.9, 122.8, 123.3, 125.6, 129.1, 135.5, 141.5, 147.9, 149.2, 
149.9, 167.5.  
Method E: Catalytic hydrogenation 
To a solution of a methylene compound (1 equiv) in methanol (8 mL) was added 5% Pd/C (15% weight). 
Subsequently, the reaction was stirred under a hydrogen atmosphere (maintained with balloons) for 10 h 
followed by filtration through a Celite cake and concentration in vacuo. The crude product was purified by 
flash chromatography on silica gel to yield the corresponding saturated product. 
8-(1-Pyridin-3-ylethyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (2). 13C-NMR (125 MHz, 
CDCl3): δ 21.8, 24.5, 27.8, 31.6, 42.3, 45.3, 120.1, 122.4, 123.3, 124.7, 129.2, 134.7, 140.0, 140.7, 141.6, 
147.6, 149.3, 167.4.  
8-(1-Pyridin-4-ylethyl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (11). 13C-NMR (125 
MHz, CDCl3): δ 21.3, 24.4, 27.7, 31.6, 44.1, 45.3, 120.1, 122.5, 122.8, 124.8, 129.2, 140.1, 149.9, 155.1, 
167.5.  
Method F: Sodium Borohydride Reduction 
To a solution of a ketone (1.0 equiv) in methanol (8 mL) was added sodium borohydride (2.0 equiv) at 0 
°C. The mixture was stirred at the same temperature for 1 h before concentration in vacuo. The resulting 
solid was washed with water and diethylether in sequence to yield the corresponding alcohol. 
8-[Hydroxy(pyridin-3-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (4). The title 
compound was obtained according to Method E using 5b (200 mg, 0.72 mmol) and sodium borohydride (54 
mg, 1.44 mmol) as offwhite solids (163 mg, 81%), 162–164 °C. 1H-NMR (500 MHz, CDCl3): δ 2.63 (t, J = 
7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.13 (t, J = 8.5 Hz, 2H), 3.39 (s, br, 1H), 4.04 (t, J = 8.5 Hz, 2H), 5.80 
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(s, 1H), 6.99 (s, 1H), 7.06 (s, 1H), 7.25 (dd, J = 4.8, 7.8 Hz, 1H), 7.71 (dt, J = 1.5, 7.9 Hz, 1H), 8.44 (dd, J = 
1.3, 4.7 Hz, 1H), 8.57 (d, J = 1.6 Hz, 1H).13C-NMR (125 MHz, CDCl3): δ  24.4, 27.7, 31.5, 45.4, 74.0, 120.2, 
121.8, 123.4, 124.1, 129.4, 134.0, 138.8, 139.6, 141.1, 148.0, 148.6, 167.6. MS (ESI) m/z = 281 [M+H] +. 
8-[Hydroxy(pyridin-4-yl)methyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (15). The title 
compound was obtained according to Method E using 13b (200 mg, 0.72 mmol) and sodium borohydride (55 
mg, 1.44 mmol) as white solids (190 mg, 94%), 252–253 °C. 1H-NMR (500 MHz,  DMSO-d6): δ 2.52 (t, J = 
7.7 Hz, 2H), 2.87 (t, J = 7.7 Hz, 2H), 3.08 (t, J = 8.5 Hz, 2H), 3.90 (t, J = 8.5 Hz, 2H), 5.63 (d, J = 4.0 Hz, 
1H), 6.00 (d, J = 4.0 Hz, 1H), 7.02 (s, 1H), 7.08 (s, 1H), 7.36 (dd, J = 1.6, 4.5 Hz, 2H), 8.46 (dd, J = 1.6, 4.5 
Hz, 2H). 13C-NMR (125 MHz, DMSO-d6): δ 23.7, 27.0, 31.0, 44.9, 73.0, 119.6, 121.0, 121.2, 123.4, 128.7, 
139.3, 140.3, 149.3, 154.3, 166.5. MS (ESI) m/z = 281 [M+H] +. 
 
2. HPLC purity control of all final compounds. 
The Surveyor®-LC-system consisted of a pump, an autosampler, and a PDA detector. Mass spectrometry 
was performed on a TSQ® Quantum (Thermo Electron Corporation, Dreieich, Germany). The triple 
quadrupole mass spectrometer was equipped with an electrospray interface (ESI). The system was operated 
by the standard software Xcalibur®. 
A RP C18 NUCLEODUR® 100-5 (125 × 3 mm) column (Macherey-Nagel GmbH, Duehren, Germany) 
was used as stationary phase. All solvents were HPLC grade. 
In a gradient run the percentage of acetonitrile (containing 0.1% triflouro-acetic acid) in water was 
increased from an initial concentration of 3% at 0 min to 100% at 15 min and kept at 100% for 3 min. 
The injection volume was 10 µl and flow rate was set to 350 µl/min. MS analysis was carried out at a 
spray voltage of 3800 V, a capillary temperature of 350 °C and a source CID of 10 V. Spectra were acquired 
in positive mode from 100 to 1000 m/z and full scan UV-mode. In some cases APC ionization had to be 
applied. 
Compd. RT (min) Purity [%] 
1 11.71 99.4% 
2 12.29 99.7% 
3 12.81 98.0% 
4 9.11 99.6% 
5 13.73 99.7% 
6 12.56 98.0% 
7 13.25 97.3% 
8 13.48 96.2% 
9 13.54 96.3% 
10 11.70 98.6% 
11 12.31 99.7% 
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Compd. RT (min) Purity [%] 
12 10.81 98.9% 
13 9.71 99.9% 
14 11.51 99.9% 
15 8.90 99.6% 
16 13.82 99.6% 
17 7.78 98.1% 
18 12.59 98.3% 
19 13.45 99.8% 
20 12.08 99.7% 
21 13.60 99.1% 
22 13.81 97.5% 
23 9.55 99.3% 
24 12.54 99.7% 
25 9.27 99.9% 
26 14.97 99.6% 
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3.IV. Novel Imidazol-1-ylmethyl Substituted 1,2,5,6-
Tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones as Potent 
CYP11B1 Inhibitors for the Treatment of Cushing’s 
Syndrome 
 
 
 
Introduction 
Cortisol is the principal human glucocorticoid exhibiting many important physiological functions, such as 
regulation of protein, carbohydrate and fat metabolism, it is counteracting insulin, maintaining blood 
pressure and cardiovascular function, and suppressing the immune system’s inflammatory response. Cortisol 
is biosynthesized in the adrenal cortex with the final conversion of 11-deoxycortisol catalyzed by 11β-
hydroxylase (CYP11B1). Normally, the production and secretion of cortisol are precisely controlled by 
adrenocorticotropic hormone (ACTH) within the negative feedback cycle of the hypothalamic-pituitary-
adrenal axis. However, pathological changes in adrenal and upstream regulation can cause overproduction of 
cortisol. This disease state is termed hypercortisolism or Cushing’s syndrome. In addition to symptoms like 
central obesity and physical or psychological discomfort such as fatigue, backache, headache, depression and 
anxiety in patients with hypercortisolism, overproduction of cortisol is also associated with a higher risk of 
hypertension and diabetes mellitus type II,1 which in the long run leads to increased mortality.  
Apart from surgical removal of some adrenal or pituitary tumors, CYP11B1 inhibition as a 
pharmacotherapeutic approach to block cortisol biosynthesis is an important alternative in the treatment of 
hypercortisolism. Currently, inhibitors of adrenal steroidogenesis employed clinically include ketoconazole 
(KET), etomidate (ETO) and metyrapone (MET) (Chart 1). Among them, the antifungal agent KET 
(inhibiting CYP11B1, CYP11B2, CYP17, and CYP11A1.) and the anesthetic ETO (inhibiting CYP11B1, 
CYP11B2, CYP11A1) are used as non-selective enzyme inhibitors. They are accompanied by severe side 
effects,2 whereas MET is the unique one being mentioned as a relatively selective CYP11B1 inhibitor.2 
Chart 1. Structures of drugs in clinic for the treatment of hypercortisolism. 
N
O
N
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N
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Studies have demonstrated that MET can effectively reduce cortisol levels in patients with all types of 
Cushing’s syndrome.3 However, long-term administration of MET in high doses results in nausea, dizziness, 
skin rash, edema, acne, and hirsutism.4 This absence of an effective and safe therapy for high cortisol levels 
encouraged us and others to design CYP11B1 inhibitors more potent and more selective CYP11B1 
inhibitors.5 
Many CYP inhibitors have been successfully designed based on a sp2 hybrid nitrogen coordinating to the 
heme iron located as the center ion of the porphyrin moiety of CYP enzymes, e.g. inhibitors of CYP11B2,6 
CYP177 and CYP198. This reversible inhibition manner is employed to design new CYP11B1 inhibitors with 
high potency. However, the selectivity is a challenging goal to achieve, especially over CYP11B2 due to 
high sequence homology of more than 93% shared between CYP11B1 and CYP11B2. Inhibition of other 
important steroidogenic enzymes, such as CYP17 and CYP19, should also be avoided because this would 
result in severe side effects. Recently, compounds originating from ETO have been reported to exhibit strong 
CYP11B1 inhibition.5,9 Some of them also showed improved selectivity.9 
In the present study, ETO (IC50 = 0.5 nM) was also used as a starting point as well as reference compound 
I6e (IC50 = 13 nM) to design novel inhibitors (Chart 2). The replacement of phenyl moiety of the ETO 
scaffold by the tetrahydropyrroloquinolinone group from reference compound I led to a series of imidazol-1-
ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones. It seemed reasonable that this 
hybrid would inherit the potent inhibition of CYP11B1. The introduction of the CH bridge between the 
tetrahydropyrroloquinolinone core and the N-containing heterocycle were deemed to be advantageous for the 
selectivity over CYP11B2. After optimization of the substituents on the CH bridge with various functional 
groups differing in electrostatic potential and bulkiness, such as aliphatic groups, substituted phenyl, and 
heteroaryls, the selectivity could be further improved. Besides evaluation of CYP11B1 inhibition and 
selectivity toward CYP11B2, the potent and selective compounds were further tested for selectivity against 
CYP17 and CYP19. Furthermore, after chiral separation the biological activities of R- and S-enantiomers  
Chart 2. Drug design concept. 
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N
R
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N
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were investigated with compounds 4 and 7, which to the most extent inclined to inhibit CYP11B1 or 
CYP11B2, respectively. 
Results and Discussions 
Chemistry. The syntheses of compounds 1–17 are shown in Schemes 1–3. A common synthetic route was 
exploited for the final compounds 1–5 and 7–16 (Schemes 1–2). The tetrahydropyrroloquinolinone core 1c, 
as the common intermediate, was synthesized from commercially available 2,3-dihydro-1H-indole via N-
acylation with 3-chloro-propionyl chloride  followed by cyclization with AlCl3 under melting conditions. 1c 
was subsequently converted into substituted ketone intermediates, from which the desired final compounds 
were obtained after further reduction with sodium borohydride, and thereafter imidazolation with 1,1'-
sulfonyldiimidazole in THF.10 The ketone intermediates were prepared via two different approaches. Only 
for the introduction of acetyl (1b), propanoyl (2b) and benzoyl (14b), Friedel-Crafts acylation with the 
corresponding acyl chlorides gave the desired products (Scheme 1).11 For the synthesis of the other  
Scheme 1a 
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R
O
NO
R
OH
NO
R
N N
v
+
1, 2, 141a, 2a, 14a
1b, 2b, 14b1c1d
Cl
Cl
O
2
1 R = Me
2 R = Et
14 R = Ph
 
a Reagents and conditions: (i) pyridine, THF, 0 °C; (ii) AlCl3, 140 °C; (iii) Method A: RCOCl, AlCl3, 
CH2Cl2, reflux, then 6 N aq. HCl; (iv) Method B: NaBH4, MeOH, 0 °C; (v) Method C: imidazole, SOCl2, 
THF, room temp. 
 
Scheme 2a 
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Sn(n-Bu)3
NO
O
R
NO
OH
R
NO
R
N
ii
iv v
N
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3-5,7-13,15-163a-5a, 7a-13a, 15a-16a
3b-5b, 7b-13b, 15b-16b
iii
3c3d1c
R
3 isopropyl
4 cyclopropyl
5 cyclobutyl
7 2-F Ph
8 3-F Ph
9 4-F Ph
R
10 3-MeO Ph
11 4-MeO Ph
12 3-CN Ph
13 4-CN Ph
15 2-furanyl
16 2-thiophenyl  
a Reagents and conditions: (i) NBS, DMF, 0 °C; (ii) Sn2Bu6, Pd(PPh3)4, toluene; (iii) Method D: RCOCl, 
PdCl2(PPh3)2, toluene; (iv) Method B: NaBH4, MeOH, 0 °C; (v) Method C: imidazole, SOCl2, THF, room 
temp. 
3 Results and Discussions 
Lina Yin Dissertation 
- 96 - 
Scheme 3a 
i
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N N
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NO
N
N
N
N
17
+
1b  
a Reagents and conditions: (i) imidazole, SOCl2, CH2Cl2, room temp. 
derivatives, the core was first brominated with NBS12 and subsequently stannated with bis(tributyltin) to 
afford the key intermediate 3c, which subsequently coupled with various acyl chlorides to give the 
corresponding ketones 3b–5b, 7b–13b and 15b–16b in 25–75% yields13 (Scheme 2). In order to abrogate the 
chiral center, 1b was reacted with an excess of 1,1'-sulfonyldiimidazole and imidazole in CH2Cl2 to give the 
vinyl imidazole analogue 6 as the minor product, and the diimidazolyl compound 17 as the major one. 14  
Inhibition of Human CYP11B1 and CYP11B2. The synthesized compounds were evaluated for their 
inhibitory activities in V79 MZh cells expressing either human CYP11B1 or CYP11B2.15 IC50 values are 
presented in comparison to the reference compounds I, and etomidate and the CYP11B1 inhibitor 
metyrapone (Table 1). 
Most the compounds showed strong inhibition of CYP11B1, with IC50 values ranging from 1.4 to 110 nM. 
Analogues with aliphatic chains at the CH bridge (1–6, IC50 < 20 nM) exhibited a stronger inhibition than 
compounds substituted with aromatic rings (7–17, IC50 values ranging from 13 to 144 nM). For the aliphatic 
analogues 1–5 the size of the substituents exhibited a significant influence on the inhibitory potency. With 
increasing bulkiness of the aliphatic substituents were increasing (Me < Et < cyclopropyl < cyclobutyl < 
isopropyl),16 the potency of the corresponding compounds increased from 17 nM (1, Me) to 1.4 nM (3, 
isopropyl). Thus, compound 3 turned out to be the most potent CYP11B1 inhibitor in this study, being ten-
fold more potent than metyrapone (IC50 = 15 nM), the drug used in clinic. However, compound 3 also 
exhibited strong inhibition of CYP11B2 (IC50 = 3.8 nM), resulting in poor selectivity (SF = 2.7). On the 
contrary, compound 4 exceeded metyrapone both in terms of inhibitory potency (IC50 = 2.2 nM) and 
selectivity (SFs of 11 and 4.8 for 4 and metyrapone, respectively). Dehydrogenation of the methyl group to 
methylene (6) resulted in a similarly potent compound with improved selectivity (SF = 5.3) compared to 1. 
However, further modification by introducing the more bulky phenyl group onto the CH bridge (14) led to 
a slight decrease in inhibition (IC50 = 50 nM), which might be due to some steric hindrance. This hypothesis 
is substantiated by the fact that only F substitution (compounds 7–9) led to similarly active compounds (IC50 
ranging 27–40 nM), whereas analogues substituted with the more bulky MeO or CN (compounds 10–13) 
mostly exhibited reduced inhibitory activity (IC50 ranging 40–144 nM). It certainly has also to be taken into 
account that MeO donates electrons, while CN is a strong electron withdrawing group. Moreover, the 
position of the substituent at the phenyl group is also important for inhibitory potency. It is obvious that 
analogues with para- substitution are more potent than the ones with meta- substitution, especially for MeO 
and CN, where the para- substituted analogues 11 and 13 (IC50 = 40 and 70 nM) are more than the  
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Table 1. Inhibition of CYP11B1 and CYP11B2 by compounds 1–17. 
NO
N
N
N
N
NO
R
N N
171-16  
Compd R CYP11B1a 
IC50 b (nM) 
CYP11B2c 
IC50 b (nM) 
S. F.d 
1 Me 17 15 0.9 
2 Et 6.5 5.8 0.9 
3 i-propyl 1.4 3.8 2.7 
4 c-propyl 2.2 24 11 
5 c-butyl 3.4 4.2 1.2 
6 =CH2 19 100 5.3 
7 2-F Ph 40 19 0.5 
8 3-F Ph 29 18 0.6 
9 4-F Ph 27 29 1.1 
10 3-MeO Ph 110 88 0.8 
11 4-MeO Ph 40 104 2.6 
12 3-CN Ph 144 304 2.1 
13 4-CN Ph 70 308 4.4 
14 Ph 50 33 0.7 
15 2-furanyl 20 47 2.4 
16 2-thiophenyl 13 18 1.4 
17 - 438 851 1.9 
I  13 0.2 0.02 
Etomidate  0.5 0.1 0.5 
Metyrapone  15 72 4.8 
a Hamster fibroblasts expressing human CYP11B1; substrate deoxycorticosterone, 100 nM. b Mean value of at least three 
experiments, relative standard deviation usually less than 25%. c Hamster fibroblasts expressing human CYP11B2; substrate 
deoxycorticosterone, 100 nM. d IC50 CYP11B2/IC50 CYP11B1. 
corresponding meta- substituted compounds 10 and 12 (IC50 = 110 and 144 nM). Interestingly, the para- 
substituted analogues 11 and 13 (SF = 2.6 and 4.4) also exhibited a better selectivity compared to the non- or 
meta- substituted compounds. 
Furthermore, replacement of the phenyl group by its less bulky bioisosters 2-furanyl (15) and 2-thiophenyl 
(16) elevated the inhibition of CYP11B1 to around 15 nM. However, analogue 17 with a methyl and an 
additional imidazolyl group at the CH bridge exhibited a dramatic decrease in inhibitory activity (IC50 = 438 
nM). It is interesting to observe that this exchange of phenyl by heterocycles (15–17) actually improved the 
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selectivity compared to 14. 
With compound 4 as the most selective one (SF = 11), the synthesized compounds are much more 
selective than their parent compounds, especially compared to reference compound I (SF = 0.02). This 
achievement is certainly attributed to the introduction of the CH bridge between the 
tetrahydropyrroloquinolinone core and the N-containing heterocycle, and probably also to the replacement of 
isoquinolinyl by imidazolyl. 
No Significant Difference between R- and S-Enantiomers in Biological Activity. In order to investigate 
the possible influence of different configurations on inhibitory potency or selectivity, the racemic 
compounds 4 and 7 were separated by HPLC and tested. However, no significant difference between the 
bioactivity of the corresponding pure enantiomers was found for either compound (data not shown). 
Selectivity against Human CYP17 and CYP19. Since CYP17 and CYP19 are crucial enzymes involved 
in androgen and estrogen biosynthesis respectively, the selectivities for four of the most potent and / or 
selective compounds against these two enzymes were further tested as criteria to evaluate safety (Table 2).  
As can be seen, compounds 3 and 4 exhibited weak CYP17 inhibition with IC50 values over 1500 nM, 
whereas compounds 6 and 12 showed almost no effect (IC50 > 5000 nM). Moreover, due to the structural 
similarity of the synthesized compounds to the clinically used CYP19 inhibitors like letrozole, the inhibition 
of CYP19 was not a surprise. Compounds 6 and 12 showed strong inhibition with IC50 values of 17 nM and 
43 nM (Table 2), respectively, which is probably due to the presence of methylene or phenyl substituents at 
the CH bridge. In contrast, compounds 3 and 4 with saturated alkyl groups exhibited only modest inhibition 
of CYP19 (IC50 > 200 nM, Table 2). Accordingly, good selectivity was achieved with selectivity factor (IC50 
CYP19 / IC50 CYP11B1) of 357 for compound 3 and 104 for compound 4 due to the extremely potent inhibition of 
CYP11B1. 
Table 2. Inhibition of CYP17, CYP19 and rat CYP11B1 by selected compounds. 
Compd CYP17a 
IC50 e (nM) 
CYP19b 
IC50 e (nM) 
Rat CYP11B1c 
Inhib. % f 
3 1550 >500 n.d. 
4 2880 228 91 
6 >5000 17 n.d. 
11 >5000 43 n.d. 
I   31 
a E. coli expressinghuman CYP17; substrate progesterone, 25 μM; Abiraterone, IC50 = 72 nM. b Human placental CYP19; 
substrate androstenedione, 500 nM, inhibitor concentration 500 nM; fadrozole, IC50 = 41 nM. c Hamster fibroblasts expressing rat 
CYP11B1; substrate deoxycorticosterone, 500 nM; inhibitor concentration 2.0 μM. d IC50 CYP19 / IC50 CYP11B2. e Mean value of at 
least three experiments, standard deviation usually less than 10%; n.d. = not determined. f Mean value of at least three experiments, 
relative standard deviation usually less than 20%. 
Inhibition of Rat CYP11B1. Drug candidates always need to be evaluated in animals (usually rats) for 
pharmacokinetic and pharmacodynamic properties before finally entering into clinical trials. Potent 
inhibition of rat enzyme is therefore the precondition to observe the desired curative effects in the rat disease 
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models. Compound 4 showed 91% inhibition of rat CYP11B1 at a concentration of 2 µM, in comparison to 
31% for reference compound I. This high potency toward rat enzyme facilitates further evaluation in vivo. 
Conclusion 
Starting from two leads, etomidate and reference compound, which both showed strong inhibition of 
CYP11B1 but even more potent inhibition of CYP11B2, novel imidazol-1-ylmethyl substituted 1,2,5,6-
tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones were designed and synthesized aiming at the development of 
potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome. The replacement of the 
phenyl moiety in the ETO scaffold by a tetrahydropyrroloquinolinone group from reference compound I 
sustained the potent inhibition of CYP11B1, while the improved selectivity was attributed to the CH bridge 
between the tetrahydropyrroloquinolinone core and the heme binding imidazolyl. 
It has been elucidated that the bulkiness of the substituents on the CH bridge was a determinant of 
inhibitory potency. With increasing bulkiness of the aliphatic chains, the inhibitory potency increased from 
about 20 nM to less than 5 nM. However, when phenyl was introduced, the inhibition was decreased to 50 
nM. The inhibitory activity was improved again to around 15 nM when furanyl and thiophenyl were 
employed as less bulky bioisosters of phenyl. Moreover, similar steric limitations were observed when 
substituents were introduced on phenyl group. Intriguingly, compounds with substitutents at the para- 
position of phenyl group showed improved inhibition and selectivity compared to non- or meta- substituted 
phenyl analogues. 
Furthermore, compound 4 was identified as a CYP11B1 inhibitor more potent (IC50 = 2.2 nM) and 
selective (SF = 11) than the lead compounds and metyrapone, the drug in clinical use. Since this compound 
also showed potent inhibition of rat CYP11B1 (facilitating in vivo test) and good selectivity over CYP17 and 
CYP19, it is considered to be a promising lead compound for further evaluation in vivo.  
Experimental Section 
Biology 
Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human/rat CYP11B1 or CYP11B2 were incubated with [1,2-3H]-11-
deoxycorticosterone as the substrate and the inhibitor at different concentrations.. The assay was performed 
as previously described.15 
CYP17 preparation and assay 
Human CYP17 was expressed in E. coli 17a (coexpressing human CYP17 and NADPH-P450 reductase), 
and the assay was performed using method previously described, progesterone as the substrate and NADPH 
as the cofactor.17b 
CYP19 preparation and assay 
Human CYP19 was obtained from microsomal preparations of human placenta and the assay was 
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performed using the 3H2O-method as previously described and [1β-3H]androstenedione as the substrate.18 
Chemistry 
General Method 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. 1H-NMR 
spectra were measured on a Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million 
(ppm), and TMS was used as an internal standard for spectra obtained. All coupling constants (J) are given 
in Hz. ESI (electrospray ionization) mass spectra were determined on a TSQ quantum (Thermo Electron 
Corporation) instrument. The purities of the final compounds were controlled by Surveyor-LC-system. 
Purities were greater than 95%. Column chromatography was performed using silica-gel 60 (50-200 µm), 
and reaction progress was determined by TLC analysis on Alugram SIL G/UV254 (Macherey-Nagel). 
Reagents and solvents commercially available were used directly without further purification.  
Method A: Friedel-Crafts Acylation 
To a solution of 1c (1.0 equiv) and AlCl3 (3.0–7.0 equiv) in dry dichloromethane was added dropwise an 
acyl chloride (1.5–2.0 equiv) at room temperature. The mixture was then refluxed for 18 h, cooled to ambient 
temperature and quenched by addition of a cold mixture of concentrated hydrochloric acid (2.0 equiv) and 
water. Extraction with EtOAc three times, followed by drying over MgSO4 and removal of the solvent in 
vacuo gave a ketone. 
Method B: Borohydride Reduction 
The ketone (1.0 equiv) was dissolved in methanol. Sodium hydride (1.2–2.0 equiv) was added in portions 
at 0 °C. After stirring for 1 h at the same temperature, water was added and the resulting mixture was 
extracted with EtOAc three times. The combined organic layers were dried over MgSO4 and concentrated in 
vacuo to give the corresponding alcohol. 
Method C: Imidazylation 
A solution of the obtained alcohol (1.0 equiv) in dry THF was added to a solution of thionylbis(imidazo1e) 
(prepared previously by reaction of imidazole (16 equiv) with thionyl chloride (4.0 equiv) in dry THF and 
filtration to remove precipitated imidazole hydrochloride) at 0 °C. The reaction mixture was stirred for 1 h at 
0 °C and an additional 18–30 h at ambient temperature. Water was added and the mixture extracted with 
ethyl acetate three times, the combined organic extracts washed with water and brine, and the solvent was 
evaporated in vacuo after drying over MgSO4. The crude product was purified by flash chromatography to 
yield the corresponding product. 
Method D: Stille Coupling 
3c (1.0 equiv), dichlorobis(triphenylphosphine)palladium(II) (0.1 equiv) and an acyl chloride (2.0 equiv) 
were suspended in 25 mL dry toluene under an atmosphere of nitrogen. The mixture was refluxed for 2 h 
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before it was concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel 
to yield the corresponding ketone. 
8-[1-(1H-imidazol-1-yl)-2-methylpropyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (3). The 
title compound was synthesized according to Method C using 3a (0.20 g, 0.82 mmol), imidazole (0.90 g, 
13.0 mmol), SOCl2 (0.24 mL, 3.26 mmol) and dry THF (10 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 1:50) to yield  pale yellow solids (35 mg, 15%). mp 150–152 °C, Rf = 
0.20 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 MHz, CDCl3): δ 0.91 (t, J = 6.9 Hz, 6H), 2.54 (m, 1H), 2.66 (t, J 
= 7.8 Hz, 2H), 2.94 (t, J = 7.8 Hz, 2H), 3.16 (t, J = 8.5 Hz, 2H), 4.07 (t, J = 8.5 Hz, 2H), 4.55 (d, J = 10.5 
Hz, 1H), 6.92 (s, 1H), 6.99 (s, 1H), 7.01 (s, 1H), 7.06 (s, 1H), 7.68 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 
20.1, 20.5, 24.4, 27.7, 31.4, 32.5, 45.4, 69.5, 117.4, 120.4, 122.3, 124.7, 128.9, 129.6, 134.6, 136.1, 141.5, 
167.5. MS (ESI) m/z = 229 [M-imidazole] +. 
Resolution of Racemate. Enantiomers were separated via preparative HPLC on a Agilent Technologies 
1200 series system (quaternary pump, MWD, fraction collector) using a NucleoCel Delta column, 0.8 cm × 
25 cm. Retention times (tR) were determined with an analytical column using 0.3 mL/min and UV detection 
(254 nm). The ee values were measured on a Merck-Hitachi LaChrome D-7000 System (isocratic pump 
L7100, diode array detector L7455, autosampler L-7200) using a Chiracel OD-H column, 0.46 cm × 25 cm. 
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Supporting Information 
1. The synthetic procedures and characterization of all intermediates and all final compounds as well 
as 1H-NMR and 13C-NMR of all final compounds except for compound 3. 
Method A: Friedel-Crafts Acylation 
To a solution of 1c (1.0 equiv) and AlCl3 (3.0–7.0 equiv) in dry dichloromethane was added dropwise an 
acyl chloride (1.5–2.0 equiv) at room temperature. The mixture was then refluxed for 18 h, cooled to ambient 
temperature and quenched by addition of a cold mixture of concentrated hydrochloric acid (2.0 equiv) and 
water. Extraction with EtOAc three times, followed by drying over MgSO4 and removal of the solvent in 
vacuo gave a ketone. 
Method B: Borohydride Reduction 
The ketone (1.0 equiv) was dissolved in methanol. Sodium hydride (1.2–2.0 equiv) was added in portions at 
0 °C. After stirring for 1 h at the same temperature, water was added and the resulting mixture was extracted 
with EtOAc three times. The combined organic layers were dried over MgSO4 and concentrated in vacuo to 
give the corresponding alcohol. 
Method C: Imidazylation 
A solution of the obtained alcohol (1.0 equiv) in dry THF was added to a solution of thionylbis(imidazo1e) 
(prepared previously by reaction of imidazole (16 equiv) with thionyl chloride (4.0 equiv) in dry THF and 
filtration to remove precipitated imidazole hydrochloride) at 0 °C. The reaction mixture was stirred for 1 h at 
0 °C and an additional 18–30 h at ambient temperature. Water was added and the mixture extracted with 
EtOAc three times, the combined organic extracts washed with water and brine, and the solvent was 
evaporated in vacuo after drying over MgSO4. The crude product was purified by flash chromatography to 
yield the corresponding product. 
Method D: Stille Coupling 
3c (1.0 equiv), dichlorobis(triphenylphosphine)palladium(II) (0.1 equiv) and an acyl chloride (2.0 equiv) 
were suspended in 25 mL dry toluene under an atmosphere of nitrogen. The mixture was refluxed for 2 h 
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before it was concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel 
to yield the corresponding ketone. 
3-Chloro-1-(2,3-dihydro-indol-1-yl)-propan-1-one (1d). To a solution of indoline (25.0 mL, 223 mmol) 
and pyridine in 100 ml THF was added dropwise 3-chloropropanoyl chloride (23.4 ml, 245 mmol) at 0 °C 
under N2. Immediately a lot of precipitate was formed. The suspension was allowed to warm to ambient 
temperature and stirred overnight. TLC monitored the reaction complete. Water was added to quench 
followed by extraction with EtOAc (3 x 100 ml). After the combined organic layers were washed with brine 
(3 x 200 ml) and dried over MgSO4. Evaporation gave pink solids, which were directly used in the next step. 
1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (1c). A molten mixture of 1d (44.5 g, 212 mmol) and 
AlCl3 (149 g, 1.12 mol) was stirred at 140 °C for 4 h. Upon cooling to 0 °C, a mixture of water/ice (500 g) 
was added to decompose excess AlCl3. The resulting solution was extracted with EtOAc (3 x 200 ml), 
followed by drying over MgSO4 and removal of the solvent gave a yellow solid, which was purified by flash 
chromatography (EtOAc/n-Hexane, 1:20 to 2:5) to yield 1c as white solids (25.7 g, 70%). 1H-NMR (500 
MHz, CDCl3): δ 2.68 (t, J = 7.8 Hz, 2H), 2.97 (t, J = 7.8 Hz, 2H), 3.18 (t, J = 8.5 Hz, 2H), 4.07 (t, J = 8.5 Hz, 
2H), 6.92 (t, J = 7.4 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H); 7.07 (d, J = 7.3 Hz, 1H); 13C-NMR (125 MHz, 
CDCl3): δC 24.4, 27.8, 31.6, 45.1, 120.2, 123.2, 123.3, 125.3, 128.9, 141.3, 167.7; MS (ESI) m/z = 174 
[M++H]. 
8-Bromo-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (3d). To a solution of 1c (1.00 g, 5.77 mmol) 
in 18 ml dry DMF was added dropwise a solution of N-bromosuccinimide (1.09 g, 6.12 mmol) in 18 ml dry 
DMF at 0 °C. The mixture was stirred at 0 °C for 2 h, then 36 ml water was added and the resulting solution 
was extracted with EtOAc (3 x 40 ml). The organic phase was washed with water (2 x 20 ml), then dried 
over MgSO4 and evaporated, affording brown solids which was purified by washing with flash 
chromatography (EtOAc/n-Hexane, 2:5) to yield 3d as white solids (0.93 g, 65%). MS (ESI) m/z = 252 [M] +. 
8-(Tributylstannanyl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (3c). To a solution of 3d (9.07 g, 
36.0 mmol) and 1,1,1,2,2,2-hexabutyldistannane (29.1 mL, 57.6 mmol) in 40 mL degassed dry toluene was 
added tetrakis(triphenylphosphine)palladium(0) (4.16g, 3.60 mmol) under an atmosphere of nitrogen, and the 
mixture was stirred overnight at 90 °C. After cooling to ambient temperature, the mixture was concentrated 
in vacuo. The crude product was purified by flash chromatography (EtOAc/n-Hexane, 1:10, Rf = 0.1) to yield 
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pure 3c as a light yellow oil (7.50 g, 45%). 1H-NMR (500 MHz, CDCl3): δ 0.89 (t, J = 7.3 Hz, 9H), 1.03 (m, 
6H), 1.34 (sext, J = 7.3 Hz, 6H), 1.53 (m, 6H), 2.68 (t, J = 7.8 Hz, 2H), 2.97 (t, J = 7.8 Hz, 2H), 3.18 (t, J = 
8.4 Hz, 2H), 4.05 (t, J = 8.4 Hz, 1H), 7.05 (s, 1H), 7.16 (s, 1H); 13C-NMR (125 MHz, CDCl3): δ 9.7, 13.6, 
24.4, 27.4, 27.8, 29.1, 31.8, 45.0, 120.0, 128.8, 130.9, 132.9, 135.9, 141.5, 167.7. 
8-Acetyl-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (1b). The title compound was synthesized 
according to Method A using 1c (1.79 g, 10.0 mmol), AlCl3 (9.31 g, 70.0 mmol) and acetyl chloride (1.18 g, 
15.0 mmol) in dry CH2Cl2 (50 mL) to yield the crude product as a yellow solid (1.79 g, 83%). 1H-NMR (500 
MHz, CDCl3): δ 2.56 (s, 3H), 2.72 (t, J = 7.8 Hz, 2H), 3.02 (t, J = 7.8 Hz, 2H), 3.23 (t, J = 8.5 Hz, 2H), 4.13 
(t, J = 8.5 Hz, 2H), 7.67 (s, 1H), 7.72 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.2, 26.5, 27.3, 31.4, 45.7, 
119.6, 124.2, 127.0, 129.2, 133.2, 145.7, 167.9, 196.8. 
8-(1-Hydroxy-ethyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (1a). The title compound was 
synthesized according to Method B using 1b (1.79 g, 8.31 mmol) and sodium hydride (452 mg, 12.0 mmol) 
in Methanol (50 mL) to yield a yellow solid (1.81 g, 100%). 1H-NMR (500 MHz, CDCl3): δ 1.48 (d, J = 6.4 
Hz, 3H), 2.01 (s, br, 1H) , 2.66 (t, J = 7.8 Hz, 2H), 2.95 (t, J = 7.8 Hz, 2H), 3.16 (t, J = 8.4 Hz, 2H), 4.06 (t, J 
= 8.4 Hz, 2H), 4.84 (q, J = 6.2 Hz, 1H), 7.02 (s, 1H), 7.10 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 25.4, 
27.7, 31.6, 45.4, 70.3, 120.0, 120.6, 122.8, 129,1, 140.7, 141.5, 167.6. 
8-Propionyl-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (2b). The title compound was synthesized 
according to Method A using 1c (1.79 g, 10.0 mmol), AlCl3 (4.00 g, 30 mmol) and propionyl chloride (1.31 
ml, 15.0 mmol) in dry dichloromethane (80 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (hexanes/ EtOAc, 3:7, Rf = 0.16) to yield a green solid (1.20 g, 52%). 1H-NMR 
(500 MHz, CDCl3): δ 1.20 (t, J = 7.2, 3H),  2.70 (t, J = 7.6, 2H), 2.93 (t, J = 7.2, 2H), 3.00 (t, J = 7.6, 2H), 
3.21 (t, J = 8.5, 2H), 4.12 (t, J = 8.5, 2H), 7.71 (1H, s), 7.67 (1H, s). 13C-NMR (125 MHz, CDCl3): δ 8.5, 
24.25, 27.3, 31.4, 31.6, 45.7, 119.6, 123.8, 126.5, 129.1, 132.9, 145.4, 167.84, 199.5. 
8-(1-Hydroxy-propyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (2a). The title compound was 
synthesized according to Method B using 2b (1.20 g, 5.20 mmol) and sodium hydride (236 mg, 6.21 mmol) 
in Methanol (26 mL) to yield a yellow solid (0.63 g, 52%). 1H-NMR (500 MHz, CDCl3): δ 0.90 (t, J = 7.2, 
3H), 1.68–1.83 (m, 2H), 2.66 (t, J = 7.9, 2H), 2.94 (t, J = 7.9, 2H), 3.16 (t, J = 8.5, 2H), 4.06 (t, J = 8.5, 2H), 
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4.52 (t, J = 6.6, 1H), 6.97 (s, 1H), 7.05 (s, 1H),. 13C-NMR (125 MHz, CDCl3): δ 10.5, 24.8, 28.0, 31.9, 32.3, 
45.6, 76.3, 120.2, 121.4, 123.6, 129.2, 140.5, 141.0, 167.8. 
8-Isobutyryl-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (3b). The title compound was synthesized 
according to Method D using 3c (1.50 g, 3.24 mmol), isobutyryl chloride (0.68 mL, 6.49 mmol) and 
dichlorobis(triphenyl phosphine)palladium(II) (0.23 g, 0.32 mmol) in dry toluene (20 mL) to yield the crude 
product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:50 to 2:5) to yield a yellow 
solid (0.19 g, 24%). Rf = 0.15 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 1.21 (d, J = 6.8 Hz, 6H), 
2.72 (t, J = 7.8 Hz, 2H), 3.02 (t, J = 7.8 Hz, 2H), 3.23 (t, J = 8.5 Hz, 2H), 3.50 (sept, J = 6.8 Hz, 1H), 4.13 (t, 
J = 8.5 Hz, 2H), 7.68 (s, 1H), 7.72 (s, 1H). 
8-(1-Hydroxy-2-methyl-propyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (3a). The title 
compound was synthesized according to Method B using 3b (1.88 g, 0.77 mmol) and sodium hydride (59.0 
mg, 1.54 mmol) in Methanol (8 mL) to yield a yellow solid (0.19 g, 100%). 1H-NMR (500 MHz, CDCl3): δ 
0.79 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 1.69 (s, br, 1H), 1.92 (sext, J = 6.8 Hz, 1H), 2.67 (t, J = 7.8 
Hz, 2H), 2.96 (t, J = 7.8 Hz, 2H), 3.17 (t, J = 8.4 Hz, 2H), 4.08 (t, J = 8.4 Hz, 2H), 4.28 (d, J = 7.2 Hz, 1H), 
6.95 (s, 1H), 7.03 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 18.4, 19.1, 24.5, 27.7, 31.6, 35.4, 45.4, 80.2, 
119.7, 121.6, 123.9, 128.8, 139.3, 140.7, 167.6. 
8-Cyclopropanecarbonyl-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (4b). The title compound 
was synthesized according to Method D using 3c (1.50 g, 3.24 mmol), cyclopropane carbonyl chloride (0.59 
mL, 6.49 mmol) and dichlorobis(triphenyl phosphine)palladium(II) (0.23 g, 0.32 mmol) in dry toluene (25 
mL) to yield the crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:50 
to 1:1) to yield a pale yellow solid (0.58 g, 74%). Rf = 0.07 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 
1.01 (m, 2H), 1.21 (m, 2H), 2.60 (m, 1H), 2.72 (t, J = 7.8 Hz, 2H), 3.03 (t, J = 7.8 Hz, 2H), 3.23 (t, J = 8.5 
Hz, 2H), 4.14 (t, J = 8.5 Hz, 2H), 7.74 (s, 1H), 7.78 (s, 1H). 
8-(Cyclopropyl-hydroxy-methyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (4a). The title 
compound was synthesized according to Method B using 4b (0.58 g, 0.24 mmol) and sodium hydride (0.18 g, 
4.80 mmol) in Methanol (15 mL) to yield a yellow solid (0.56 g, 96%). 1H-NMR (500 MHz, CDCl3): δ 0.33–
0.38 (m, 1H), 0.45–0.50 (m, 1H), 0.54–0.59 (m, 1H), 0.63–0.68 (m, 1H), 1.17–1.24 (m, 1H), 1.93 (d, J = 2.9 
Hz, 1H), 2.68 (t, J = 7.8 Hz, 2H), 2.97 (t, J = 7.8 Hz, 2H), 3.18 (t, J = 8.4 Hz, 2H), 3.93 (dd, J = 2.7, 8.4 Hz, 
1H), 4.08 (t, J = 8.4 Hz, 2H), 7.07 (s, 1H), 7.15 (s, 1H). 
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8-Cyclobutanecarbonyl-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (5b). The title compound was 
synthesized according to Method D using 3c (1.20 g, 2.60 mmol), cyclobutane carbonyl chloride (0.42 mL, 
5.20 mmol) and dichlorobis(triphenyl phosphine)palladium(II) (0.18 g, 0.26 mmol) dry toluene (20 mL) to 
yield the crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:50 to 1:2) to 
yield a pale yellow solid (0.42 g, 64%). Rf = 0.09 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 1.87–
1.94 (m, 1H), 2.03–2.12 (m, 1H), 2.24–2.31 (m, 2H), 2.36–2.44 (m, 2H), 2.71 (t, J = 7.8 Hz, 2H), 3.01 (t, J = 
7.8 Hz, 2H), 3.21 (t, J = 8.5 Hz, 2H), 3.93 (quin, J = 8.5 Hz, 1H), 4.12 (t, J = 8.5 Hz, 2H), 7.60 (s, 1H), 7.65 
(s, 1H). 
8-(Cyclobutyl-hydroxy-methyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (5a). The title 
compound was synthesized according to Method B using 5b (0.58 g, 0.24 mmol) and sodium hydride (0.18 g, 
4.80 mmol) in Methanol (15 mL) to yield a yellow solid (0.56 g, 96%) after purification by flash 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 1:100). Rf = 0.15 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 
MHz, CDCl3): δ 1.73–1.90 (m, 4H), 1.92 (d, J = 3.2 Hz, 1H), 1.95–2.02 (m, 1H), 2.07–2.14 (m, 1H), 2.60 
(quad, J = 8.0 Hz, 1H), 2.65 (t, J = 7.8 Hz, 2H), 2.94 (t, J = 7.8 Hz, 2H), 3.16 (t, J = 8.4 Hz, 2H), 4.06 (t, J = 
8.4 Hz, 2H), 4.50 (dd, J = 3.3, 8.2 Hz, 1H), 6.95 (s, 1H), 7.03 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 17.7, 
24.4, 25.0, 27.7, 31.6, 42.5, 45.3, 78.6, 119.6, 121.3, 123.6, 128.9, 138.7, 140.8, 167.6. 
8-(2-Fluoro-benzoyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (7b). The title compound was 
synthesized according to Method D using 3c (1.20 g, 2.60 mmol), 2-fluorobenzoyl chloride (0.42 mL, 5.20 
mmol) and dichlorobis(triphenyl phosphine)palladium(II) (0.18 g, 0.26 mmol) dry toluene (20 mL) to yield 
the crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:20 to 1:2) to yield 
a yellow semisolid (0.64 g, 84%). Rf = 0.15 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.72 (t, J = 7.8 
Hz, 2H), 3.02 (t, J = 7.8 Hz, 2H), 3.24 (t, J = 8.4 Hz, 2H), 4.13 (t, J = 8.4 Hz, 2H), 7.11–7.20 (m, 3H), 7.26–
7.31 (m, 2H), 7.38 (td, J = 1.8, 7.8 Hz, 1H). 
8-[(2-Fluoro-phenyl)-hydroxy-methyl]-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (7a). The title 
compound was synthesized according to Method B using 7b (0.64 g, 2.18 mmol) and sodium hydride (0.17 g, 
4.36 mmol) in Methanol (20 mL) to yield a yellow solid (0.17 g, 26%) after purification by flash 
chromatography on silica gel (MeOH/CH2Cl2, 1:500 to 1:100). Rf = 0.21 (MeOH/CH2Cl2, 1:20). 1H-NMR 
(500 MHz, CDCl3): δ 2.28 (d, J = 2.9 Hz, 1H), 2.65 (t, J = 7.8 Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H), 3.15 (t, J = 
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8.5 Hz, 2H), 4.06 (t, J = 8.5 Hz, 2H), 6.08 (d, J = 2.8 Hz, 1H), 7.02 (m, 1H), 7.04 (s, 1H), 7.11 (s, 1H), 7.18 
(td, J = 1.1, 7.5 Hz, 1H), 7.27 (m, 1H), 7.57 (td, J = 1.7, 7.6 Hz, 1H). 
8-(3-Fluoro-benzoyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (8b). The title compound was 
synthesized according to Method D using 3c (1.50 g, 3.24 mmol), 3-fluorobenzoyl chloride (0.79 mL, 6.48 
mmol) and dichlorobis(triphenyl phosphine)palladium(II) (0.23 g, 0.32 mmol) dry toluene (20 mL) to yield 
the crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:50 to 1:2) to yield 
a yellow solid (0.70 g, 73%). Rf = 0.15 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.74 (t, J = 7.8 Hz, 
2H), 3.03 (t, J = 7.8 Hz, 2H), 3.24 (t, J = 8.5 Hz, 2H), 4.15 (t, J = 8.5 Hz, 2H), 7.25–7.29 (m, 1H), 7.42–7.48 
(m, 2H), 7.52 (m, 2H), 7.57 (s, 1H). 
8-[(3-Fluoro-phenyl)-hydroxy-methyl]-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (8a). The title 
compound was synthesized according to Method B using 8b (0.49 g, 1.66 mmol) and sodium hydride (0.13 g, 
3.33 mmol) in Methanol (15 mL) to yield a yellow solid (0.43 g, 87%) after purification by flash 
chromatography on silica gel (EtOAc/PE, 1:500 to 1:100). Rf = 0.06 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, 
CDCl3): δ 2.28 (d, J = 2.9 Hz, 1H), 2.63 (t, J = 7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.14 (t, J = 8.5 Hz, 2H), 
4.04 (t, J = 8.5 Hz, 2H), 5.76 (s, 1H), 6.94 (m, 1H), 6.99 (s, 1H), 7.06 (s, 1H), 7.13 (m, 2H), 7.29 (m, 1H). 
13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.4, 75.5 (d, 4JC,F = 1.3 Hz), 113.2 (d, 2JC,F = 22.1 Hz), 
114.2 (d, 2JC,F = 21.1 Hz), 120.1, 121.8, 124.1, 129.3, 130.0 (d, 3JC,F = 8.2 Hz), 139.2, 141.0, 146.7 (d, 3JC,F = 
6.5 Hz), 163.0 (d, 1JC,F = 246 Hz), 167.6. 
8-(4-Fluoro-benzoyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (9b). The title compound was 
synthesized according to Method D using 3c (3.11 g, 6.73 mmol), 4-fluorobenzoyl chloride (1.60 mL, 13.5 
mmol) and dichlorobis(triphenyl phosphine)palladium(II) (0.47 g, 0.67 mmol) dry toluene (30 mL) to yield 
the crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 7:3) to yield a 
yellow solid (1.29 g, 65%). Rf = 0.15 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.73 (t, J = 7.8 Hz, 
2H), 3.02 (t, J = 7.8 Hz, 2H), 3.23 (t, J = 8.5 Hz, 2H), 4.15 (t, J = 8.5 Hz, 2H), 7.16 (m, 2H), 7.50 (s, 1H), 
7.54 (s, 1H), 7.78 (m, 2H). 
8-[(4-Fluoro-phenyl)-hydroxy-methyl]-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (9a). The title 
compound was synthesized according to Method B using 9b (0.55 g, 1.86 mmol) and sodium hydride (0.14 g, 
3.71 mmol) in Methanol (10 mL) to yield a pale yellow solid (0.37 g, 66%) after purification by flash 
chromatography on silica gel (MeOH/CH2Cl2, 1:500 to 1:100). Rf = 0.04 (MeOH/CH2Cl2, 1:50). 1H-NMR 
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(500 MHz, CDCl3): δ 2.32 (d, J = 3.4 Hz, 1H), 2.65 (t, J = 7.8 Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H), 3.14 (t, J = 
8.5 Hz, 2H), 4.06 (t, J = 8.5 Hz, 2H), 5.77 (d, J = 3.1 Hz, 1H), 6.99 (s, 1H), 7.03 (m, 2H), 7.06 (s, 1H), 7.35 
(m, 2H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.4, 75.5, 115.3, 120.1, 121.7, 124.0, 128.0 (d, 
3JC,F = 8.1 Hz), 128.5 (d, 2JC,F = 12.2 Hz), 129.2, 132.1 (d, 3JC,F = 9.9 Hz), 139.4, 139.8 (d, 4JC,F = 3.0 Hz), 
141.0, 161.1 (d, 1JC,F = 246 Hz), 167.6. MS (ESI) m/z = 298 [M+H] +. 
8-(3-Methoxy-benzoyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (10b). The title compound was 
synthesized according to Method D using 3c (1.50 g, 3.24 mmol), m-anisoyl chloride (0.98 mL, 6.48 mmol) 
and dichlorobis(triphenyl phosphine)palladium(II) (0.23 g, 0.32 mmol) dry toluene (20 mL) to give the crude 
product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:20 to 4:5) to yield a pale 
yellow solid (0.70 g, 69%). Rf = 0.13 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.73 (t, J = 7.7 Hz, 
2H), 3.02 (t, J = 7.7 Hz, 2H), 3.23 (t, J = 8.5 Hz, 2H), 3.86 (s, 3H), 4.15 (t, J = 8.5 Hz, 2H), 7.12 (m, 1H), 
7.28 (m, 2H), 7.38 (t, J = 7.9 Hz, 1H), 7.54 (s, 1H), 7.59 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.2, 27.4, 
31.5, 45.7, 55.5, 114.3, 118.2, 119.5, 122.3, 126.1, 128.8, 129.0, 129.2, 133.1, 139.7, 145.4, 159.6, 167.9, 
195.5. 
8-[Hydroxy-(3-methoxy-phenyl)-methyl]-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (10a). The 
title compound was synthesized according to Method B using 10b (0.69 g, 2.24 mmol) and sodium hydride 
(0.17 g, 4.48 mmol) in Methanol (10 mL) to yield a white solid (0.57 g, 82%) after purification by flash 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 1:50). Rf = 0.25 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 
MHz, CDCl3): δ 2.31 (d, J = 3.4 Hz, 1H), 2.64 (t, J = 7.8 Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H), 3.14 (t, J = 8.5 
Hz, 2H), 3.80 (s, 3H), 4.05 (t, J = 8.5 Hz, 2H), 5.75 (d, J = 3.2 Hz, 1H), 6.81 (ddd, J = 0.8, 2.5, 8.2 Hz, 1H), 
6.96 (m, 2H), 7.02 (s, 1H), 7.08 (s, 1H), 7.26 (m, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.6, 45.4, 
55.2, 76.1, 112.0, 112.7, 118.6, 120.0, 121.8, 124.0, 129.1, 129.6, 139.4, 140.9, 145.7. 159.8, 167.6. 
8-(4-Methoxy-benzoyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (11b). The title compound was 
synthesized according to Method D using 3c (2.00 g, 4.33 mmol), p-anisoyl chloride (1.17 mL, 8.66 mmol) 
and dichlorobis(triphenyl phosphine)palladium(II) (0.30 g, 0.43 mmol) dry toluene (20 mL) to yield the 
crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:50 to 4:5) to yield a 
pale yellow solid (0.85 g, 64%). Rf = 0.30 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.73 (t, J = 7.8 
Hz, 2H), 3.02 (t, J = 7.8 Hz, 2H), 3.23 (t, J = 8.5 Hz, 2H), 3.89 (s, 3H), 4.15 (t, J = 8.5 Hz, 2H), 6.97 (m, 2H), 
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7.49 (s, 1H), 7.54 (s, 1H), 7.78 (m, 2H). 13C-NMR (125 MHz, CDCl3): δ 24.3, 27.4, 31.5, 45.7, 55.5, 113.5, 
119.5, 125.8, 128.5, 128.9, 130.7, 132.2, 133.8, 144.9, 162.9, 167.9, 194.7. 
8-[Hydroxy-(4-methoxy-phenyl)-methyl]-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (11a). The 
title compound was synthesized according to Method B using 11b (570 mg, 1.85 mmol) and sodium hydride 
(140 mg, 3.70 mmol) in Methanol (10 mL) to yield a pale yellow solid (165 mg, 54%) after purification by 
flash chromatography on silica gel (EtOAc/PE, 1:10 to 2:1). Rf = 0.09 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, 
CDCl3): δ 2.32 (d, J = 3.4 Hz, 1H), 2.65 (t, J = 7.7 Hz, 2H), 2.93 (t, J = 7.7 Hz, 2H), 3.14 (t, J = 8.4 Hz, 2H), 
3.80 (m, 4H), 4.06 (t, J = 8.4 Hz, 2H), 5.75 (s, br, 1H), 6.88 (m, 2H), 7.01 (s, 1H), 7.08 (s, 1H), 7.29 (m, 2H). 
3-(4-Oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline-8-carbonyl)-benzonitrile (12b). The title 
compound was synthesized according to Method D using 3c (1.20 g, 2.60 mmol), 3-cyanobenzoyl chloride 
(0.86 g, 5.20 mmol) and dichlorobis(triphenyl phosphine)palladium(II) (0.18 g, 0.26 mmol) dry toluene (20 
mL) to yield the crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:50 
to 1:1) to yield a pale yellow solid (0.46 g, 58%). Rf = 0.12 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 
2.75 (t, J = 7.8 Hz, 2H), 3.04 (t, J = 7.8 Hz, 2H), 3.25 (t, J = 8.5 Hz, 2H), 4.16 (t, J = 8.5 Hz, 2H), 7.49 (s, 
1H), 7.54 (s, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.85 (dt, J = 1.4, 7.8 Hz, 1H), 7.98 (m, 2H). 13C-NMR (125 MHz, 
CDCl3): δ 24.2, 27.3, 31.3, 45.8, 112.7, 118.0, 119.9, 126.1, 128.9, 129.4, 129.4, 131.8, 133.0, 133.5, 134.9, 
139.4, 146.1, 167.9, 193.3. MS (ESI) m/z = 279 [M+H] +. 
3-[Hydroxy-(4-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-8-yl)-methyl]-benzonitrile (12a). 
The title compound was synthesized according to Method B using 12b (455 mg, 1.50 mmol) and sodium 
hydride (114 mg, 3.00 mmol) in Methanol (10 mL) to yield a pale yellow solid (375 mg, 82%) after 
purification by flash chromatography on silica gel (MeOH/CH2Cl2, 0 to 1:50). Rf = 0.15 (MeOH/CH2Cl2, 
1:20). 1H-NMR (500 MHz, CDCl3): δ 2.55 (d, J = 3.3 Hz, 2H), 2.65 (t, J = 7.8 Hz, 2H), 2.94 (t, J = 7.8 Hz, 
2H), 3.15 (t, J = 8.5 Hz, 2H), 4.06 (t, J = 8.5 Hz, 2H), 5.79 (d, J = 2.9 Hz, 1H), 6.97 (s, 1H), 7.04 (s, 1H), 
7.44 (t, J = 7.8 Hz, 1H), 7.55 (dt, J = 1.3, 7.6 Hz, 1H), 7.63 (m, 1H), 7.69 (m, 1H). 13C-NMR (125 MHz, 
CDCl3): δ 24.4, 27.7, 31.5, 45.4, 75.2, 112.5, 118.8, 120.4, 121.9, 124.2, 129.2, 129.6, 129.9, 130.6, 131.0, 
138.5, 141.4, 145.4, 167.6. 
4-(4-Oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline-8-carbonyl)-benzonitrile (13b). The title 
compound was synthesized according to Method D using 3c (1.50 g, 3.24 mmol), 4-cyanobenzoyl chloride 
(1.08 g, 6.49 mmol) and dichlorobis(triphenyl phosphine)palladium(II) (0.22 g, 0.32 mmol) dry toluene (20 
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mL) to yield the crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:10 
to 1:1) to yield a yellow solid (0.71 g, 72%). Rf = 0.12 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.74 
(t, J = 7.8 Hz, 2H), 3.02 (t, J = 7.8 Hz, 2H), 3.24 (t, J = 8.5 Hz, 2H), 4.16 (t, J = 8.5 Hz, 2H), 7.50 (s, 1H), 
7.55 (s, 1H), 7.80 (m, 4H). 4-[Hydroxy-(4-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-8-yl)-
methyl]-benzonitrile (13a). The title compound was synthesized according to Method B using 13b (704 mg, 
2.33 mmol) and sodium hydride (177 mg, 4.66 mmol) in Methanol (15 mL) to yield a offwhite solid (475 mg, 
67%) after purification by flash chromatography on silica gel (MeOH/CH2Cl2, 1:200 to 1:50). Rf = 0.03 
(MeOH/CH2Cl2, 1:50). 1H-NMR (500 MHz, DMSO-d6): δ 2.50 (t, J = 7.7 Hz, 2H), 2.86 (t, J = 7.7 Hz, 2H), 
3.08 (t, J = 8.5 Hz, 2H), 3.90 (t, J = 8.5 Hz, 2H), 5.71 (d, J = 3.9 Hz, 1H), 6.03 (d, J = 4.0 Hz, 1H), 7.02(s, 
1H), 7.08 (s, 1H), 7.56 (m, 2H), 7.75 (m, 2H). 
8-Benzoyl-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (14b). The title compound was synthesized 
according to Method A using 1c (1.94 g, 10.8 mmol), AlCl3 (3.99 g, 29.9 mmol) and benzoyl chloride (3.14 
g, 22.3 mmol) in dry dichloromethane (50 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (hexanes/ EtOAc, 1:1, Rf = 0.14) to yield a yellow crystal (1.82 g, 61%). 1H-
NMR (500 MHz, CDCl3): δ 2.72 (t, J = 7.7 Hz, 2H), 3.01 (t, J = 7.7 Hz, 2H), 3.22 (t, J = 8.5 Hz, 2H), 4.14 (t, 
J = 8.5 Hz, 2H), 7.47 (m, 2H), 7.52 (s, 1H), 7.57 (m, 2H), 7.73 (m, 2H). 13C-NMR (125 MHz, CDCl3): δ 24.2, 
27.3, 31.4, 45.7, 119.5, 126.1, 128.2, 128.8, 128.9, 129.6, 131.9, 133.1, 138.3, 145.3, 167.8, 195.7. 
8-(Hydroxy-phenyl-methyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (14a). The title 
compound was synthesized according to Method B using 14b (1.82 g, 6.56 mmol) and sodium hydride (378 
mg, 10.0 mmol) in Methanol (50 mL) to yield a yellow solid (1.41 g, 77%). 1H-NMR (500 MHz, CDCl3): δ 
2.42 (s, br, 1H), 2.64 (t, J = 7.7 Hz, 2H), 2.95 (t, J = 7.7 Hz, 2H), 3.13 (t, J = 8.4 Hz, 2H), 4.04 (t, J = 8.4 Hz, 
2H), 5.78 (s, 1H), 7.02 (s, 1H), 7.08 (s, 1H), 7.27 (m, 1H), 7.36 (m, 4H). 13C-NMR (125 MHz, CDCl3): δ 
24.4, 27.7, 31.5, 45.3, 76.2, 120.0, 121.8, 124.0, 126.3, 127.5, 128.5, 129.1, 139.6, 140.8, 144.0, 167.6. 
8-(Furan-2-carbonyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (15b). The title compound was 
synthesized according to Method D using 3c (1.20 g, 2.60 mmol), 2-furoyl chloride (0.51 mL, 5.20 mmol) 
and dichlorobis(triphenyl phosphine)palladium(II) (0.18 g, 0.26 mmol) dry toluene (20 mL) to yield the 
crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:50 to 1:1) to yield an 
amber solid (0.38 g, 72%). Rf = 0.04 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.73 (t, J = 7.8 Hz, 
2H), 3.04 (t, J = 7.8 Hz, 2H), 3.25 (t, J = 8.5 Hz, 2H), 4.14 (t, J = 8.5 Hz, 2H), 6.59 (dd, J = 1.7, 3.5 Hz, 1H), 
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7.23 (d, J = 3.4 Hz, 1H), 7.69 (m, 1H), 7.74 (s, 1H), 7.78 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.3, 27.4, 
31.4, 45.7, 112.1, 119.7, 119.7, 125.4, 128.0, 129.1, 132.7, 145.5, 146.6, 152.7, 167.8, 181.3. 
8-(Furan-2-yl-hydroxy-methyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (15a). The title 
compound was synthesized according to Method B using 15b (360 mg, 1.35 mmol) and sodium hydride (102 
mg, 2.69 mmol) in Methanol (10 mL) to yield an amber solid (344 mg, 95%) after purification by flash 
chromatography on silica gel (MeOH/CH2Cl2, 1:200 to 1:50). Rf = 0.30 (MeOH/CH2Cl2, 1:20). 1H-NMR 
(500 MHz, CDCl3): δ 2.55 (d, J = 4.2 Hz, 1H), 2.66 (t, J = 7.8 Hz, 2H), 2.95 (t, J = 7.8 Hz, 2H), 3.17 (t, J = 
8.4 Hz, 2H), 4.07 (t, J = 8.4 Hz, 2H), 5.76 (d, J = 4.0 Hz, 1H), 6.18 (m, 1H), 6.33 (dd, J = 1.8, 3.2 Hz, 1H), 
7.08 (s, 1H), 7.15 (s, 1H), 7.38 (m, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.4, 70.2, 107.0, 
110.2, 120.0, 121.9, 124.1, 129.1, 136.4, 141.3, 142.5, 156.1, 167.6. 
8-(Thiophene-2-carbonyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (16b). The title compound 
was synthesized according to Method D using 3c (1.20 g, 2.60 mmol), 2-thiophene carbonyl chloride (0.56 
mL, 5.20 mmol) and dichlorobis(triphenyl phosphine)palladium(II) (0.18 g, 0.26 mmol) dry toluene (20 mL) 
to yield the crude product, which was purified by flash chromatography on silica gel (EtOAc/PE, 1:50 to 4:5) 
to yield a yellow solid (0.50 g, 67%). Rf = 0.05 (EtOAc/PE, 1:1). 1H-NMR (500 MHz, CDCl3): δ 2.74 (t, J = 
7.8 Hz, 2H), 3.04 (t, J = 7.8 Hz, 2H), 3.25 (t, J = 8.5 Hz, 2H), 4.15 (t, J = 8.5 Hz, 2H), 7.16 (dd, J = 3.8, 4.9 
Hz, 1H), 7.60 (s, 1H), 7.63 (dd, J = 1.0, 3.8 Hz, 1H), 7.65 (s, 1H) , 7.69 (dd, J = 1.1, 4.9 Hz, 1H). 13C-NMR 
(125 MHz, CDCl3): δ 24.2, 27.4, 31.4, 45.7, 119.7, 125.2, 127.8, 127.9, 129.1, 133.6, 133.7, 134.0, 143.8, 
145.2, 167.8, 167.8, 187.0. 
8-(Hydroxy-thiophen-2-yl-methyl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (16a). The title 
compound was synthesized according to Method B using 16b (480 mg, 1.69 mmol) and sodium hydride (129 
mg, 3.39 mmol) in Methanol (15 mL) to yield an amber solid (400 mg, 83%) after purification by flash 
chromatography on silica gel (MeOH/CH2Cl2, 0 to 1:50). Rf = 0.22 (MeOH/CH2Cl2, 1:20). 1H-NMR (500 
MHz, CDCl3): δ 2.66 (t, J = 7.8 Hz, 2H), 2.95 (t, J = 7.8 Hz, 2H), 3.16 (t, J = 8.4 Hz, 2H), 4.07 (t, J = 8.4 Hz, 
2H), 6.00 (d, J = 3.1 Hz, 1H), 6.91 (d, J = 3.5 Hz, 1H), 7.00 (dd, J = 3.5, 5.0 Hz, 1H), 7.09 (s, 1H), 7.16 (s, 
1H), 7.26 (m, 2H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.5, 45.4, 70.4, 120.0, 121.5, 123.8, 124.5, 
125.3, 126.7, 129.2, 138.9, 141.1, 148.5, 167.7. 
8-[(1-1H-imidazol-1-yl-ethyl)]-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one (1). The title compound 
was synthesized according to Method C using 1a (1.80 g, 8.30 mmol), imidazole (4.52 g, 66.4 mmol), SOCl2 
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(1.20 mL, 16.6 mmol), and dry THF (40 mL). The crude product was purified by two subsequent 
crystallizations from acetone to yield pale yellow crystals (488 mg, 22%). mp 196–198 °C, . 1H-NMR (500 
MHz, CDCl3): δ 1.82 (d, J = 6.9 Hz, 3H), 2.65 (t, J = 7.7 Hz, 2H), 2.92 (t, J = 7.7 Hz, 2H), 3.14 (t, J = 8.5 
Hz, 2H), 4.07 (t, J = 8.5 Hz, 2H), 5.27 (q, J = 6.9 Hz, 1H), 6.79 (s, 1H), 6.85 (s, 1H), 6.91 (s, 1H), 7.07 (s, 
1H), 7.58 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 22.3, 24.4, 27.7, 31.5, 45.4, 56.6, 117.9, 120.4, 121.2, 
123.5, 129.3, 129.6, 135.9, 136.9, 141.4, 167.5. MS (ESI) m/z = 268 [M+H] +.  
8-[1-(1H-imidazol-1-yl)propyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (2). The title 
compound was synthesized according to Method C using 2a (0.63 mg, 2.73mmol), imidazole (2.94 g, 43.2 
mmol), SOCl2 (0.78 mL, 10.7 mmol) and dry THF (25 mL). The crude product was purified by flash 
chromatography (EtOAc/MeOH, 9:1, Rf = 0.11) to yield white solids (0.20 g, 26%). mp 194–196 °C. 1H-
NMR (500 MHz, CDCl3): δ 0.93 (t, J = 7.2, 3H), 2.13–2.25 (m, 2H), 2.65 (t, J = 7.9, 2H), 2.93 (t, J = 7.9, 
2H), 3.14 (t, J = 8.5, 2H), 4.06 (t, J = 8.5, 2H), 4.90–4.94 (t, 3J = 7.6, 1H), 6.82 (s, 1H), 6.90 (s, 1H), 6.92 (s, 
1H), 7.06 (s, 1H), 7.59 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 11.4, 24.6, 27.9, 29.0, 31.7, 45.6, 63.6, 117.8, 
120.6, 121.9, 124.3, 129.6, 129.8, 135.8, 136.4, 141.7, 167.7. MS (ESI) m/z = 282 [M+H] +. 
8-[Cyclopropyl(1H-imidazol-1-yl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (4). The 
title compound was synthesized according to Method C using 4a (0.56 g, 2.30 mmol), imidazole (1.88 g, 
27.6 mmol), SOCl2 (0.50 mL, 6.90 mmol) and dry THF (20 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 1:50) to yield white crystals (0.50 g, 74%). mp 146–147 °C, Rf = 0.14. 
1H-NMR (500 MHz, CDCl3): δ 0.42–0.50 (m, 2H), 0.76–0.85 (m, 2H), 1.46–1.54 (m, 1H), 2.66 (t, J = 7.8 
Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H), 3.15 (t, J = 8.5 Hz, 2H), 4.08 (t, J = 8.5 Hz, 2H), 4.30 (d, J = 9.3 Hz, 1H), 
6.82 (s, 1H), 6.90 (s, 1H), 6.95 (s, 1H), 7.07 (s, 1H), 7.67 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 4.8, 5.3, 
16.6, 24.4, 27.7, 31.5, 45.4, 66.3, 118.3, 120.3, 121.8, 124.1, 129.3, 129.4, 135.6, 136.4, 141.4, 167.5. MS 
(ESI) m/z = 226 [M-imidazole] +. The racemate 4 was separated by preparative HPLC on chiral stationary 
phase (NucleoCel Delta column, 0.8 cm × 25 cm, 45% hexane/ethanol, 1.0 mL/min) to yield 4-1 (99.6% ee 
and tR = 19.2 min by analytical HPLC using 30% hexane/ethanol) and 4-2 (93.3% ee and tR = 22.9 min by 
analytical HPLC using 30% hexane/ethanol). 
8-[Cyclobutyl(1H-imidazol-1-yl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (5). The title 
compound was synthesized according to Method C using 5a (0.20 g, 0.78 mmol), imidazole (0.85 g, 12.4 
3 Results and Discussions 
Lina Yin Dissertation 
- 114 - 
mmol), SOCl2 (0.23 mL, 3.11 mmol) and dry THF (10 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 1:50) to yield white crystals (0.20 g, 84%). mp 120–122 °C, Rf = 0.14. 
1H-NMR (500 MHz, CDCl3): δ 1.76–1.99 (m, 4H), 2.01–2.07 (m, 1H), 2.14–2.21 (m, 1H), 2.65 (t, J = 7.8 
Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.08 (m, 1H), 3.13 (t, J = 8.5 Hz, 2H), 4.06 (t, J = 8.5 Hz, 2H), 4.93 (d, J = 
10.4 Hz, 1H), 6.80 (s, 1H), 6.85 (s, 1H), 6.87 (s, 1H), 7.03 (s, 1H), 7.51 (s, 1H). 13C-NMR (125 MHz, 
CDCl3): δ 17.5, 24.5, 26.3, 26.9, 27.8, 31.5, 39.8, 45.4, 67.3, 117.8, 120.3, 122.3, 124.4, 129.4, 129.5, 134.4, 
136.2, 141.7, 167.3. MS (ESI) m/z = 240 [M-imidazole] +. 
8-[(2-Fluorophenyl)(1H-imidazol-1-yl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (7). 
The title compound was synthesized according to Method C using 7a (0.16 g, 0.55 mmol), imidazole (0.6 1g, 
8.88 mmol), SOCl2 (0.16 mL, 2.22 mmol) and dry THF (10 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 1:10) to yield pale yellow solids (0.10 g, 55%). mp 175–177 °C, Rf = 
0.11. 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.91 (t, J = 7.8 Hz, 2H), 3.14 (t, J = 8.5 Hz, 
2H), 4.08 (t, J = 8.5 Hz, 2H), 6.73 (s, 1H), 6.74 (s, 1H), 6.80 (s, 1H), 6.85 (s, 1H), 6.88 (m, 1H), 7.08–7.16 
(m, 3H), 7.35 (m, 1H), 7.41 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.3, 27.6, 31.4, 45.4, 58.5 (d, 3JC,F = 
4.0 Hz), 115.8 (d, 2JC,F = 21.2 Hz), 119.3, 120.0, 123.0, 124.6 (d, 4JC,F = 3.5 Hz), 125.4, 127.0 (d, 3JC,F = 13.1 
Hz), 128.7 (d, 4JC,F = 2.9 Hz), 129.5, 129.6, 130.3 (d, 3JC,F = 8.3 Hz), 133.0, 137.3, 141.8, 160.0 (d, 1JC,F = 
249 Hz), 167.5. MS (ESI) m/z = 280 [M-imidazole] +. The racemate 7 was separated by preparative HPLC on 
chiral stationary phase (NucleoCel Delta column, 0.8 cm × 25 cm, 20% hexane/isopropanol, 1.0 mL/min) to 
yield 7-1 (100% ee and tR = 22.2 min by analytical HPLC using 20% hexane/isopropanol) and 7-2 (71.4% ee 
and tR = 27.3 min by analytical HPLC using 20% hexane/isopropanol). 
8-[(3-Fluorophenyl)(1H-imidazol-1-yl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (8). 
The title compound was synthesized according to Method C using 8a (230 mg, 0.77 mmol), imidazole (843 
mg, 8.88 mmol), SOCl2 (0.22 mL, 3.09 mmol) and dry THF (10 mL). The crude product was purified by 
flash chromatography (MeOH/CH2Cl2, 1:200 to 1:50) to yield pale yellow solids (60 mg, 22%). mp 194–196 
°C, Rf = 0.12. 1H-NMR (500 MHz, CDCl3): δ 2.68 (t, J = 7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.15 (t, J = 
8.5 Hz, 2H), 4.09 (t, J = 8.5 Hz, 2H), 6.43 (s, 1H), 6.75 (s, 1H), 6.78 (m, 1H), 6.81 (s, 1H), 6.84 (s, 1H), 6.88 
(m, 1H), 7.04 (m, 1H), 7.11 (s, 1H), 7.34 (m, 1H), 7.41 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 
31.4, 45.4, 64.4, 114.9 (d, 2JC,F = 22.8 Hz), 115.4 (d, 2JC,F = 21.1 Hz), 120.5, 123.3, 123.4, 123.4, 125.7, 
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129.7, 129.7, 130.5 (d, 3JC,F = 8.2 Hz), 133.6, 141.9, 142.0, 142.0, 163.0 (d, 1JC,F = 248 Hz), 167.5. MS (ESI) 
m/z = 281 [M-imidazole] +. 
8-[(4-Fluorophenyl)(1H-imidazol-1-yl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (9). 
The title compound was synthesized according to Method C using 9a (0.35 g, 1.18 mmol), imidazole (1.28 g, 
18.8 mmol), SOCl2 (0.34 mL, 4.72 mmol) and dry THF (12 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 1:50) to yield pale yellow solids (0.30 g, 73%). mp 201–203 °C, Rf = 
0.11. 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.15 (t, J = 8.5 Hz, 
2H), 4.09 (t, J = 8.5 Hz, 2H), 6.46 (s, 1H), 6.73 (s, 1H), 6.78 (s, 1H), 6.85 (s, 1H), 7.06 (s, 2H), 7.07 (s, 2H), 
7.13 (s, 1H), 7.47 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.4, 45.4, 64.5, 116.0 (d,2JC,F = 21.8 
Hz), 119.3, 120.5, 123.1, 125.5, 128.9, 129.6 (d, 3JC,F = 8.2 Hz), 129.8, 133.9, 135.0 (d, 4JC,F = 3.5 Hz), 
137.0, 141.9, 162.5 (d, 1JC,F = 248 Hz), 167.5. MS (ESI) m/z = 281 [M-imidazole] +. 
8-[(1H-imidazol-1-yl)(3-methoxyphenyl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (10). 
The title compound was synthesized according to Method C using 10a (0.40 g, 1.29 mmol), imidazole (1.06 
g, 15.5 mmol), SOCl2 (0.28 mL, 3.88 mmol) and dry THF (20 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 1:50) to yield white crystals (0.42 g, 87%). mp 65–67 °C, Rf = 0.10. 
1H-NMR (500 MHz, CDCl3): δ 2.66 (t, J = 7.8 Hz, 2H), 2.91 (t, J = 7.8 Hz, 2H), 3.13 (t, J = 8.5 Hz, 2H), 
3.76 (s, 3H), 4.08 (t, J = 8.5 Hz, 2H), 6.40 (s, 1H), 6.61 (t, J = 2.0 Hz, 1H), 6.67 (d, J = 7.6 Hz,1H), 6.75 (s, 
1H), 6.81 (s, 1H), 6.84 (m, 1H), 6.87 (dd, J = 2.5, 8.2 Hz, 1H), 7.08 (m, 1H), 7.27 (t, J = 7.8 Hz, 1H), 7.40 (s, 
1H). 13C-NMR (125 MHz, CDCl3): δ 24.3, 27.6, 31.4, 45.4, 55.3, 64.8, 113.2, 114.0, 119.3, 120.1, 120.3, 
123.2, 125.6, 129.4, 129.5, 129.9, 134.2, 137.3, 140.9, 141.6, 160.0, 167.5. MS (ESI) m/z = 360.60 [M+H] +. 
8-[(1H-imidazol-1-yl)(4-methoxyphenyl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (11). 
The title compound was synthesized according to Method C using 11a (340 mg, 1.10 mmol), imidazole (1.20 
g, 17.6 mmol), SOCl2 (0.32 mL, 4.40 mmol) and dry THF (15 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 1:50) to yield white crystals (30 mg, 9%). mp 54–56 °C, Rf = 0.06. 1H-
NMR (500 MHz, CDCl3): δ 2.66 (t, J = 7.8 Hz, 2H), 2.91 (t, J = 7.8 Hz, 2H), 3.14 (t, J = 8.5 Hz, 2H), 3.81 (s, 
3H), 4.08 (t,3J = 8.5 Hz, 2H), 6.40 (s, 1H), 6.72 (s, 1H), 6.78 (s, 1H), 6.86 (m, 1H), 6.88 (m, 2H), 7.02 (m, 
2H), 7.11 (s, 1H), 7.43 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.4, 45.4, 55.3, 64.6, 114.3, 
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114.5, 116.6, 117.1, 120.4, 123.0, 125.3, 129.2, 129.6, 131.1, 134.7, 141.6, 159.6, 167.5. MS (ESI) m/z = 
293 [M-imidazole] +. 
3-[(2,4,5,6-Tetrahydro-4-oxo-1H-pyrrolo[3,2,1-ij]quinolin-8-yl)(1H-imidazol-1-yl)methyl]Benzonitrile 
(12). The title compound was synthesized according to Method C using 12a (180 mg, 0.59 mmol), imidazole 
(644 mg, 9.46 mmol) and SOCl2 (0.17 mL, 2.37 mmol) and dry THF (10 mL). The crude product was 
purified by flash chromatography (MeOH/CH2Cl2, 0 to 1:20) to yield white solids (30 mg, 14%). mp 201–
202 °C, Rf = 0.07. 1H-NMR (500 MHz, CDCl3): δ 2.68 (t, J = 7.8 Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H), 3.16 (t, J 
= 8.5 Hz, 2H), 4.10 (t, J = 8.5 Hz, 2H), 6.48 (s, 1H), 6.73 (s, 1H), 6.78 (s, 1H), 6.83 (s, 1H), 7.14 (s, 1H), 
7.30 (d, J = 7.9 Hz, 1H), 7.34 (s, 1H), 7.42 (s, 1H), 7.50 (t, J = 8.0 Hz, 1H) , 7.64 (d, J = 7.7 Hz, 1H). 13C-
NMR (125 MHz, CDCl3): δ 24.3, 27.6, 31.3, 45.4, 64.2, 113.2, 118.1, 120.7, 123.4, 125.7, 129.8, 130.0, 
131.1, 131.9, 132.0, 132.7, 141.2, 142.2, 167.5.  MS (ESI) m/z = 287 [M-imidazole] +. 
4-[(2,4,5,6-Tetrahydro-4-oxo-1H-pyrrolo[3,2,1-ij]quinolin-8-yl)(1H-imidazol-1-yl)methyl]Benzonitrile 
(13). The title compound was synthesized according to Method C using 13a (460 mg, 1.51 mmol), imidazole 
(1.22 g, 18.0 mmol), SOCl2 (0.33 mL, 4.53 mmol) and dry THF (20 mL). The crude product was purified by 
flash chromatography (MeOH/CH2Cl2, 1:500 to 1:50) to yield white solids (302 mg, 56%). mp 114–116 °C, 
Rf = 0.12. 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.15 (t, J = 8.5 
Hz, 2H), 4.09 (t, J = 8.5 Hz, 2H), 6.49 (s, 1H), 6.74 (s, 1H), 6.79 (s, 1H), 6.82 (s, 1H), 7.13 (s, 1H), 7.16 (d, J 
= 8.3 Hz, 2H),7.40 (s, 1H), 7.66 (d, J = 8.3 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ 24.3, 27.6, 31.3, 45.4, 
64.5, 112.4, 118.1, 119.0, 120.7, 123.5, 126.0, 128.2, 130.0, 130.0, 132.6, 132.7, 137.1, 142.2, 144.8, 167.4. 
MS (ESI) m/z = 356 [M+H] +. 
8-[(1H-imidazol-1-yl)(phenyl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (14). The title 
compound was synthesized according to Method C using 14a (1.41 g, 5.06 mmol), imidazole (2.72 g, 40.0 
mmol), SOCl2 (0.73 mL, 10.0 mmol) and dry THF (40 mL). The crude product was purified by two 
subsequent crystallizations from acetone to yield colorless needles (385 mg, 23%). mp185–187 °C. 1H-NMR 
(500 MHz, CDCl3): δ 2.67 (t, J = 7.7 Hz, 2H), 2.92 (t, J = 7.7 Hz, 2H), 3.14 (t, J = 8.5 Hz, 2H), 4.09 (t, J = 
8.5 Hz, 2H), 6.45 (s, 1H), 6.75 (s, 1H), 6.81 (s, 1H), 6.85 (s, 1H), 7.09 (m, 3H), 7.33–7.39 (m, 3H), 7.41 (s, 
1H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.7, 31.4, 45.4, 65.0, 119.3, 120.4, 123.3, 125.6, 127.8, 128.4, 
128.9, 129.4, 129.6, 134.4, 137.3, 139.3, 141.6, 167.5. MS (ESI) m/z = 330 [M+H] +. 
8-(Furan-2-yl(1H-imidazol-1-yl)methyl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (15). The title 
compound was synthesized according to Method C using 15a (200 mg, 0.74 mmol), imidazole (809 mg, 11.9 
mmol), SOCl2 (0.22 mL, 2.97 mmol) and dry THF (10 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 3:100) to yield yellow solids (65 mg, 28%). mp 151–153 °C, Rf = 0.08. 
1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.15 (t, J = 8.5 Hz, 2H), 
4.08 (t, J = 8.5 Hz, 2H), 6.17 (d, J = 3.3 Hz, 1H), 6.38 (m, 2H), 6.78 (s, 1H), 6.84 (s, 1H), 6.89 (s, 1H), 7.08 
(s, 1H), 7.45 (s, 2H). 13C-NMR (125 MHz, CDCl3): δ 24.3, 27.6, 31.4, 45.4, 58.8, 110.2, 110.5, 118.7, 120.4, 
122.3, 124.7, 129.4, 129.6, 132.6, 136.8, 141.8, 143.4, 151.4, 167.5. MS (ESI) m/z = 252 [M-imidazole] +. 
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8-[(1H-imidazol-1-yl)(thiophen-2-yl)methyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (16). The 
title compound was synthesized according to Method C using 16a (200 mg, 0.70 mmol), imidazole (762 mg, 
11.2 mmol), SOCl2 (0.20 mL, 2.80 mmol) and dry THF (10 mL). The crude product was purified by flash 
chromatography (MeOH/CH2Cl2, 0 to 3:100) to yield yellow solids (150 mg, 64%). mp 169–171 °C, Rf = 
0.15. 1H-NMR (500 MHz, CDCl3): δ 2.67 (t, J = 7.8 Hz, 2H), 2.92 (t, J = 7.8 Hz, 2H), 3.15 (t, J = 8.5 Hz, 
2H), 4.08 (t, J = 8.5 Hz, 2H), 6.61 (s, 1H), 6.82 (s, 1H), 6.86 (dt, J = 1.0, 3.5Hz, 1H), 6.88 (s, 1H), 6.91 (m, 
1H), 7.00 (dd, J = 3.6, 5.1 Hz, 1H), 7.09 (s, 1H), 7.34 (dd, J = 1.2, 5.1 Hz, 1H), 7.48 (s, 1H). 13C-NMR (125 
MHz, CDCl3): δ 24.3, 27.7, 31.4, 45.4, 60.5, 118.9, 120.4, 122.3, 124.7, 126.7, 127.0, 127.5, 129.5, 129.6, 
134.8, 136.9, 141.8, 142.5, 167.5. MS (ESI) m/z = 268 [M-imidazole] +. 
8-[1-(1H-imidazol-1-yl)vinyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (6); 8-[1,1-Di(1H-
imidazol-1-yl)ethyl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one (17). To a solution of imidazole 
(2.28 g, 33.4 mmol) in dry dichloromethane (15 mL) was added SOCl2 (0.40 mL, 5.6 mmol) under an 
atmosphere of nitrogen at 0 °C. The mixture was stirred for 30 min, and 1b (1.00 g, 4.60 mmol) was added. 
The mixture was stirred at ambient temperature for 96 h, consequently neutralized with aqueous NaHCO3 
and extracted with CHCl3 (3 x 15 mL). The extracts were washed with water and brine, dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatograph (MeOH/CH2Cl2, 0 to 1:50) to 
yield 6 as pale yellow solids (28 mg, 2%). mp 125–126 °C, Rf = 0.11. 1H-NMR (500 MHz, CDCl3): δ 2.69 (t, 
J = 7.7 Hz, 2H), 2.96 (t, J = 7.7 Hz, 2H), 3.18 (t, J = 8.5 Hz, 2H), 4.11 (t, J = 8.5 Hz, 2H), 5.21 (d, J = 9.9 Hz, 
2H), 6.97 (s, 1H), 7.03 (m, 2H), 7.13 (s, 1H), 7.62 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ 24.3, 27.5, 31.4, 
45.5, 105.2, 119.3, 120.2, 122.5, 124.9, 129.4, 129.7, 131.2, 137.2, 142.8, 143.2, 167.5. MS (ESI) m/z = 198 
[M-imidazole] +. Subsequent elution (MeOH/CH2Cl2, 1:50 to 1:10) yielded 17 as pale yellow solids (330 mg, 
22%). mp 189 °C, Rf = 0.04. 1H-NMR (500 MHz, CDCl3): δ 2.53 (s, 3H), 2.67 (t, J = 7.8 Hz, 2H), 2.91 (t, J 
= 7.8 Hz, 2H), 3.14 (t, J = 8.5 Hz, 2H), 4.10 (t, J = 8.5 Hz, 2H), 6.52 (s, 1H), 6.56 (s, 1H), 6.82 (s, 2H), 7.13 
(s, 2H), 7.35 (s, 2H). 13C-NMR (125 MHz, CDCl3): δ 24.4, 27.6, 30.3, 31.3, 45.5, 75.9, 118.0, 120.4, 121.2, 
123.5, 129.8, 130.3, 135.6, 136.2, 142.8, 167.4. MS (ESI) m/z = 266 [M-imidazole] +. 
2. HPLC purity control of all final compounds. 
The Surveyor®-LC-system consisted of a pump, an autosampler, and a PDA detector. Mass spectrometry 
was performed on a TSQ® Quantum (Thermo Electron Corporation, Dreieich, Germany). The triple 
quadrupole mass spectrometer was equipped with an electrospray interface (ESI). The system was operated 
by the standard software Xcalibur®. 
A RP C18 NUCLEODUR® 100-5 (125 × 3 mm) column (Macherey-Nagel GmbH, Duehren, Germany) 
was used as stationary phase. All solvents were HPLC grade. 
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In a gradient run the percentage of acetonitrile (containing 0.1% triflouro-acetic acid) in water was 
increased from an initial concentration of 3% at 0 min to 100% at 15 min and kept at 100% for 3 min. 
The injection volume was 10 µl and flow rate was set to 350 µl/min. MS analysis was carried out at a 
spray voltage of 3800 V, a capillary temperature of 350 °C and a source CID of 10 V. Spectra were acquired 
in positive mode from 100 to 1000 m/z and full scan UV-mode. In some cases APC ionization had to be 
applied. 
Comp. RT (min) Purity [%] 
1 6.74 99.0% 
2 6.01 95.1% 
3 5.57 98.2% 
4 5.24 95.6% 
5 7.82 99.9% 
6 7.86 98.0% 
7 6.07 99.7% 
8 6.25 98.2% 
9 6.36 99.7% 
10 6.51 97.3% 
11 6.26 95.3% 
12 7.19 99.9% 
13 5.84 99.0% 
14 9.01 98.8% 
15 5.51 96.8% 
16 5.92 98.0% 
17 8.79 99.3% 
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4 Summary and Conclusions 
4.1 CYP11B2 Inhibitors 
Our previously designed CYP11B2 inhibitors with a naphthalene core showed strong potentcy and good 
selectivity toward CYP11B163–66. However, high inhibition of an important hepatic enzyme, CYP1A2, was 
observed65,66. In order to improve the selectivity toward CYP1A2, structural modifications regarding 
aromaticity, planarity, and structural flexibility/rigidity were carried out on the core structure by altering 
cycle size, presence of H-bond forming groups and removal of bridge bonds. In this study, 21 analogues of 
3-pyridinyl substituted aliphatic cycles were designed, synthesized and biologically evaluated as novel 
CYP11B2 inhibitors. Among them, compounds I-2, I-4, I-12, I-13 and I-14 (Figure 16) were identified as 
potent CYP11B2 inhibitors with good selectivity toward CYP11B1. On one hand, the presence of H-bond 
forming groups was observed to reduce inhibitory potency. On the other hand, an α-double bond together 
with a H-bond forming group in medium size cycles promoted inhibitory activity and selectivity, whereas 
deterioration was observed for medium size cycles without H-bond forming groups. This phenomenon is 
probabably due to the fact that the binding mode altered when H-bond forming groups interacted with some 
amino acid residues. Furthermore, flexible 8 to 10 membered medium or bicyclic rings are appropriate for 
the binding site, whereas flexible 12-membered ring or rigid bicyclic analogues are not tolerated. In addition, 
the design concept employed in this study through dearomatisation of the lipophilic core and destruction of 
planarity to reduce CYP1A2 inhibition was proven successful. For the five most potent and selective 
CYP11B2 inhibitors, the CYP1A2 inhibition was significantly decreased compared to their aromatic 
precursors. Since selectivity toward hepatic CYP enzymes is always a key issue for safety reasons associated 
with drug discovery, the results demonstrated in this study can be helpful in the optimization of steroidogenic 
CYP inhibitors aimed at improvement of selectivity toward CYP1A2. 
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Figure 16. CYP11B2 inhibitors. 
Moreover, on the basis of a dihydroquinolinone core67, 69 and a dihydropyrroloquinolinone core70, a series 
of N containing heterocycle substituted indolines and indoles were designed, synthesized and identified as 
highly potent and selective CYP11B2 inhibitors via ligand-based approach. Especially, compounds II-11 and 
II-20 (Figure 16) showed IC50 values around 2 nM and SFs around 170. It is notable that they showed no 
inhibition of other steroidogenic enzymes such as CYP17 and CYP19. These compounds can be considered 
as candidates for further evaluation in vivo. In this study, it has been found that bulky substituents at the 
amido moiety dramatically reduced inhibitory potency. The methyl group turned out to be the most suitable 
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one. Introduction of electron donating groups, such as methyl, methoxy and phenyl on the pyridyl 
significantly increased CYP11B2 inhibition. Finally, dehydrogenation of the indoline core to indole led to an 
increase in CYP11B2 inhibition, but no improvement of selectivity. 
4.2 Dual Inhibitors of CYP19 / CYP11B2 
The same inhibition mechanism of heme iron complexing CYP 
enzyme inhibitors and a certain homology among this superfamily 
become advantegous for the design of dual inhibitors. Through 
combination of the key structure features of the target enzyme 
inhibitors, a series of potent dual CYP19 / CYP11B2 inhibitors 
were designed, synthesized and tested. 3-Pyridinyl, a favorable N 
containing heterocycle for CYP11B2 inhibitors, has been found not to be suitable for this purpose, whereas 
4-pyridinyl led to potent dual inhibitors. The substituents on the CH bridge showed significant influence on 
the inhibitory activity, in which contradictory SARs were commonly observed for the inhibition of these two 
enzymes. For example, when alkyl groups were introduced, the enhancement of bulkiness increased CYP19 
inhibition but reduced that of CYP11B2. Besides, substituted phenyl groups were introduced instead of alkyl 
groups, resulting in compounds with strong inhibition toward both enzymes. Similarly, contradictory SARs 
were observed when methoxy or fluoro at the phenyl moiety were shifted from the 2- or 3-position into the 
4-position, leading to decrease in CYP19 inhibition but an increase in CYP11B2 inhibition. Contrarily, 
chloro and methyl substitution led to potent dual inhibitors of CYP19 and CYP11B2 regardless their 
positions on the phenyl ring. It has been observed that 3-substituted Ph compounds were more potent toward 
CYP19, whereas 4-substituted Ph derivatives showed a stronger inhibition of CYP11B2, and compounds 
with 3-substituted Ph were more selective than the corresponding 4-substituted Ph analogues. Moreover, the 
resolution of a racemic mixture led to an increase in CYP19 inhibition but to a reduction of CYP11B2 
inhibition and selectivity regarding CYP11B1 for one enantiomer; while for the other one opposite results 
were observed. The compromise of these conflicts led to compounds III-1[9, III-20, III-23 and III-25 as 
potent and selective dual inhibitors of CYP19 and CYP11B2. Especially compound III-25, exhibiting IC50 
values of 32 and 41 nM for CYP19 and CYP11B2, respectively, and a SF of 33 over CYP11B1, is deemed to 
be superior to the leads fadrozole which is an unselective CYP19 inhibitor showing potent inhibition of 
CYP11B2 and CYP11B1. This compound could be a drug candidate for treatment of BC patients with risk of 
CVD after further evaluation in vivo. 
4.3 CYP11B1 Inhibitors 
Starting from etomidate and 8-(isoquinolin-4-yl)-5,6-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-4(2H)-one 
(Figure 18), modification of the etomidate scaffold by replacement of the phenyl group by the 
tetrahydropyrroloquinolinone group led to a series of imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-
pyrrolo[3,2,1-ij]quinolin-4-ones. Through optimization of substituents on the CH bridge between the 
tetrahydropyrroloquinolinone core and the imidazolyl, the selectivity toward CYP11B2 was improved. The 
NO
N
R
III-19: R = m-OMe
III-20: R = p-OMe
III-23: R = m-Cl
III-25: R = m-Me
Figure 17. CYP19 / 11B2 dual inhibitors. 
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inhibitory potency increased from about 20 nM to less than 5 nM with increasing bulkiness of the aliphatic 
chains. However, steric limitations were observed when substituted aromatic phenyl groups were introduced. 
Moreover, compounds with substitutents at the para- position of the phenyl group showed improved 
inhibition and selectivity compared to non- or 
meta- substituted phenyl analogues. Compound 
IV-4 was identified as a potent (IC50 = 2.2 nM) 
and selective (versus CYP11B2, CYP17, and 
CYP19) CYP11B1 inhibitor. Since this 
compound also showed potent inhibition of rat CYP11B1 (facilitating in vivo test), it is considered to be a 
promising lead compound for further modification. 
Furthermore, it is interesting to observe that the simple exchang of N containing heterocycles (Figure 19), 
e.g. imidazolyl, 3-pyridyl or 4-pyridyl, dramatically changed the tendency of inhibiton. 4-Pyridyl substituted 
on the CH bridge resulted in CYP11B2 inhibitors, whereas imdazolyl and 3-pyridyl led to CYP11B1 
inhibitors. This finding further demonstrated that a minor group could be the key to selectivity among CYP 
enzymes. 
N
NNO
IV-4
Het
R
NO
NO
N
III-25
NO N
III-2
CYP19 / 11B2 dual inhibitor CYP11B1 inhibitors  
 Figure 19. Different heterocycles on the CH bridge. 
In conclusion, inhibition of CYP enzymes is a promising therapeutic strategy for treatment of severe 
hormone dependent diseases. In this study, compounds II-11, II-20 as well as IV-4 have been identified as 
potent and selective inhibitors of CYP11B2 and CYP11B1 inhibitor, respectively. Compound III-25 is 
discovered to be a promising dual inhibitor of CYP19 / 11B2. These compounds can be considered as drug 
candidates of the further evaluation in vivo. Moreover, the SARs found in this study, such as CYP1A2 
inhibition and minor changes of heterocycles alter the preference among CYP enzymes, could be valuable 
for further desigh of potent and selective inhibitors of various CYP enzymes. 
 
N
NNONO
N
IV-4  
Figure 18. CYP11B1 inhibitor IV-4 was designed. 
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